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Infection with HPV genomes is a primary cause of cervical cancer. In HPV-16 
transformed cell lines, we showed that the HPV-16 genome is targeted by DNA 
methylation. In a clinical study using methylation sensitive restriction enzyme McrBc, it 
was discovered that genomic hypomethylation of the LCR and promoter region correlated 
with carcinogenic progression. 
The HPV-16 genome could be demethylated by depleting DNMT1 in the CaSki cells, 
using 5AzadC and MMS. This led to the induction of the late genes, and an inhibition of 
the early genes.   
A phenomenon of TSA induced repression of the HPV-16 promoter was investigated. We 
found an increased association of DNMT1 and transcriptional inhibitors YY1 and HDAC1 
through Chromatin IP on the p97 promoter upon treatment of TSA, which could play a 
role in the repression of the promoter.     
DNMT1 and PCNA were found to interact with two distinct regions of Hsc70. PCNA 
interacts with the N-terminus ATPase domain of Hsc70, while DNMT1 bound to the C-
terminus substrate-binding domain. The binding site of Hsc70 was localized to aa141-152, 
probably to the PXPXP sequence at the N-terminus of DNMT1.  The presence of an 
additional 17aa inserted in the middle of this region in the splice variant DNMT1b, 
abolished its interaction with Hsc70. PCNA acts as a co-activator by increasing the Hsp40 
induced ATPase activity of Hsc70. This interaction could play a role in binding to 
DNMT1 and hence, protecting the complex from attack by p21Waf1/Cip1.        
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CHAPTER 1  INTRODUCTION  
1.1 DNA Methylation  
The genome of most organisms contains information in two forms, genetic and epigenetic. The 
genetic information provides the blueprint for the expression of proteins necessary for the 
survival of organisms. The epigenetic information provides instruction on precisely when and 
where the genetic information should be used. Ensuring the precise expression of genes at the 
right time is as important as switching off their expression when not required. This epigenetic 
control of gene expression in the mammalian cells is mainly through DNA methylation.   
     
1.1.1 Role of DNA methylation   
DNA methylation involves the enzymatic transfer of a methyl group from the methyl- donor S-
Adenosyl-L-methionine (SAM) onto the DNA by a class of enzymes called DNA 
methyltransferases. The two most studied base modifications are the addition of a methyl group 
onto the C5-position of cytosine (Hotchkiss, 1948)  and at the N6-position of adenine (Dunn and 
Smith, 1955). 
In the prokaryotes, DNA methylation has historically been associated with DNA restriction-
modification systems thought to be important in protecting cells from foreign DNAs such as 
transposons and viral DNAs. The bacterial genomes contain restriction enzymes that distinguish 
the host 5-methyl-2’-deoxycytidine (5meC) and 6-methyl-adenine (6meA) methylation patterns 
in comparison with that of foreign DNA which then digest the unmodified foreign DNAs (Low et 
al., 2001). DNA adenine methylase (Dam) which mediates the methylation of N-6 adenine in the 
GATC sequence is also functionally involved in other processes in E.coli. They play a role in 
regulating DNA replication as the preferential binding of SeqA protein to hemimethylated GATC 
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sequence near the origin of replication (oriC) delays their methylation, hence resulting in the 
release of sequestrated hemimethylated oriC (Kang et al., 1999). They are also involved in the 
segregation of chromosomal DNA (Meury et al., 1995) and mismatch repair namely the mut 
repair system where MutH binds to hemimethylated DNA and cleaves the non-methylated strand 
(Au et al., 1992).     
In the mammalian genome, the modification of cytosine to 5meC is the predominant modified 
base. It is considered as the only heritable and reprogrammable modification of the genomic 
DNA. 5meC was discovered in vivo more than half a century ago by Rollin Hotchkiss in calf 
thymus DNA (Hotchkiss, 1948). In the mammalian genome, 5meC residues are mainly found in 
the context of CpG dinucleotides with a small proportion also observed in CpA and CpT residues 
(Ramsahoye et al., 2000). About 70% of all CpGs are methylated, but the distribution of 5meC 
or the CpG dinucleotides in the genome is not random (Cooper and Krawczak, 1989). CpG 
dinucleotides though under-represented, can be found in small genomic regions called CpG 
islands which are about one kilo-base in length (Bird et al., 1985). Although a large proportion of 
CpGs are methylated, the CpG islands are usually hypomethylated and associated with actively 
transcribed genes such as acetylated histones (Cross and Bird, 1995).     
Even though DNA methylation might have originated early in evolution, there has been no 
evidence of methylated DNA present in Schizosaccharomyces pombe. This is probably because, 
the DNMT homolg pmt1 in S. pombe has a proline-to-serine substitution in the conserved motif 
IV (Pinarbasi et al., 1996), resulting in a loss of activity (Wilkinson et al., 1995). Only recently 
has there been evidence that methylation of cytosines exist in Drosophila melanogaster where 
5meC was found in the context of non-CpG dinucleotides (CpA, CpT) attributed to dDnmt2 
(Kunert et al., 2003).          
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DNA methylation has a profound effect on expression and stability of the mammalian genome. 
Initial studies demonstrated that in vitro methylation of promoter sequences repressed gene 
activity in transfection studies (Razin and Cedar, 1991). The role of DNA methylation in gene 
silencing was based on the finding that gene specific methylation patterns inversely co-related 
with gene activity, examples for which are the silencing of p16 INK4a , BRCA1 and hMLH1 due 
to hypermethylation (Szyf et al., 2004).  
Some of the other effects of methylation include: transcriptional repression, chromatin structure 
modulation, X chromosome inactivation, genomic imprinting and suppression of foreign and 
parasitic DNA (Baylin and Herman, 2000; Jones and Laird, 1999; Robertson and Wolffe, 2000). 
DNA methylation is also one of the major epigenetic mechanisms in oncogenesis due its ability 
to silencing tumor suppressor genes like p16 (Laird and Jaenisch, 1996).   
 
1.1.2 Mammalian methyltransferases 
In 1975 the first DNA methyltransferase was purified and characterised (Roy and Weissbach, 
1975). It was not until 1988 that the first mammalian DNA (cytosine-5) methyltransferase 
(DNMT) was cloned and found to contain in its C-terminal region ten motifs required for the 
catalytic activities of the bacterial type-II cytosine restriction methyltransferases (Bestor et al., 
1988; Bestor, 1988). 
The mammalian DNA methylation machinery consists of the maintenance and de novo 
methylases encoded by three or more independently encoded DNMTs .The major 
methyltransferase DNMT1 is known to have maintenance methylation activity (Bestor et al., 
1988, Yen et al., 1992). DNMT1 is involved in the maintenance of the methylation pattern 
during DNA replication where, the methylation of the parental strand is faithfully copied onto the 
daughter strand. Two other families of enzymes DNMT3a and DNMT3b, participate in the 
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establishment of de novo methylation pattern (Okano et al., 1999) which refers to the addition of 
a methyl group on a previously unmethylated CpG.  
 
DNMT1 
The maintenance methylase DNMT1 is the most abundant DNA methyltransferase in 
mammalian cells (Robertson et al., 1999). It is has a 10-40 fold preference towards 
hemimethylated DNA in vitro (Flynn et al., 1996; Pradhan et al., 1997; Pradhan et al., 1999) and 
accounts for 90% of DNA methylation in the mammalian genome. DNMT1 is a large protein 
consisting of 1620 amino acids. Its N-terminal ~1100 amino acids constitute the regulatory 




               
 
Fig I. Schematic alignment of human protein sequences with homology to DNMTs. Adapted 
from (Robertson, 2001). The black stripes with the Roman numerals represent the conserved 
motifs of the catalytic domains. pmt1 and dDnmt2 represent the fission yeast and Drosophila 
homologs of DNMT2 respectively.      
 
The two regions are separated by the (KG)5 hinge region closer to the C-terminus (Bestor et al., 
1988). The N-terminal has multiple domains for nuclear localization (Leonhardt et al., 1992), 
replication targeting (Chuang et al., 1997) as well as  DNA and Zn binding (Chuang et al., 1996). 
The expression of DNMT1 protein is cell cycle dependent with the protein and activity highest in 
the S phase (Szyf et al., 1991).  
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DNMT1 has several isoforms, which includes a splice variant known as DNMT1b which 
incorporates an additional 48 nt in the N terminus (See section 3.8.5, Fig71) (Bonfils et al., 2000; 
Hsu et al., 1999). The functional significance of this isoform has not yet been deciphered. 
Another isoform is the oocyte specific DNMT1o lacking the first 118 amino acids from the N-
terminus of DNMT1 (Mertineit et al., 1998). It is synthesized and stored in the oocyte cytoplasm 
and is transported into the eight cell nucleus during pre-implantation development, where it 
maintains DNA methylation patterns on alleles of imprinted genes (Ratnam et al., 2002). 
DNMT1 is known to interact with several key cellular proteins, notable are: proliferative cell 
nuclear antigen (PCNA) (Chuang et al., 1997), HDAC (Fuks et al., 2000b; Rountree et al., 
2000), Rb (Pradhan and Kim, 2002; Robertson et al., 2000), DNMT3a, DNMT3b (Kim et al., 
2002) and MeCP2 (Kimura and Shiota, 2003). 
It was also reported that serine 514 in the murine DNMT1 was targeted for phosphorylation by a 
yet unidentified kinase and that the peptide sequence surrounding the site was conserved between 
human, murine, chicken, sea urchin and frog DNA methyltransferases (Glickman et al., 1997). 
This site is located in a region required for targeting to the replication foci during the S phase of 
the cell cycle (Leonhardt et al., 1992) as well as binding to PCNA (Chuang et al., 1997). Due to 
the conserved nature of the sequence around the site, the function of DNMT1 could be controlled 
by the phosphorylation of serine 514, which would then affect its subcellular localization as well 
as its ability to interact with other proteins.        
Homozygous knockouts of the DNMT1 were embryonic lethal (Li et al., 1992) demonstrating 
the importance of DNMT1. Selective depletion of DNMT1 using either antisense or siRNA 
resulted in lower cellular maintenance methyltransferase activity, global and gene-specific 
demethylation and re-expression of tumour-suppressor genes in human cancer cells (Robert et 
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al., 2003). These results indicate that DNMT1 is crucial for the maintenance of the methylation 
in normal cells.   
 
DNMT2 
This is a relatively small protein of 391 amino acids (Okano et al., 1998b) This enzyme lacks the 
regulatory N-terminal region that is found in DNMT1 and DNMT3 enzymes. DNMT2 
homologues are found in the fission yeast genome (pmt1p), but do not seem to have any 
enzymatic properties as the purified proteins were unable to methylate DNA in vitro (Wilkinson 
et al., 1995). DNMT2 homolog has been found in the Drosophila melanogaster (dDnmt2) where, 
over expression of the protein from an inducible transgene resulted in significant genomic 
methylation at CpT and CpA dinucleotides (Kunert et al., 2003). 
Inactivation of the Dnmt2 gene by targeted deletion of the putative catalytic PPC motif in in 
embryonic stem cells did not affect methylation of the newly integrated retroviral DNA 
indicating DNMT2 was not essential for DNA methylation and development  (Okano et al., 
1998b). However, a recent study suggested that  DNMT2 could be catalytically active in vivo by 
using an antibody-based method which showed that the endogenous DNMT2 stably and 
selectively bound  to genomic DNA containing 5-aza-2'-deoxycytidine (Liu et al., 2003). 
Selective binding to aza-dC containing DNA was indicative of the fact that DNMT2 was 
catalytically active in the cell. It was also shown that the genomes of transgenic flies over 
expressing the dDnmt2 protein became hypermethylated and transient transfection studies in 
combination with sodium bisulphite sequencing demonstrated that dDnmt2 as well as its mouse 
ortholog, mDnmt2, were capable of methylating a co-transfected plasmid DNA (Tang et al., 
2003). 
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Since dDnmt2 is considered as the single DNA methyltransferase responsible for genome 
methylation of the fruit flies, it was recently discovered that they are involved in the longevity of 
Drosophila. The intactness of the gene was required for the maintenance of the normal life span 
and over-expression resulted in prolonging the life span (Lin et al., 2005). Hence, suggesting that 




The de novo methylases DNMT3a and DNMT3b methylate hemimethylated and unmethylated 
DNA at the same rate in vitro (Okano et al., 1998a). The DNMT3 enzyme family is similar to 
DNMT1 but have a slightly smaller N-terminal regulatory region linked to a catalytic C-terminal 
domain. They bind to DNMT1 via their N-terminal region and it is hypothesised that this 
interaction could be a co-operative event during DNA methylation (Fuks et al., 2000b; Rhee et 
al., 2002). DNMT3b knockout mice show embryonic lethality similar to DNMT1, while Dnmt3a 
-/- die 4 weeks after birth (Okano et al., 1999). The knockout studies showed that they blocked 
de novo methylation in ES cells and early embryos, but had no effect on the maintenance of 
imprinted methylation patterns. Unlike DNMT1 the sequence specificity of DNMT3s are not 
limited to CGs; non CGs (CA, CT or CC) have also shown to be methylated (Aoki et al., 2001; 
Gowher and Jeltsch, 2002; Yokochi and Robertson, 2002). A specific function of DNMT3b 
revealed through knockout studies is the maintenance of DNA methylation of satellite repeats 
adjacent to the centromeres. Supportive data for this function comes from the finding that in 
patients with the ICF syndrome who suffer from the centromeric instability of chromosomes 1, 9, 
and 16 associated with abnormal hypomethylation of CpG sites in their pericentromeric satellite 
regions had catalytic domain mutations in DNMT3b (Hansen et al., 1999; Xu et al., 1999).   
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1.1.3 How does methylation suppress transcription? 
 
FigII: Direct (A) and indirect (B) suppression of gene expression by CpG methylation 
TF, transcription factor(s); MBD, methylated CpG binding proteins; green lollipops, methylated 
CpGs.  
 
The repressive signals of DNA methylation can be interpreted in two ways. The methylation of 
DNA directly affects the binding of some transcription factors whose binding sites contain CpGs. 
Examples of these are c-Myc/Myn,AP-2, E2F and ATF/CREB- like proteins binding to cAMP 
responsive elements (Tate and Bird, 1993).  
Alternatively, DNA methylation can act indirectly through transcriptional repressors, such as the 
methylated CpG binding proteins (MBDs). The first of its kind was MeCP2 discovered in 1992 
(Lewis et al., 1992; Meehan et al., 1992). It is a multidomain protein containing the methylated 
DNA binding domain (MBD) which can recognise and interact with methylated CpG and a 
transcriptional repressor domain (TRD) which interacts with other regulatory proteins (Nan et 
al., 1997). The TRD of MeCP2 interacts with mSin3A, a co-repressor that exists in a complex 
with histone deacetylase (HDAC) (Jones et al., 1998; Nan et al., 1998). Independently it has 
been shown that DNMT1 could bind to HDAC1 and 2 (Fuks et al., 2000b; Rountree et al., 2000). 
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The other MBDs, MBD1-4 (Hendrich and Bird, 1998) were discovered as EST clones with 
sequence similarities to the MBD motif of MeCP2. Similar to MeCP2, MBD1 is able to repress 
transcription from methylated promoters which requires both its TRD and MBD motifs (Fujita et 
al., 1999). MBD2 is a component of the MeCP1 histone deacetylase complex in which it was 
shown to recruit the nucleosome remodelling and histone deacetylase NuRD to methylated DNA 
in vitro (Feng and Zhang, 2001).       
Evidence for the mechanistic link between DNA methylation and histone deacetylation was 
demonstrated by treating cells with a combination of DNMT1 inhibitor 5AzadC and histone 
deacetylase inhibitor trichostatin A (TSA). Low doses of 5AzadC resulted in low-level re-
expression and demethylation of hypermethylated genes such as MLH1, p15 and p16INK4a. The 
expression was attenuated with the addition of TSA, but TSA on its own had no effect (Cameron 
et al., 1999). This revealed that DNA methylation and histone deacetylation worked 
synergistically and that DNA methylation played the dominant role. 
Therefore the MBDs provide evidence linking nucleosome remodelling and histone deacetylation 
to methylated gene silencing  (Robertson and Wolffe, 2000). 
 
1.1.4 Imprinting 
Gametic imprinting is a developmental process that leads to parental specific expression or 
repression of autosomal and X-chromosome-linked genes (Ruvinsky, 1999). Imprinted genes are 
differentially expressed depending on their parental origin and this is often reflected by the 
differential methylation pattern on the paternal and maternal chromosomes (Barlow, 1997). Of 
all imprinted genes discovered, it is believed that parental origin specific methylation plays a role 
either in establishing or maintaining the imprint.  
 11
The maintenance of imprinting and X inactivation is dependent on the activity of DNMT1. 
Mutant mice that are deficient in DNA methyltransferase activity led to the transcription of the 
normally imprinted and silenced H19 gene (Li et al., 1993), while ectopic Xist expression, 
induced by DNA hypomethylation in Dnmt mutant embryos, may lead to the inactivation of X-
linked genes (Panning and Jaenisch, 1996).  An oocyte specific isoform of DNMT1 (DNMT1o) 
was also shown to maintain the methylation marks of imprinted genes during cleavage as, the 
transient nuclear localization of Dnmt1o in 8-cell embryos provides maintenance 
methyltransferase activity specifically at imprinted loci (Howell et al., 2001).  
 
1.2 DNA methylation and cancer 
The analysis of the DNA methylation profile, suggests the existence of several differences 
between normal and cancer cells. Both sporadic and hereditary cancers show cytosine 
methylation imbalance with recent studies providing evidence that hereditary cancers mimic the 
DNA methylation patterns observed in sporadic tumours  (Esteller et al., 2001). These patterns 
suggest that methylation of specific subsets of genes may contribute to the development of a 
specific tumour type. Therefore, the DNA methylation profile of a cell type may serve as a 
biological marker with a diagnostic and prognostic value. DNA methylation defects include 
genome-wide hypomethylation and hypermethylation of specific CpG islands. Together, these 







1.2.1 Hypomethylation in cancer  
The first epigenetic abnormality observed in cancer was that of DNA hypomethylation in cancer 
cells. Using Southern blot analysis of DNA digested with methylation sensitive restriction 
enzymes it was found that there was a specific hypomethylation of a number of CpG islands in 
cancer cells with respect to their normal counterparts (Feinberg and Vogelstein, 1983a). 
Examples for which are HRAS (Feinberg and Vogelstein, 1983b) and cMYC (Ghazi et al., 
1992). Similar results were found in malignant neoplasia as compared to normal tissues and 
benign tumours (Gama-Sosa et al., 1983).  
The best characterised cell features associated with hypomethylation are: gene activation, 
chromosomal instability and repetitive elements de-repression (Feinberg and Tycko, 2004).     
Hypomethylation of DNA was shown to lead to gene activation of certain proto-oncogenes. 
Strong support for this include, promoter CpG demethylation in the over expression of cyclin D2 
(Oshimo et al., 2003) and maspin (Akiyama et al., 2003) in gastric carcinoma, MN/CA9 
overexpression in human renal cell carcinoma (Cho et al., 2001) and S100A4 metastasis 
associated gene in colon cancer (Nakamura and Takenaga, 1998)  
Several studies have demonstrated that tumour hypomethylation in cancer is linked to 
chromosomal instability. This is particularly severe in pericentromic satellite sequences and 
several cancers such as Wilms tumour, ovarian and breast cancers which contain frequent 
unbalanced chromosomal translocations (Qu et al., 1999b). A recent study shows that 
hypomethylation on pericentromeric satellite regions may participate in the development and 
progression of urothelial carcinomas by inducing loss of heterozygosity on chromosome 9 
(Nakagawa et al., 2005).  
It has also been observed that hypomethylation of repetitive elements occurs in tumours and the 
degree of hypomethylation correlates with disease progression (Narayan et al., 1998; Qu et al., 
 13
1999a). Hypomethylation of satellite 2 DNA are a characteristic feature of patients with the rare 
recessive genetic disease, ICF.   
Although hypomethylation was the originally identified epigenetic change in some cancers, it 
was overlooked in preference to hypermethylation due to the bias in the experimental design, 
which looked at altered methylation at sites, which were previously unmethylated. This however 
is now undergoing a renaissance.           
 
1.2.2 Hypermethylation in cancer 
The most emphasized alteration of DNA methylation in cancer is the aberrant methylation of 
CpG islands surrounding certain gene promoter regions (Herman and Baylin, 2000). The 
hypermethylation of CpG island promoters may inactivate both alleles of an onco-suppressor 
gene or may act together with the more classical genetic mechanisms such as point mutations or 
deletions.  
Aberrant CpG island methylation has been shown to be involved in the silencing of the 
retinoblastoma (pRb) gene (Stirzaker et al., 1997) in familial cases of retinoblastoma as well as 
the von Hippel Lindau (VHL) gene (Herman et al., 1994) in renal cancer. The cyclin dependent 
kinases such as p16 INK4a are also thought to be silenced in a large number of human cancer cell 
lines and primary tumours by an epigenetic pathway that correlates with CpG hypermethylation 
of their gene promoters (Gonzalez-Zulueta et al., 1995; Herman et al., 1995; Little and 
Wainwright, 1995; Merlo et al., 1995). Cell lines with hypermethylated p16 INK4a were subjected 
to treatment with DNMT1 inhibiting drug 5AzadC, the transcription of as p16 INK4a was restored 
in all cases (Herman et al., 1995; Merlo et al., 1995) thus providing a direct link of 
hypermethylation involved in its gene silencing.   
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Thus, the role of DNA methylation in cancer is as an example of epigenetic deregulation, with 
both hypo and hypermethylation having significant roles in tumorigenesis. They confer a 
selective advantage upon cancer cells by targeting different sets of genes with opposing roles in 
cellular transformation. 
 
1.2.3 Loss of imprinting  
Loss of imprinting (LOI) implies biallelic expression or the loss of expression of genes that are 
usually expressed in monoallelically in a parent-specific manner. Defects arising due to LOI are 
seen in cases like Wilms’ tumor and Beckwith-Weidemann syndrome, in which,  two active 
parental alleles of the imprinted growth factor IGF-II are retained and hence over-expressed 
while the two alleles of the tumour suppressor H19 are inactivated (Henry et al., 1991; Taniguchi 
et al., 1995). Other examples are due to embryonic loss of hetrozygosity that retains either the 
paternal alleles leading to Angelman syndrome or the maternal alleles causing Prader-Willi 
syndrome (Shemer et al., 2000).  
 
 
1.2.4 Role of DNMT1 in oncogenesis 
There is considerable evidence indicating an up regulation of DNMT1 in cancer (Baylin and 
Herman, 2000; Belinsky et al., 1996; Szyf, 2003). Forced over-expression of murine DNMT1 in 
NIH3T3 cells resulted in cellular transformation (Wu et al., 1993b). In human fibroblasts, 
sustained over-expression of DNMT1 resulted in a 1- to 50-fold increase in the level of DNMT1 
protein and enzyme activity compared with that of the parental cell line. This lead to 
hypermethylation of a number of CpG islands in HIC-1, estrogen receptor (ER), α-globin locus 
(HBA), E-cadherin (E-CAD) and somatostatin genes (SST) (Vertino et al., 1996). Conversely 
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there are studies showing that the reduction of DNMT1 levels have a protective effect. Mice 
predisposed to colonic polyp formation (Min mice) develop fewer polyps in a  DNMT1 
hetrozygous background (Laird and Jaenisch, 1996). Reduction of DNMT1 using antisense 
technology has also been shown to block tumourigenesis (MacLeod and Szyf, 1995; 
Ramchandani et al., 1997; Szyf, 2002). Since expression of DNMT1 is crucial to the cells, de-
regulation of the protein levels could have deleterious effects leading to oncogenesis.      
 
1.2.5 DNMT1- depleting agents 
5-azacytidine (5AzaC) and 5-aza-2’-deoxycytidine (5AzadC, Decitabine) are two well-known 
inhibitors of DNMT1. Their incorporation into the DNA leads to a rapid loss of DNMT1 as it 
becomes irreversibly bound to the incorporated azacytidine residue (Christman et al., 1983) 
resulting in significant demethylation after repeated replications (Santini et al., 2001). 
 Treatment with decitabine has been shown to cause demethylation in both cells lines and ex vivo 
cells from human patients with leukaemia (Wilson et al., 1983). Furthermore, decitabine was 
shown to induce re-expression of p16INK4a in the bladder tumour cell line T24 as well as the 
colon tumour cell lines HCT15 and HCT116 (Bender et al., 1998). Effect of decitabine was also 
observed in the re-expression of hMLH1 in colorectal cancer cell lines (Deng et al., 1999). With 
its potential to act as a chemotherapeutic drug, decitabine have been involved in various phase I 
and phase II clinical trials. In summary, decitabine has shown single-agent efficacy in acute 
leukaemia and modest activity in progressing chronic myelogenous leukaemia (CML) (Goffin 
and Eisenhauer, 2002). 
Sulphonate derived methylating agents such as MMS and DMS have also shown to be potent 
inhibitors of DNMT1 (Chuang et al., 2002). The mechanism behind the specific depletion of 
DNMT1 by these agents seems to be elusive as there were no significant changes in the levels of 
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other proteins. An interesting observation was that this depletion was independent of p53 as it 
was observed in cells with wild type, mutated or inactivated p53 (Chuang et al., 2002).   
Zebularine is another cytidine analog originally synthesised as a cytidine deaminase inhibitor 
(Driscoll et al., 1991) but functions efficiently as a DNA methylation inhibitor (Yoo et al., 2004). 
Compared to its cytidine homologs 5AzaC and 5AzadC, it has a much higher half-life.   
Orally administered zebularine was shown to cause demethylation and reactivation of the 
silenced p16INK4a gene in human bladder cells grown in nude mice(Cheng et al., 2003). Another 
crucial property of the drug is its preference for tumour cells relative to normal fibroblasts 




          Cytidine                  5-azacytidine         5-aza-2’-deoxycytidine       Zebularine            
       (Decitabine) 
 
Fig III: Chemical structure of cytidine and its analogues  
 
Other novel agents of demethylation that are potentially useful are DNMT1 antisense 
oligodeoxynucleotide (MG98) and small interference RNA (SiRNA). MG98 hybridises to the 
DNMT1 mRNA sequence and causes it degradation, treatment with which resulted in the 
demethylation and re-expression of p16INK4a in bladder and colon cancer cell lines   (Goffin and 
Eisenhauer, 2002). RNA interference to specifically down-regulate DNMT1 protein expression 
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was used in NCI-H1299 lung cancer and HCC1954 breast cancer cells. Inhibition of DNMT1 
protein expression resulted in reduction of promoter methylation and re-expression of p16INK4a, 
CDH1, RASSF1A, and SEMA3B in NCI-H1299; and p16INK4a, RASSF1A, and HPP1 in 
HCC1954 (Suzuki et al., 2004a).           
 
1.3 Relationship of DNMT1 with DNA replication 
 
1.3.1 Expression of DNMT1 during S phase 
With the critical role that DNMT1 plays in the normal cell, expression of the protein should be a 
tightly linked with the cell cycle progression. Expression of DNMT1 mRNA varies in a cell 
cycle-dependent manner. It has been shown to be at its maximum during S phase. The steady 
state levels of DNMT1 mRNA were determined using northern blot assays of RNA purified from 
growth-induced Balb/c 3T3 cells  (Szyf et al., 1991). In a recent study through analysis of RNA 
from quiescent and serum-stimulated NIH 3T3 cells, revealed a strong induction of  DNMT1 
transcript which started to accumulate at 9 h after serum stimulation (lateG1/early S phase) and 
reached maximum levels at 20 h (S phase) (Kimura et al., 2003).  Kimura et al went on to show 
that there were two major cis-elements in the promoter region of mouse DNMT1 that controlled 
the transcriptional levels during the cell cycle. One of them was controlled by a yet unknown 
transcription factor (binding to site A) whereas the other cis-element was regulated in a cell cycle 
dependent manner by the E2F transcription factor. E2F binding was shown to regulate 
transcriptional activity of DNMT1 both positively and negatively.  
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At G0/G1 phase, binding of E2F to the E2F binding site can interact with Rb which in-turn 
recruits HDAC to the complex, resulting in the repression of transcription of Dnmt1. During this 
time, a transcription factor bound to site A (TFBA) maintains low-level transcription of Dnmt1. 
At G1/S phase transition, the E2F mediated inhibition of Dnmt1 is released and E2F along with 
TFBA work co-operatively to increase the expression levels.   
The coordination of the two regulatory sites controls the basal and functional activation of 
Dnmt1 promoter in proliferating cells (Chuang et al., 2002; Kimura et al., 2003).  
 
1.3.2 DNMT1 binding to DNA 
 
DNMT1’s ability to bind DNA has been shown to be present in three distinct domains. The DNA 
recognition domain was shown to be present at aa 122-417  of the N-terminal of DNMT1 
(Araujo et al., 2001). But this was contradictory to reports suggesting that DNMT1s specificity 
towards hemimethylated CpGs was found at the catalytic domain in the C-terminus of the 
enzyme (Fatemi et al., 2001). Studies from Chuang et al (Chuang et al., 1996) had also showed 
the presence of a DNA binding domain at aa 323-336 at the N-terminal (DB1). Therefore, the 
presence of different DNA binding domains could have functional significance perhaps at 
different stages of the cell cycle. 
 Targeting of DNMT1 to the early and late replication foci is attributed to two domains (Chuang 
et al., 1997; Kimura et al., 2003; Leonhardt et al., 1992; Liu et al., 1998b). The early foci 
targeting domain (aa 122-207) binds directly to PCNA, which serves as a sliding clamp for the 
polymerase delta (Chuang et al., 1997). This interaction can be disrupted by p21Waf1/Cip1. 
DNMT1 and p21Waf1/Cip1 share significant homology in their PCNA binding domain and hence 
compete for its binding.   
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 1.4 Role of PCNA in replication  
Proliferating cell nuclear antigen (PCNA) was originally discovered as an auto antigen in 
patients suffering from Lupus Erythematosus (Miyachi et al., 1978). Its name is derived from the 
fact that it is a nuclear protein in proliferating cells of eukaryotic organisms. It is a highly acidic 
29-32kD protein encoded by a single gene. The human protein has 36% homology to yeast; 65% 
with plants and 70% with D. melanogaster (Jonsson and Hubscher, 1997).   
During DNA replication, DNA polymerase I complex with PCNA moves progressively along the 
template while adding nucleotides to the growing chain. These sliding clamp complexes enable 
the succession of polymerization steps without release of the enzyme from the template (Bruck 
and O'Donnell, 2001). Thus long stretches of DNA can be synthesized without pausing. This 
mechanism is known as processive replication mediated by PCNA.     
In the mammalian system, PCNA is the processivity factor of DNA polymerase δ and 
polymeraseε, and therefore it is crucial for DNA replication. The prokaryotic counterpart of 
PCNA is the beta subunit of DNA pol III holoenzyme found in E.coli (Kuriyan and O'Donnell, 
1993). 
 
1.4.1 Structure of PCNA  
The beta subunit of DNA polymerase III in E. coli was first crystallized by Kong et al (Kong et 
al., 1992). It was shown to be a ring structure consisting of two monomeric molecules linked by 
12 alpha helices that could clamp the duplex DNA. The structure was highly symmetrical, with 
each monomer containing three domains of identical topology. Later the crystal structure of the 
eukaryotic PCNA from S. cerevisiae revealed a trimeric closed circular ring, with a 3 fold axis of 
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symmetry. Internal symmetry in each monomer of PCNA leads to a hexagonal symmetry in the 
trimer (Krishna et al., 1994). Although the polymerase beta subunit and PCNA share a low level 
of amino acid sequence identity, they form nearly identical six-fold symmetrical ring structures 
even though the beta polymerase is a dimer (Kong et al., 1992). In both cases, the outer shell of 
the ring is composed of a series of anti-parallel β strands and the central cavity is lined with 
twelve α helices. 
 
1.4.2 Interactions with other proteins 
 
Replication factor-C (RFC) 
RFC is a complex of five subunits of 145,40,38,37 and 36 kD proteins which are essential for its 
activity in DNA replication (Cai et al., 1996; Ellison and Stillman, 1998; Podust and Fanning, 
1997). It functions as a clamp loader and unloader for PCNA onto the DNA during DNA 
replication in an ATP dependent manner (Yao et al., 1996). 
PCNA was shown to interact directly with p145, p40, p38 and p36 (Uhlmann et al., 1997) 
subunits of RFC. The PCNA binding region of the p145 subunit of RFC has been localized to 
residues 481-728 (Fotedar et al., 1996). This region has sequence similarities with that of the 
remaining three sub-units which also interacts directly with PCNA, perhaps similar to p145.  
PCNA and RFC interaction is an essential component of the DNA replication machinery. 
 
Cyclins and cyclin/cdk complexes 
PCNA is found to interact with several pairs of cyclins/cdks; including cyclin D/cdk4, 
cyclinE/cdk2, cyclinA/cdk2 and cyclinB/cdc2 that control the entry points of G1, S, G2 and the 
G2/M boundary of the cell cycle (Kelman and Hurwitz, 1998; Prosperi, 1997). PCNA has also 
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been found in complexes with cyclin kinase inhibitor p21Waf1/Cip1 (Ball and Lane, 1996), which is 
an inducer of G1 arrest (Waldman et al., 1995). This effect seems to involve direct competition 
between p21Waf1/Cip1 and the polymerase for PCNA since p21Waf1/Cip1 does not inhibit the tracking 
of PCNA along DNA nor dissociate PCNA trimers that have already been loaded onto the DNA 
(Podust et al., 1995). Thus p21Waf1/Cip1 may be involved in the inhibition of initiation of a new 
round of DNA replication by blocking the entry into S-phase. Recent structural studies using a 
20-mer peptide sequence from p21Waf1/Cip1 showed that it can be associated simultaneously with 
PCNA and CDK/cyclin complexes. The quaternary complex shows little direct interaction 




DNMT1 was shown to co-localize to the replication foci during the S phase of the cell cycle 
where it methylates the newly replicated hemi-methylated DNA. A region within the amino-
terminal of DNMT1 was shown to interact with PCNA directly (Chuang et al., 1997) in early S 
phase. Interestingly, p21Waf1/Cip1, which shares similar PCNA binding sequence, has an inhibitory 











1.5 Role of Heat shock protein 70 (Hsp70) in DNA replication 
Another family of proteins associated with DNA replication are the heat shock proteins (Hsp70). 
Heat shock proteins were first identified as inducible proteins in cells subjected to elevated 
temperatures above the physiological levels. Hsp70 is the most abundant heat shock protein, 
which is very well conserved in organisms as distantly related as bacteria (DnaK) and man (Hunt 
and Morimoto, 1985). Hsp70 is a member of a multi-gene family first identified in 
D.melanogaster (Mirault et al., 1979). Later several homologs were identified which were not 
induced by an increase in temperature or stress but were expressed during the normal 
development of the fly (Ingolia and Craig, 1982; Craig et al., 1983). These were called the heat 
shock cognate genes Hsc70 as their products were also 70kD in size. They were, however, 
particularly abundant in embryos and ovaries. DnaK from the bacterial system is a member of the 
same Hsc70 family of chaperones. 
In E.coli a mutant DnaK (dnak111) was found to be conditionally defective in the initiation of 
DNA replication. These cells were unable to initiate a new round of replication at high 
temperatures after the termination of the previous round (Sakakibara, 1988). DnaK along with 
DnaJ also plays a part in the initiation of bacteriophage lambda DNA. They function together in 
an ATP dependent manner to release lambda P protein from the preprimosomal complex 
consisting of lambda origin of replication-lambda O-lambda, P and DnaB protein (Liberek et al., 
1988). Even in small circular DNA, the plasmid p1, DnaK is involved in its DNA replication. It 
renders the plasmid P1 initiator RepA protein 100 fold more active for binding to the P1 origin of 
replication by dissociating the RepA dimers (Wickner et al., 1991). In the transformed human 
cell line HeLa, it was shown that the expression of the Hsp70 gene was tightly regulated during 
the cell cycle and the level of Hsp70 mRNA rapidly increase 10-15 fold upon entry into S phase 
and declines by late S to G2 (Milarski and Morimoto, 1986). In subcellular localization, Hsp70 is 
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diffused throughout G1 and G2 and becomes localized during S phase (Milarski and Morimoto, 
1986). Together these observations suggested that Hsp70 could have an active role in DNA 
replication through the activation of accessory replication factors. 
Hsp70 also plays an essential role under normal physiological conditions. This includes assisting 
the folding and translocation of proteins across the mitochondrial membrane (Schneider et al., 
1994), disassembling oligomeric protein structures (Freeman and Yamamoto, 2002), facilitating 
proteolytic degradation of unstable proteins (Stuart et al., 1994) and in some cases control the 
biological activity of folded regulatory proteins, such as transcription factors (Bukau and 
Horwich, 1998; Hartl, 1996). They are also involved in many house keeping functions including 
signal transduction and regulation of cell cycle and cell death (Beere and Green, 2001).  
 
1.5.1 Structure and sequence of Hsc70 
 
The first complete genomic sequence for the heat shock cognate gene Hsc70 was discovered by 
Dworniczak and Mirault (Dworniczak and Mirault, 1987). Its sequence is split by 8 introns and 
encodes a protein of which, 81% is homologous to Hsp70.  
The cDNA codes for a protein of 647 amino acid residues. All Hsc70 family members have a 
highly conserved domain structure. This consisting of a large amino terminal ATPase domain of 
44kD whose crystal structure showed that it was nearly identical in shape to that of its E.coli 
homolog DnaK (Flaherty et al., 1990). The carboxy terminal region of 25kD is divided into a 
front 15kD conserved substrate binding domain (Zhu et al., 1996) and a back 10kD end that is 






























Fig V: Schematic diagram of the different functional domains present in Heat shock 
protein (Hsc70). The aa 1-355 constitute the conserved ATPase domain, aa355-540 the substrate 
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1.5.2 Reaction cycle of Hsc70 
               
Fig VII: Model of the interaction of the Hsp70 chaperones with substrates. Hsp70 protein is 
illustrated with its two major domains, the ATPase domain (dark blue) and the substrate binding 
domain (light blue) with the alpha-helical lid of the substrate binding domain shown in green. 
The binding of a new polypeptide to the ATPase state of Hsp70 results in a weak interaction with 
an open conformation of the alpha-helical lid. Hsp40 binds to the ATPase domain, hydrolyzing 
the ATP which allows for the conformational change of the lid into a closed conformation 
leading to a high affinity state. The substrate is released upon nucleotide exchange. (Modified 
adaptation from (Rassow et al., 1997a))         
 
The Hsp70s are a family of highly conserved ATPases, their prokaryotic homolog is DnaK. The 
amino terminal domain of Hsp70 therefore, binds to ATP and the subsequent ATP hydrolysis is 
used to drive conformational changes in the C-terminal substrate binding domain which operates 
largely through a β-structured domain. Structural analysis of the bacterial homolog DnaK has 
shown that the peptide binding domain contains an alpha-helical lid whereby its open and closed 
conformation depends on the ATP and ADP states of the protein  respectively (Mayer et al., 
2000).    
ATP binding to the ATPase domain of Hsp70 proteins decreases the affinity of the substrate 
binding domain for substrates by 5 to 85 fold. This decrease in affinity is due to an increase in 
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the dissociation rate of Hsp70 substrate complexes by two to three fold (Mayer et al., 2000). 
Thus Hsp70 chaperones alternate between an ATP state in which the substrate binding pocket is 
open but has a low affinity and high exchange rate for substrates and the ADP state in which the 
binding pocket is closed and has a high affinity as well as low exchange rates thus trapping the 
substrates. 
The ATP hydrolysis is generally very slow and is activated by DnaJ proteins like Hsp40 by about 
ten fold and in the presence of substrates by about two to ten fold. The simultaneous interaction 
of Hsp70s with the DnaJ proteins and the substrate stimulates the ATPase activity up to several 
thousand folds (Laufen et al., 1999). The ATP hydrolyses step is considered as rate limiting for 
binding as the ATP state has a low affinity for binding the substrate and requires the hydrolysis 
to ADP for a strong interaction. The nucleotide exchange is considered rate limiting for substrate 
release.   
For some prokaryotic and mitochondrial Hsp70, the nucleotide exchange factor is GrpE and 
promotes the release of ADP from the ATPase domain. Subsequently, a new ATP molecule 
binds to the ATPase domain of Hsp70, thus releasing the "modified" peptide substrate and 
allowing a new peptide to bind (Zhu et al., 1996). In the case of mammalian cytosolic Hsc70 this 
role is played by the BAG-1 protein (Alberti et al., 2003; Sondermann et al., 2001). 
Hsc70 proteins are generally cytosolic in nature. A basic domain (aa 246-262) of Hsc70 acts as a 
nuclear localization signal and promotes nuclear import. However, inactivation of this signal had 
no effect on the nuclear import suggesting an alternative mechanism different from classical 
nuclear localization signal may also play a role in the nuclear import pathway (Lamian et al., 
1996). To determine the expression and the nuclear translocation of the constitutive Hsc70, rat 
astrocytomic C6 glioma cells were synchronized and released from serum starvation. Maximal 
cellular Hsc70 content was observed in early to mid S phase followed by a drastic decline while 
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cells pass through G2/M. Analysis of the nuclear and cytoplasmic protein fractions showed a 
significant increase of Hsc70 translocation into the nucleus during early S phase. Whereas, there 
was no detection of the inducible Hsp70 protein in either asynchronously proliferating, serum-
starved or in serum-stimulated C6 cells (Zeise et al., 1998). This suggested a role for Hsc70 but 
not for Hsp70 in the process of S phase entry under physiological conditions.  
The subcellular localization of Hsp70 is dependent on the type of stress experienced by the cells. 
Heat shock is known to induce a rapid translocation of Hsp70 into the nucleus, a similar effect is 
observed with oxidative stress but not with apoptosis (Dastoor and Dreyer, 2000).     
  
1.6 Role of DNA methylation in virus related carcinogenesis 
A number of virus infections have been associated with cancer. Among these are Epstein –Barr 
virus (EBV) associated with Burkitt’s lymphoma, Hodgkin’s disease and  nasopharyngeal 
carcinoma (Brooks et al., 1992; Deacon et al., 1993; Tao et al., 1998). Human papilloma virus 
(HPV) with cervical carcinoma (Schiffman and Brinton, 1995; zur, 1996a), Hepatitis B virus 
(HBV) and hepatitis C virus (HCV) with hepatocelluar carcinoma, human T cell leukemia virus 
(HTLV-1) with adult T cell leukaemia, simian virus (SV40) with malignant mesothelioma (MM) 
(Gazdar and Carbone, 2003)  are just a few examples. Apart from the viruses alone, it has been 
demonstrated that methylation can play a role in the development of malignancies associated 
with these infectious agents. 
 
1.6.1 EBV 
EBV has been the most studied virus with respect to regulation of its genes by methylation. It has 
been associated with Burkitt’s lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma and 
infectious mononucleosis (Young and Rickinson, 2004). It achieves immune evasion in healthy 
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lymphocytes and in tumours by suppression of its viral antigens through methylation of its 
promoters (Klein, 1994). The EBV genome exists in the host in the linear (lytic phase) or as a 
circular episomal form (Latent phase). Three promoters Cp, Wp and LANA1 (latency associated 
nuclear antigen 1) are responsible in maintaining the virus in the latent phase, abnormal 
activation of which leads to the lytic phase. The Cp promoter is known to be methylated and 
hence silenced in Burkitt's lymphoma (BL) cell lines (Minarovits et al., 1994). This could be re-
activated by 5-azacytidine to produce Cp derived antigens (Masucci et al., 1989; Robertson et 
al., 1995). In lymphoblastoid cell lines (LCLs) and nasopharyngeal carcinoma (NPC) cells, 
transcripts for latent membrane protein 1 (LMP1) are initiated from LMP1p, a promoter 
regulated by CpG methylation (Salamon et al., 2001). LMPlp is silent in BL cell lines but can be 
activated by demethylating agents (Li and Minarovits, 2003). This provides a link between the 
role of methylation and EBV functioning. Therefore, methylation plays a crucial part in the 
promoter activity in each case of the EBV latency-associated promoters.  
 
1.6.2 HBV  
Animal models have been developed to study the link between methylation and development of 
hepatocarcinogenesis due to HBV. Methylation of HBV DNA was observed in 14p3HB 
transgenic mice, with three tandem copies of the HBV DNA, which co-related with the absence 
of viral protein production. Treatment with 5AzaC lead to the detection of HBV surface antigen 
(HbsAg)  in mice which were three weeks old (Araki et al., 1989). In the human hepatoblastoma-
derived cell line HB 611, HBV DNA integrated into the cellular genome was found to be 
hypermethylated. Treatment with 5AzaC for 3 days, resulted in the hypomethylation of the 
integrated HBV DNA as observed from the Southern blot analysis of DNA digested with 
methylation sensitive restriction enzymes HpaII or MspI, thus leading to an increased expression 
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of HbsAg (Miyoshi et al., 1992). Therefore, the repression of the HBV DNA could be alleviated 
by inhibiting the DNA methylation machinery. This suggested a crucial role of DNA methylation 
in the expression of HBV genes.        
  
1.6.3 Human immunodeficiency virus (HIV) 
In HIV, there is an indirect effect of methylation where there is an increased expression of 
DNMT1 when CD4+ cells are infected with the virus. This in turn resulted in the 
hypermethylation of genes like gamma interferon (Fang et al., 2001). The LTR region of HIV-1 
contains three Sp1 sites, which are methylated in HIV infected cells. Binding of HIV-1 
methylation binding protein 2 (HMBP-2) to this region occurs when only one of the Sp1 sites is 
methylated while HMBP-1 binds with enhanced affinity when all three sites are methylated 
(Shao, 1997) This indicates the ability of methylation to determine the binding specificity of 
cellular proteins such as HMBP-1 and 2 to specific virus sequences. The binding characteristics 
suggest that HMBP-1 and 2 may recognize newly replicated DNA and thereby play a role in 
differentiation. If HMBP is able to compete with Sp1 sites in vivo and repress transcription, it 
may play a role in HIV latency.      
 
1.6.4 SV40 
Methylation of the SV40 DNA in itself has not been reported, hence the expression of its own 
genes are not under the regulation of the DNMTs. Yet DNA methylation is known to play a 
causal role in cellular transformation induced by SV40 T antigen. T antigen expression in 
immortalized but non-transformed Balb/c 3T3 cells resulted in the elevation of DNMT1 mRNA, 
protein levels, and global genomic DNA methylation as determined by a nearest neighbour 
analysis (Slack et al., 1999). In malignant mesothelioma (MM) the SV40 induced transformation 
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of normal mesothelial cells was associated with the progressive methylation of the tumour 
suppressor gene, RASSF1A (Toyooka et al., 2002). Further investigation showed that 
frequencies of TSGs (HPP1, RASSF1A, Cyclin D2 , RRAD) methylation was higher in SV40 
positive MMs than in SV40 negative ones (Suzuki et al., 2004b). These results suggest that SV40 
uses the DNA methylation machinery as a downstream effector in the induction of cellular 
transformation.  
     
 1.6.5 HPV 
 It was shown about 20 years ago that HPV-1 and cotton tail rabbit papilloma  were methylated 
using methylation-sensitive restriction endonucleases HhaI, MspI and HpaII (Burnett and 
Sleeman, 1984; Wettstein and Stevens, 1983). In-vitro methylated HPV-16 genomes were found 
to be transcriptionally incompetent after transfection into culture cells (Rosl et al., 1993). In the 
same study using a restriction enzyme accessibility assay on both the DNA and chromatin levels, 
it could be demonstrated that, in vivo, extensively methylated viral DNA was nucleosomally 
organized. These data suggested that DNA methylation was an important regulatory pathway in 
the modulation of HPV expression and as a consequence the proliferation rate of virus-infected 
cells.    
With the life cycle of HPVs closely tied with the differentiation state of the stratified squamous 
epithelia, Kim et al. found that in highly differentiated cells from HPV-16 patients, the long 
control region (LCR) was hypomethylated. In contrast, HPV16 LCR from poorly differentiated, 
basal cells contained multiple methylated cytosines (Kim et al., 2003b). The same study also 




1.7 Human Papilloma Virus (HPV) 
1.7.1 Classification  
Over 100 types of Human papilloma viruses have been identified and they infect either cutaneous 
or squamous epithelia (Chan et al., 1995; Villa, 1997). They are broadly classified into low risk 
HPV types which include 6, 11,42,43,44 causing genital and laryngeal warts as well as non-
malignant lesions. The high risk HPVs of which there are about 20 but most prominently include 
16,18,31 causing neoplastic lesions that progress to invasive cancer (zur Hausen H., 1996). Over 
90% of cervical malignancies contain the high risk HPVs most common among them being 
HPV-16. 
 
1.7.2 Cervical Cancer 
World wide about 500,000 new cases of invasive cancer of the cervix are diagnosed each year of 
which close to 300,000 proves to be fatal. In developing countries, cancer of the cervix is the 
most frequent female malignancy and constitutes about 24% of all cancers in women (WHO 
regional statistics). Nearly all cervical cancers originate in the ‘transformation zone’, which is 
located at the end of the cervix. The cells of the transformation zone are particularly susceptible 
to carcinogens.  
Invasive cancer is preceded by progressive stages of lesions classified as cervical intraepithelial 
neoplasia (CIN) 1, 2 and 3. The severity of the lesions are graded by the extent to which the 
normally differentiating, non-mitotic suprabasal cells of the cervical epithelium are replaced by 
the non-differentiating and mitotically active basal like cells. The evidence linking high risk 
HPVs with cervical carcinoma has been derived from many studies wherein almost all of them 
test positive for HPVs with HPV-16 being detected in 60% of all cases (Bosch et al., 1995; 
Lorincz et al., 1992; Munoz et al., 1994).         
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1.7.3 Genome organization  
Papilloma viruses are from the Papovaviridae family. They are DNA tumour viruses 
characterized by a double stranded circular DNA genome of 7800 to 7900 base pairs. They have 
a non enveloped icosahedral capsid of  72 capsomeres that measure about 45-55 nm in diameter 
(Baker et al., 1991). The viral genome is organised into three main regions: two proteins 
encoding regions the early and late genes and a non-coding upstream regulatory region.  
                       
Fig VIII: Circular genomic map of HPV-16.  
The genome organization with relative location of the HPV-16 genes. 
 
The genome has eight ORFs (open reading frames) encoding six early genes (E1, E2, E3, E4, E5, 
E6 and E7) and two late genes (L1 and L2). The upstream regulatory region (URR) or long 
control region (LCR) is located between the L1 and E6 ORFs. The size and location of the genes 
as well as the functions of the proteins are conserved among all the papilloma viruses 





















1.7.4 Early proteins 
 
E1 protein 
E1 protein is mainly involved in the replication of the virus by binding to the origin of replication 
(ori) in the 3’ end of the LCR (Ustav et al., 1991). It is shown to possess ATP dependent helicase 
activity (Yang et al., 1993). In its episomal form, the replication of the genome require the E2 
protein along with E1 (Ustav et al., 1991), though in vitro it was shown that E1 alone is sufficient 
to support ori replication (Yang et al., 1991). E1 interacts with the p180 subunit of the cellular 
polymerase alpha primase and thus possibly recruits the cellular DNA replication machinery to 
the viral ori (Park et al., 1994) in initiating DNA replication.  
 
E2 protein 
E2 is a 45 kD protein consisting of an N-terminal region of about 200 amino acid containing an 
activation domain, a hinge region and a C-terminal DNA binding domain of about 70 amino 
acids. E2 proteins exist as dimers and bind specifically to ACCN6GGT known as E2 binding 
sites (E2BS), first discovered in BPV (Androphy et al., 1987; Moskaluk and Bastia, 1988). E2 
functions as a regulator of replication by binding to the E1 protein and recruiting it to the LCR 
ori as E1 on its own does not have sequence specificity. In BPV-1 binding of E2 to its binding 
sites in the LCR region was found to be a strong transcriptional activator (Haugen et al., 1987). 
However, in HPVs it was found to play a major role in repression of transcription from the p97 
promoter rather than activation as will be discussed further. 
The LCR and promoter region of HPVs contains four E2BS. In HPV-16, they are found at 
positions 7453-7464, 7860-7871(LCR region), and 35-46 and 50-61 (promoter region) (Fig IX). 
E2 binding to the distal E2BS in the LCR region is know to be a activator of the p97 promoter in 
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co-operation with cellular transcription factors (Haugen et al., 1987; Ushikai et al., 1994). The 
promoter activity is controlled by transcription factors such as Sp1 and TFIID that bind to the 
TATA box resulting in maximal activity (Gloss and Bernard, 1990). E2 protein acts as an 
inhibitor by binding to the E2BS which displaces Sp1 whose binding sites coincide with that of 
E2 in the promoter region (Fig IX), thus down-regulating the p97 promoter. At higher E2 
concentration, it not only displaces Sp1 but also TFIID, leading to effective shut down of the 
promoter. Binding of E2 to its binding sites is controlled by the methylation status of the CpGs 
wherein E2 is unable to bind if they are methylated (Kim et al., 2003b).  
IN HPV-31 there exists E8-E2 splice variant that lacks the transcription activation domain and 
acts as a super-repressor (Stubenrauch et al., 2000; Stubenrauch et al., 2001).  
The expression levels of E2 could keep the virus in the latent episomal form rather than making 
them aggressive infectious agents geared to damage or kill the hosts’ cells with the over-
expression of the E6 and E7 onco-proteins. 
In malignant lesions, HPV-16 genomes are normally integrated leading to the disruption of the 
E2 gene (Daniel et al., 1995). This causes a de-regulation of the p97 promoter contributing to a 
more aggressive cancer phenotype, whose carcinogenicity could be reduced by transfection of 
the E2 protein (Francis et al., 2000). 
 
E4 protein 
E4 is considered as an early gene, yet it is generally expressed in parallel with late genes. It is not 
known to have any transforming properties, though it is known to destabilize intermediate 
filament (cytokeratin) networks thus facilitating the release of virons (Doorbar et al., 1991). The 
E4 ORF is translated from spliced transcripts as a fusion with the first 5 amino acids of E1 to 
generate E1^E4 fusion proteins. The E4 ORF lacks an initiator AUG codon and uses the E1 
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sequence for translation initiation. High-risk HPV E4 proteins may also play a role in regulating 
gene expression, since they interact with an RNA helicase, E4-DBD, which is a member of a 
helicase family involved in mRNA splicing, transport as well as initiation of translation (Doorbar 
et al., 2000).    
 
E5 protein 
E5 in HPV-6 interacts with membrane receptors such as epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF). This interaction could function in stimulating cell 
proliferation in HPV infected cells (Conrad et al., 1994).                             
In HPV-16 it was shown that E5 could activate epidermal growth factor receptor (EGFR) leading 
to a reduced downregulation of EGFR receptors. The activation of EGFR could then initiate the 
over-expression of a variety of proto-oncogenes and stimulate rapid cell growth (Tsai and Chen, 
2003). E5 was shown to inhibit the expression of tumour suppressor gene p21WafI/CipI in NIH3T3 
cells and human keratinocytes. The suppression was at a transcriptional level as it inhibited the 
p21Waf1/Cip1 promoter (Tsao et al., 1996). This could be one of the mechanisms with which E5 
could impair the control of cell cycle checkpoint and assist in cell proliferation. 
 
E6 protein 
E6 is a small protein of 151 amino acids which contains 2 putative zinc binding motifs (Barbosa 
et al., 1989). E6 has been found to possess transforming activity in a variety of assay systems. 
Although E6 alone has slightly weak transforming efficiency, they co-operate with the ras 
oncogene in transforming primary rodent cells (Liu et al., 1994). E6 along with E7 has been 
shown to immortalise primary human keratinocytes, which are the natural host cells of the virus 
(Munger et al., 1989).  
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E6 has many known interacting partners, of which the most studied and well know is the tumour 
suppressor protein p53 (Werness et al., 1990). Binding of E6 leads to degradation of  p53 
through a ubiquitin-dependent proteolytic pathway (Scheffner et al., 1990). As a result the p53 
levels are low in cells expressing HPV-16 or 18 E6 (Scheffner et al., 1991). The degradation of 
p53 is mediated by a cellular protein known as E6 associated protein (E6-AP) which is a 
ubiquitin ligase (Scheffner et al., 1993). This would then result in the de-regulation of the p53 
induced growth arrest and apoptosis in response to DNA damage. Compared with the E6 protein 
of low risk HPVs (6 and 11), the protein encoded by high risk HPVs (16 and 18) have a higher 
affinity for p53 which leads to an accelerated degradation of p53 (Crook et al., 1991).  
E6 proteins are also known to target and abrogate the function of the apoptosis signalling protein 
Bak in response to Ultraviolet B damage in the skin by promoting its proteolytic degradation 
both in vitro and in regenerated epithelium (Jackson et al., 2000). This leads to a resistance to 
apoptosis as well as chromosomal instability. The blockage of apoptotic signalling is also 
brought about by its ability to inhibit the tumour necrosis factor (TNF) and the Fas pathways 
(Filippova et al., 2002; Filippova et al., 2004).  
HPV E6 is known to increase the telomerase enzyme activity in primary epithelial cells by 
increasing the telomerase hTERT gene transcription (Veldman et al., 2001). This function of E6 
could help in the growth stimulation of the transformed cells. 
 
E7 protein 
E7 encodes for a 98 amino acid nuclear zinc-binding-phosphoprotein that is structurally and 
functionally related to the E1A transforming protein of adenovirus and the large T antigen of 
SV40 (Barbosa et al., 1989). E7, E1A and Large T antigen contain conserved domains that bind 
to the retinoblastoma gene product (Rb) protein and its related proteins p107 and p130 (Dyson et 
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al., 1992). This leads to the degradation of Rb, resulting in the constitutive activation of the E2F 
transcription factor (Chellappan et al., 1992). This activation of E2F could then lead to cellular 
transformation. Additional sequences in the carboxy terminal domain of E7 are required for the 
disruption of E2F/Rb complexes (Wu et al., 1993a). In a recent study HPV-16 E7 protein 
expression correlated with reduced pRb-levels in cervical biopsies (Fiedler et al., 2004).  
The repression of E2F-inducible promoters is mediated by recruitment of HDACs through  Rb 
(Brehm et al., 1998). In HPV-negative and non-transformed cells, Rb binds to HDACs and 
recruits them to E2F-inducible promoters. Recently, E7 was shown to bind HDACs 
independently of their binding to Rb, and this association is important for the role of E7 in 
immortalization as well as episomal maintenance (Longworth and Laimins, 2004b).  
Like E6, E7 alone has the ability to immortalize human cells (Halbert et al., 1991) but at a 
reduced efficiency.  
 
1.7.5 Late proteins  
L1 and L2 constitute the two late proteins. They encode the viral capsid proteins. L1 is the major 
viral capsid protein, which is highly conserved among many different HPV species. L2 encodes 
the minor capsid protein that has a considerable sequence variation between HPVs. The 
transcription from the L1 and L2 ORFs occurs when complete virons are being assembled. 
Recent findings suggest a HPV type-independent modulatory function of L2 on host-cell 
functions that involves discrete nuclear domains and alteration of the subcellular distribution of 





1.7.6 Role of p97 promoter (Early gene promoter)   
 
       
Fig IX: LCR, promoter and E6 ORF region showing the binding sites of various regulatory 
proteins of HPV-16. The boxes denote the binding sites of various transcriptional regulators.   
 
 
p97 is the early promoter located upstream of the E6 ORF in HPV 16 (Smotkin and Wettstein, 
1986). In HPV 18, it is know as p105. Transcripts that start at the p97 promoter can be 
differentially spliced to generate all eight ORFs. The E6 promoters of all HPVs contains four 
conserved cis responsive elements, two binding sites for Sp1 at position 7842-7847 and 28-33 in 
the case of HPV 16, one of which overlaps with that for E2. Another binding site for E2 nt 50-61 
overlaps with the TATA box, the binding site of TFIID (Gloss and Bernard, 1990). The E6 
promoter has only a moderate activity by itself, even with the presence of Sp1. It requires the 
stimulation by enhancer elements, which is a 400bp segment of the LCR upstream of the 
promoter and separated from it by a 100bp segment with the replication origin and a silencer. An 
unusual property of the enhancer is that, they function only in the epithelial cells (Gloss et al., 
1987). Some of the enhancers known to affect the p97 promoter are AP-1, NF-1, Oct1, TEF-1 
(Bernard, 2002).  
The LCR region of HPV-18 and HPV-16 contained multiple sites for the known repressor YY1 
(Bauknecht et al., 1992). In HPV-16 they are found at nt 7436-7443, 7775-7783, 7794-7801, 
1 
7145 7906 559 P97 
LCR E6 ORF 
SP1 site  (nt 7842-7847, 28-33) 
YY1 sites (nt 7436-7443, 7775-7783, 7794-7801,7816-7833,7843-7850) 
E2 site    (nt 7453-7464, 7860-7871, 35-46, 50-61) 
TFIID site 
Enhancer site with Oct1,TEF1,NF1 
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7816-7833, 7840-7848 (Dong et al., 1994). The last two binding sites of YY1 overlap with the 
binding of Sp1. A point mutation within this YY1 site in viral DNA from a cervical cancer, 
previously shown to prevent YY1 binding, was shown to increase SP1 binding and P97 activity 
by about 5 fold (Dong and Pfister, 1999). In other HPV-16 cervical carcinomas, mutations of 
YY1-binding sites have been identified that increase p97 activity 3-6-fold (Dong et al., 1994). 
Another transcriptional repressor found in the LCR at the E1 binding site is the CCAAT-
displacement protein (CDP) (Ai et al., 1999). As its name suggests, its ability to displace DNA 
bound proteins could inhibit the p97 promoter by competing with the replication factor E1. 
Another possible mechanism of repression by CDP would be through its interaction with 
HDAC1 (Li et al., 1999).  
In the case of HPV-16 and 18 the LCR has two nucleosomes positioned at precise positions 
overlapping with the viral enhancer and promoter (Stunkel and Bernard, 1999). Interactions of 
YY1 and CDP with HDACs could facilitate this nucleosome arrangement to silence the p97, 
keeping the HPV infected cells in a latent phase. The positioning of the two nucleosomes does 
exclude the binding site for the transcriptional activator AP-1. With a decrease in the levels of 
CDP and YY1, there is an increase in the activity of AP-1. AP-1 can then counteract the effect of 
CDP and YY1 associated HDAC activities through the activity of its co-factor CBP and its 








1.7.7 Late gene promoter 
 
 
Fig X: Linearized HPV-16 genomic DNA with possible locations of additional promoters 
controlling the various HPV-16 genes    
 
Expression of the HPV late genes is dependent upon epithelial differentiation. In the case of 
HPV-16 this differentiation dependent promoter was found to be at position p670 within the E7 
gene and could code for the E1-E4 fusion protein as well as the E5 protein (Grassmann et al., 
1996). The same promoter was also reported to serve for the transcription of E2 in a 
differentiation dependent manner (Nilsson et al., 1996). The most well studied system is that of 
HPV31b where the late genes are thought to be transcribed from p742 (Hummel et al., 1992). 
Using raft cultures it was also found that there is a promoter at p3320 which codes for E5, L1 and 
L2 in HPV31b (Ozbun and Meyers, 1998).  Geisen and Kahn studied the late upstream region of 
HPV-16 for promoter activity and discovered that the 78bp (nt 4118-4196) between the coding 
region of E5 and L2 acted as a promoter for the late genes (Geisen and Kahn, 1996). A similar 
promoter was found in HPV-18 between 4158 and 4188 (Maki et al., 1996). However, the 
transcription of E2 seems to be elusive apart from the reports that they could be transcribed from 
p670. In the case of BPV a promoter at p2443 was responsible for a major part of the expression 
of E2 and E5 gene products (Spalholz et al., 1991). Therefore, it is yet not clear as to the exact 
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In papillomaviruses, the cause for the switch between the early and late promoters seems elusive 
and complex. As will be further discussed methylation could possibly play an important role in 























1.8 Research Objective  
DNMT1 plays an important role in many aspects of the cellular process such as: gene silencing, 
genome stability and development. Aberrant methylation has shown to be a cause of many 
deleterious effects on the cell, with both hypo and hypermethylation contributing to the 
development of tumourigenesis.A number of virus infections have also been associated with 
cancer. A prime example is that of the HPV with cervical carcinoma (Schiffman and Brinton, 
1995; zur, 1996b). As methylation of the episomal form of the virus transfected into culture cells 
were transcriptionally inactive (Rosl et al., 1993), it suggests that methylation of the HPV virus 
could  play a role in the development of malignancies associated with these infectious agents. 
Yet, the methylation status of the virus has never been studied in HPV transformed cells lines. 
In this study, we aim to elucidate the role of methylation in the carcinogenic progression of 
cervical cancer. If a correlation were found between methylation and lack expression of viral 
genes in HPV transformed cell lines, then suitable methylation markers would be used to analyse 
clinical samples to see if an aberrant methylation of the viral genomes contributed towards 
tumour progression. The study also aimed at deciphering the effects of loss of DNMT1 using 
depleting agents such as 5AzadC and MMS on the methylation profile of the virus and hence, the 
transcription of the viral genes.  
In a concurrent study, while purifying the recombinant DNMT1 interacting protein PCNA by gel 
filtration, the bacterial homolg of Hsc70, DnaK was co-purified. Therefore, we went on to 
investigate if Hsc70 interacted with PCNA. We also investigated the possibility of the interaction 
of Hsc70 and DNMT1. A preliminary inquiry into the function of these interactions was carried 
out in the present work.     
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CHAPTER 2  MATERIALS AND METHODS 
2.1 Cell lines  
CaSki and SiHa cells originated from H. zur Hausen at the German Cancer Research Centre, 
Heidelberg, where they were frozen in 1986 and freshly thawed for this study (Courtesy of Hans 
Ulrich Bernard). Another set of CaSki and SiHa cells were obtained from the American Type 
Culture Collection (ATCC). CaSki and SiHa cells were cultured in Dubelco’s Minimum 
Essential Medium (DMEM) with 4500 glucose.   
HeLa D98 was obtained from A. G. Porter (IMCB, Singapore). It is a hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) negative, 8-azaguanine resistant mutant of Hela constructed 
more than 30 years ago (Bengtsson et al., 1974). Hela CCl2 (Chou et al., 1978) was received 
from the ATCC. HeLa444 cells were constructed during a study of the properties of fusion cells 
between HeLa D98 and fibroblasts (Srivatsan et al., 1986), and were made available to us by Dr. 
E. Stanbridge (University of California Irvine). The cell line C4-1, also derived from a cervical 
carcinoma (Krukcek et al., 1981), has been reported to contain one or few HPV-18 genomic 
copies (Schwarz et al., 1985; Gallego et al., 1994) and has been made available by E. Schwarz, 
Heidelberg, in 1985. Hela CCl2, D98, 444 and C4-1 were cultured in DMEM with 4500 glucose.   
MRC5SV40 was a generous gift from Dr. P. Karan (ICRF, UK) and cultured in Eagle’s 
Minimum Essential Medium (MEM) 1mM minimum essential amino acids and 1 mM sodium 
pyruvate. MCF7 and 293 cells were from ATCC and cultured in RPMI1640 and DMEM media 
respectively. 
Cells were cultured using recommended medium with 10% FBS (heat inactivated) (Hyclone, 




Monoclonal antibody mAb 2E10 for DNMT1 was courtesy of Dr. Chuang L.S.H. Antibodies 
against p53 (D01), PCNA (PC10) and GFP were from Santa Cruz Biotechnology. mAb for actin 
(clone C4) and p21Waf1/Cip1 (clone 70) were from Boehringer Mannheim and Transduction 
Laboratories. mAb against Hsc70 for cell staining were from Oncogene Science(USA) and for 
Hsp70 was from Stressgen (USA).    Stressgen Biotechnologies. Rabbit pAb towards PCNA and 
anti-GST for cell staining were courtesy of Dr. Chuang, L.S.H... Goat anti-mouse IgG-FITC and 
goat anti-rabbit IgG-Cy3 were purchased from Sigma Immuno Chemicals (USA).  
 
2.3 Bacterial strain and media 
XL1-Blue strain was used for all the transformations with the media obtained from the Institute 
of Molecular and Cell Biology's core facility. 
 
2.4 Drugs and Chemicals 
MMS, TSA and protease inhibitor cocktails were purchased from Sigma-Aldrich (USA). 5AzadC 
was purchased Fluka Chemicals.  
32P αATP was purchased from NEN (USA). 
 
2.5 Clinical specimens 
Brazilian samples originated from cross-sectional studies in two cities in the Northeast of the 
country, and consisted of cervical scrapings and tumour biopsies.  Cytological and 
histopathological analyses followed the Bethesda system. For smears classified as 
“asymptomatic”, ectocervical and endocervical cells were collected with a cytobrush. Tissue 
biopsies were classified as cervical intraepithelial lesions (CIN I and III) or invasive carcinoma, 
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and digested with proteinase K prior to DNA isolation.  DNA samples were purified by spin 
column chromatography and tested for the presence of HPV DNA by the MY09/11 PCR protocol 
for specific HPV types (Bernard et al., 1994). All specimens were number coded for privacy of 
the subjects. Asymptomatic and precursor samples from New Mexico, USA, were obtained and 
characterized during published epidemiological research (Peyton et al., 2001). Invasive cervical 
cancer specimens were obtained from ongoing case-control studies of the same population 
diagnosed between 1980 and 1999. 
 
2.6 Analysis of the genomic DNA of cell lines 
HPV-16 and HPV-18 cells genomic DNA was purified with Qiagen Blood prep minikit 
QIAGEN, Germany). For digestions with McrBc (New England Biolabs), 250 ng of  the genomic 
DNA were digested with 3 units of enzyme for 1 hr at 37oC in 25 μl NE buffer 2 (50 mM NaCl, 
10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol pH 7.9) followed by heat inactivation at 65 
oC for 20 minutes and then amplified by PCR.  
150 and 15 ng of SiHa and CaSki genomic DNAs, respectively, were digested with HpaII and 










16Amplicon  Primer name Position Sequence 
G1 G1F 515-534 GTCTTGTTGCAGATCATCAAGA 
 G1R 1528-1509 ATTCTGAAAAACTCACCCCG 
G2 G2F 1501-1520 GAGTTATACGGGGTGAGTTT 
 G2R 2526-2505 CAATGGTCTATGCTTTACATCC 
G3 G3F 2501-2522 CTATGGATGTAAAGCATAGACC 
 G3R 3501-3481 TTTCCGGTGTCTGGCTCTGAT 
G4 G4F 3471-3490 AGCGACCAAGATCAGAGCCA 
 G4R 4472-4453 GGCCTTGTTCCCAATGGAAT 
G5 G5F 4402-4421 GGTGGGTTAGGAATTGGAAC 
 G5R 5402-5383 GATGTAGAGGGTACAGATGG 
G6 G6F 5367-5386 TTCTACAACCCCGGTACCAT 
 G6R 6370-6351 GTCGCCATATGGTTCTGACA 
G7 G7F 6348-6367 TGGTGTCAGAACCATATGGC 
 G7R 7315-7293 TGCATGACACAATAGTTACACAA 
G8 (P2) G8F 7145-7184 CGTAAGCTGTAAGTATTGTATGTATGTTGAATTAG
TGTTG 
 G8R 122-94 CCTGTGGGTCCTGAAACATTGCAGTTCT 
G9 (P4) G9F 7850-7886 TGTGTGCAAACCGTTTTGGGTTACACATTTACAAG 
 G9R 559-528 TTACAGCTGGGTTTCTCTACGTGTTCTTGATG 
P1 G8F 7145-7184 See above 
 G9R 559-528 See above 
P3 G8F 7145-7184 See above 
 P3R 7560-7544 TTGGCACGCATGGCAAGCAGGAAACG 
P5 P5F 99-132 ATGCACCAAAAGAGAACTGCAATGTTTCAGGAC 
 G9R 559-528 See above 
P6 P6F 232-261 GACTTTGCTTTTCGGGATTTATGCATAGTA 
 G9R 559-528 See above 
P11 G9F 7850-7886 TGTGTGCAAACCGTTTTGGGTTACACATTTACAAG 
 G8R 122-94 CCTGTGGGTCCTGAAACATTGCAGTTCT 
Table (i): HPV-16 primers for genomic DNA amplification   
 
16 Amplicon Primer name Position Sequence 
E6 E6F 232-261 GACTTTGCTTTTCGGGATTTATGCATAGTA 
 E6R 556-531 CAGCTGGGTTTCTCTACGTGTTCTTG 
E7 E7F 544-570 AGAAACCCAGCTGTAATCATGCATGGA 
 E7R 858-832 TTATGGTTTCTGAGAACAGATGGGGCA 
E1 E1F 871-889 TGATCCTGCAGGTACCAATG 
 E1R 1490-1471 GCTAACATTGCTGCCTTTGC 
E2 E2F 2756-2775 ATGGAGACTCTTTGCCAACG 
 E2R 3854-3831 GTCATATAGACATAAATCCAGTAG 
E4 E4F 3343-3364 TACATCTGTGTTTAGCAGCAAC 
 E4R 3620-3598 CTATGGGTGTAGTGTTACTATTA 
E5 E5F 3852-3872 GACAAATCTTGATACTGCATCC 
 E5R 4077-4101 TTATGTAATTAAAAAGCGTGCATGT 
L1 L1F 5561-5583 ATGCAGGTGACTTTTATTTACAT 
 L1R 6042-6021 TAAGCACTAGCATTTTCTGTGT 
L2 L2F 4220-4242 ACTGTTATTACTTAACAATGCGA 
 L2R 4939-4922 CCTGTTGTGTTGTGCGAC 
 48
GADPH GADPH-F 254-272 TCCCATCACCATCTTCCAG 
 GADPH-R 562-543 ATGAGTCCTTCCACGATACC 
Table (ii): Primers for amplification of the HPV-16 cDNAs  
 
16 Amplicon Primer name Position Sequence 
G3.1 G3.1F 2501-2522 CTATGGATGTAAAGCATAGACC 
 G3.1R 2804-2783 GTTAGTATTTTGTCCTGACACAC 
G3.2 G3.2F 2758-2777 GGAGACTCTTTGCCAACGTT 
 G3.2R 3160-3138 TGTCCAGTTTGTATAATGCATTG 
G3.3 G3.3F 3117-3139 TTGATGGAGACATATGCAATACA 
 G3.3R 3501-3481 TTTCCGGTGTCTGGCTCTGAT 
G4.1 G4.1F 3471-3490 AGCGACCAAGATCAGAGCCA 
 G4.1R 3840-3818 AATCCAGTAGACACTGTAATAGT 
G4.2 G4.2F 3771-3790 GTGAATGGCAACGTGACCAA 
 G4.2R 4250-4229 CGTTTGTGTCGCATTGTTAAGT 
G4.3 G4.3F 4111-4139 ACATAATGTAATTGTTACATATAATTGTT 
 G4.3R 4472-4453 GGCCTTGTTCCCAATGGAAT 
 




Primer name Position Sequence 
MSP3 msp3F 4322-4348 ATTTGATATTATATTTAAGGTTGAA 
 msp3R 4970-4946 AATAATTACAAAAACAAAATCTACA 
MSP4 msp4F 7498-7522 TAGTTTTATGTTAGTAATTATGGTT 
 msp4R 161-140 ACAACTCTATACATAACTATAATA 
 
Table (iv): Primers to amplify the Bi-sulphite modified DNA 
 
18 Amplicon Primer name Position Sequence 
    
G1 G1F 7019-7038 TTTGGTTCAGGCTGGATTGC 
 G1R 56-37 CCGACCGTTTTCGGTTACTC 
G2 G2F 37-56 GAGTAACCGAAAACGGTCGG 
 G2R 930-911 CCTTCTGGATCAGCCATTGT 
G3 G3F 876-895 TTGTGTGTCCGTGGTGTGCA 
 G3R 1890-1871 AGTGCTGCAACACTACTTCG 
G4 G4F 1763-1782 GCCCTGTTGCGT ACAAATG 
 G4R 2818-2799 ATCTTCCTCTTCCTCGTGCA 
G5 G5F 2802-2821 ACGAGGAAGAGGAAGATGCA 
 G5R 3797-3778 ATTGCCTGCACCTGTCCAAT 
G6 G6F 3730-3750 GATTGCGAAAACATAGCGACC 
 G6R 4784-4765 ATACATTACCTGCCACCTCC 
G7 G7F 4721-4740 CCTGCATTTTCTGATCCGTC 
 G7R 5918-5899 ACAGGCCCACACTAAACGTT 
G8 G8F 5830-5849 TTAGGGTGCAGTTACCTGAC 
 G8R 7038-7019 GCAATCCAGCCTGAACCAAA 
 
Table (v): HPV-18 primers for genomic DNA amplification   
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Oligonucleotides used for PCR cloning of the Hsc70 fragments; Sense primers; ATP-ss, Pep-ss, 
CT-ss and anti sense primers; ATP-as, Pep-as, CT-as are from BTC (NUS, Singapore). 
Restriction sites are italicized for BamHI, underlined for EcoRI site and bold for XhoI. 
 
Primer Sequence 
ATP-ss      AAGGGATCCATGTCCAAGGGACCTGCAGTTGGTATT 
ATP-as      AAGGAATTCTTACTTGATGAGGACAGTCATGACTCC 
Pep-ss       AAGGGATCCAATGGAAAAGAACTGAATAAGAGCATCAAC 
Pep-as       AAGCTCGAGTTAATTACACTTGTCCAGAATCTTCTGTTT 
CT-ss       AAGGGATCCTCACTTGAGTCCTATGCCTTCAAC 
CT-as       AAGCTCGAGTTAATCAACCTCTTCAATGGTGGGCCC 
Table (vi): Primers for the cloning of Hsc70 fragments 
 
2.8 Reverse transcription and PCR 
RNA was extracted using the QIAshredder and RNeasy kit from QIAGEN (Germany). 1 µg of 
RNA was primed with 5 pmoles of 18 mer poly-dT primer, topped up to 11 µl with H20, heated 
at 70ºC for 10 min, and placed on ice for 5 min. A mastermix containing 2 µl of 10x NEB M-
MuLV reverse transcriptase buffer, 100 mM DTT, 0.5mM of each of the four dNTPs, 100 units 
NEB Reverse transcriptase enzyme and 20 units of RNAse Inhibitor (Roche) was added to each 
sample and incubated for 50 min at 42ºC. The enzyme was heat inactivated at 70ºC for 15min. 
PCR was carried out in 25 µl containing 0.2 mM of each of the four dNTPs, 10 pmol primers, 2.5 
µl of buffer B (supplied by the producer, Promega), 2mM MgCl2 and 0.75 units Taq polymerase 
(Promega) and 1.5 µl of the cDNA preparation. The PCR started at 94°C for 2 min followed by 
25 amplification cycles (denaturation 94°C, 10 sec, annealing 55°C, 30 sec, extension 68°C, 45 





2.9.1 HPV-16 and HPV-18 genomic walk through 
Tables (i and v) summarizes the primers for dissection of the HPV-16 and HPV-18 genome. PCR 
was carried out in 25 μl containing 0.2 mM of each of the four dNTPs, 10 pmol primers, 2.5 μl of 
buffer B supplied by the producer (Promega), 2 mM MgCl2 and 0.75 units Taq (Promega) with 
2.5μl of template DNA, uncleaved or cleaved by McrBc. The PCR started at 94°C for 1 min 
followed by 35 amplification cycles (denaturation 94°C, 10 sec, annealing 58°C, 30 sec, 
extension 68°C, 45 sec increasing by 10 sec per cycle), final extension at 68oC, 7 min. 
2.9.2 LCR, G3 and G4 dissection 
The mapping of the LCR-E6 segment (primers from table i) as well as the G3 and G4 (primers 
from table iii) region followed the same protocol as above with 94°C for 1 min followed by 35 
amplification cycles (denaturation 94°C, 10 sec, annealing 58°C, 30 sec, extension 68°C, 45 sec 
), final extension at 68oC, 7 min. 
2.9.3 HPV-16 RT-PCR   
Table (ii) summarizes the primers for RT-PCR of the all the HPV-16 genes. PCR was carried out 
using Taq (Promega) polymerase with the same conditions as above. The annealing temperature 
was 55°C with 25 amplification cycles.  
Only in the case of the E2 gene, the RT-PCR was carried out using AmpliTaq Gold (Roche). 
PCR was carried out in 25 μl containing template DNA, 5 mM dNTPs, 10 pmol primers, 2.5 μl 
of magnesium ion free buffer supplied by the manufacturer, 2mM MgCl2 and 1.25 units 
AmpliTaqGold at 94°C, 9 min followed by 25 amplification cycles (denaturation at 94°C, 10 sec, 
annealing 58°C, 30 sec, extension 68°C, 45 sec increasing by 10 sec per cycle), final extension at 
68°C, 7 min.  
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 2.9.4 Hsc70 fragments 
Table (vi) summarizes the primers for cloning of the Hsc70 fragments. PCR was carried out 
using Expand Long Template PCR kit from Boehringer Mannheim (Germany) in a 50μl reaction 
containing template DNA, 10 pmol primers, 5μl of  PCR buffer 3 supplied by the manufacturer, 
0.75mM MgCl2, 0.125 mM of each of the four dNTPs and 0.75 μl of the enzyme. The cycle 
conditions for the Hsc70 fragments were the same except for their annealing temperatures. The 
general conditions were 94°C for 2 min, 5 amplification cycles (94°C for 10s, annealing 
temperature 30s, 68°C for 45s), followed by a further 15 amplification cycles (94°C for 10s, 
annealing temperature 30s, 68°C for 2min and 25s) and a final extension at 68°C for 7 min. 
The annealing temperatures for the Hsp-ATP, Hsp-Pep, Hsp-CT, Hsp-ATPep, and Hsp-PepCT 
were 54°C; for the Hsp-FL it was 57°C. 
  
2.10 Bisulphite sequencing 
For mapping of methylated cytosine residues, DNAs were modified by the CpGenomeTm DNA 
modification kit (Serologicals Corporation) and the reaction products amplified with primers 
specific for modified HPV-16 DNA. msp3F and msp3R (table iv) spanned part of the L2 gene. 
msp4F and msp4R (table iv) amplified a segment with the enhancer-promoter. The products were 
amplified using AmpliTaqGold with an annealing temperature of 53°C and cycles as stated 
earlier. The amplification products were directly sequenced with the same primers used for the 





2.11 Cell lysis and Western Analysis 
Cell pellets were lysed in a modified RIPA buffer (50 mM Tris (pH 8.0), 0.3M NaCl, 10mM 
EDTA, 50mM NaF, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40 and 0.2mM PMSF) by 
sonication. The lysates were then centrifuged at 14,000 rpm for 20 min at 4°C (Eppendorf) and 
the supernatant was recovered. Protein concentration was determined either by the Lowry assay 
or by using the RC-DC kit from Bio-Rad (U.S.A). Cell lysates were resolved on 6.9 and 13.5% 
SDS-PAGE gels, which were prepared with 30% acrylamide solution (Bio-Rad). The samples 
were then transferred to PVDF membranes (Bio-Rad) in transfer buffer (25mM Tris-base; 
192mM glycine; 0.03% SDS) with a Bio-Rad transfer system set at 100V, 350mA for 2 hours at 
4°C or 30V, 100mA overnight at 4°C. The membranes were blocked with 5% skimmed milk in 
TBST buffer (20mM Tris.Hcl pH8.0, 0.15M NaCl, 0.05% Tween-20) for 30 min room 
temperature, followed by three washes with TBST. The blot was then incubated with the primary 
antibody at 37°C for 1 hour. The filters were washed thrice with TBST for 5 min at room 
temperature before secondary antibodies were added at 1:4000(anti-mouse IgG-HRPO from 
DAKO) or 1:10,000 (protein-A-HRPO from Transduction laboratories). A final wash as above 
was performed before addition of ECL reagents (Amersham) for visualization. Amersham 
hyperfilms were used and developed with a Kodak X-omatic automatic developer. 
 
2.12 Flow Cytometry 
A Becton Dickinson FACScan machine was used to analyse 21,000 events (using CellQuest and 
Modfit). DNA analysis was carried out by propidium iodide (PI) staining (50μg/ml at 37°C 30 




2.13 Chromatin Immunoprecipitation Assay (ChIP) 
Nuclei were prepared from fresh cell pellets by lysis in hypotonic buffer  (10mM Hepes 7.3, 
10mM KCl, 1.5mM MgCl2,1mM DTT, 0.2M PMSF 1:200 and PI 1:500) followed by Dounce 
homogenization. The lysates were layered onto 40% sucrose in hypotonic buffer and centrifuged 
at 860 rcf for 15 min at 4°C. The nuclei were treated with 1% paraformaldehyde for 30 min at 
4°C. The cross-linked nuclei were washed three times with hypotonic buffer. They were 
resuspended in two times the volume in lysis buffer (5mM Tris.HCl pH 8.0, 1% SDS, 4mM 
EDTA, 0.2M PMSF 1:200 and PI 1:500) and sonicated on ice at 30% power output with 6 pulses 
of 10s. The lysate was spun at 13,000 rpm for 10 min at 4°C. The supernatant was further 
sonified with six pulses for 10s at 30% power output, followed by six pulses of 10s at 60% power 
output on ice. After centrifugation (10 min at 13,000 rpm at 4°C), the protein concentrations 
were measured by Bradford (Bio-Rad). After diluting the supernatant (100 μg) with 9 volumes of 
IP buffer ( 0.01% SDS, 1.1% NP40, 1.2mM EDTA, 16.7mM Tris.HCl pH 8.0,167mM NaCl and 
PI 1:500 ), respective primary antibodies (5μg) were added and the resultant mixtures incubated 
at 4°C overnight. The immune complexes were recovered using protein G beads. The beads 
collected were washed extensively with the wash buffer (0.1% SDS, 1% NP40, 2mM EDTA, 
10mM Tris.HCl pH 8.0 and 150mM NaCl) and eluted in 200μl of elution buffer ( 1% SDS and 
0.1M NaHCO3). Eluates were heated at 65°C for 4 hours to reverse the cross-linking. After 
treatment with Proteinase K (Promega, USA) for 1 hour at 45°C, the DNA fragments were then 
purified by QIAquick Spin Kit (Qiagen, Germany). For PCR, 2μl of the DNA extract (50μl) was 
used. Optimized PCR conditions were used for the amplification of promoter DNAs of interest. 
The PCR conditions for the various HPV-16 fragments are as follows: V1 was amplified using 
primer 5’-CTAACCTAATTGCATATTTGGCAT-3’ (V1 sense) and 5’-
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TATAAGTTGCTTGTAAATGTGTAAC-3’ (V1 antisense); V2 was amplified using primers 5’-
TGTGTGCAAACCGTTTTGGGTTACACATTTACAAG-3’ (V2 sense) and 5’- 
CCTGTGGGTCCTGAAACATTGCAGTTCT-3’ ( V2 antisense); V3 was amplified using 
primers V1 sense and V2 antisense; P7 was amplified using primers V2 sense and 5’-
TCACGTCGCAGTAACTGTTGCTTGC-3’ (antisense). The PCR for all the amplicons were 
carried out at 94°C for 2 min, followed by 25 cycles of 94°C 10s, 58°C for 30s and 68°C for 45s 
and an elongation at 68°C for 7 min.  
 
2.14 DNA manipulation 
All plasmid preparations were carried out using QIAprep Spin columns from 
QIAGEN(USA).Restriction digests were performed using New England Biolabs (USA) 
restriction enzymes and buffers supplied, for one hour at 37°C. Ligation was performed using T4 
DNA ligase from GIBCO (USA) using 3:1 ration of insert to vector for 3 hours at room 
temperature. DNA were transformed into 100μl XL1-Blue cells by keeping on ice for 45 minutes 
followed by heat shock at 42°C for one minute and then incubated with 500μl LB 
medium(supplemented with 20mM glucose) at 37°C for 30 minutes. 100-200μl was plated on 
agar plates (1.5% agar in LB with 100μg/ml ampicillin). 
 
2.15 Expression of recombinant PCNA 
The PCNA clone was cultured in 200ml of LB overnight at 37°C.  It was then transferred to 2 
liters of LB and the protein induced with 1mM IPTG for 3 hours at 37°C. The pellets were lysed 
on ice for 30 minutes in 5ml of 25mM Tris.HCl (pH 7.5), 1mM EDTA, 25mM NaCl, 
0.01%NP40, 1 mM DTT, 1mM PMSF and 0.2 mg/ml lysozyme. The NaCl concentration was 
readjusted to 0.1M and the lysate centrifuged at 28,000 rpm at 4° C for 1 hour. Polyimine 
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precipitation was carried out, after which stepwise ammonium sulphate precipitation at 50%, 
55%, 65% performed. The 65% ammonium sulphate precipitate was dissolved in re-suspension 
buffer (0.3M NaCl, 50mM Hepes 7.0, 5% glycerol) and dialyzed in the same buffer for 2 hours at 
4°C before gel filtration purification. 
 
2.16 PCNA purification - Gel filtration of 65% ammonium sulphate protein precipitate 
A superose-6 (Pharmacia, USA) gel filtration column with a bed height of 50.5cm and a bed 
volume of 39.67ml was used to purify PCNA. The column was equilibrated with 50ml of re-
suspension buffer at 0.3ml/min. 56 fractions of 1ml/fraction collected in a Frac-100 fraction 
collector. All purification procedures were carried out at 4°C and the proteins in each fraction 
were analyzed by SDS-PAGE and western analysis.  
 
2.17 PCNA purification - FPLC chromatography on Mono Q exchanger 
Fractions containing PCNA from the gel filtration purification steps were pooled together and 
dialyzed in  bufferA [50mM Tris pH8.0, 0.1mM EDTA, 1mM DTT] and loaded onto a Mono Q 
column (Pharmacia, Sweden) at 0.3ml/min. PCNA was eluted using buffer B [50mM Tris pH8.0, 
0.1mM EDTA, 1mM DTT, 1.5M NaCl] with a linear gradient of  0-40% buffer B. 56 fractions of 
0.6 ml were collected and the fractions analyzed by SDS-PAGE and western analysis.  
 
2.18 Purification of recombinant proteins 
pMAL modified vectors provided by Ms OH H K (IMCB, Singapore) was used for the cloning of 
the various Hsc70 fragments. They were digested either with BamHI and EcoRI or BamHI and 
XhoI. Hsc70 clones inoculated overnight were transferred to fresh LB media with 100μg. ml 
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ampicillin and induced for 3 hours with 0.1M IPTG. Cells were lysed in (50mM Tris pH 7.5, 
0.3M NaCl, 1mM EDTA, and 2mM DTT) by sonication. The extracted proteins were bound to 
amylose beads for 45 minutes at 4°C. 10mM maltose was used to de-bind the protein for 30 
minutes. 
The various DNMT1 fragments were cloned into pGEX2T vector using the EcoRI and BamHI 
cloning sites. The clones were grown and lysed in a similar fashion as above. They were then 
bound to gluthatione sepharose beads (Amersham Biosciences) for 45 min at 4°C. 5mM reduced 
Glutathione (GSH) (Sigma) was used to elute the protein. 
   
2.19 In-vitro binding experiments 
The Hsc70 recombinant proteins on amylose beads were quantitated using Coomassie blue 
staining of the SDS-PAGE gels. Binding with PCNA from the monoQ fractions was carried out 
in Hsc70 binding buffer (0.1M KCl, 3mM MgCl2, 10mM HEPES pH 7.5, 10% glycerol, 0.02% 
NP40, 20mM Sodium Molybdate, 0.1mM NaF, 50mM NaVO4 ) in a maximum reaction volume 
of 50μl for 30 minutes at 4°C. The beads were washed 3 times with the binding buffer before 
running on an SDS-PAGE gel and transferred onto a nitro-cellulose membrane for western 
analysis using a semi-dry transfer blotter. 
The PCNA recombinant protein on glutathione sepharose beads (Amersham Biosciences) were 
bound to Hsc70 (Sigma, USA) in the Hsc70 binding buffer in a maximum reaction volume of 
50μl for 30 minutes at 4°C.   
Binding experiments with the different fragments of DNMT1 to Hsc70 recombinant proteins 
bound to amylose beads were carried out in PBS buffer (PBS, 0.1M KCl, 0.5% NP40) ) in a 
maximum reaction volume of 50μl for 30 minutes at 4°C. 
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2.20 Effect of ATP 
To study the effect of ATP on the in-vitro binding of Hsc70 to PCNA, the full length Hsc70 on 
amylose beads were initially washed for 10 minutes with 0.2mM ATP in the binding buffer (Sec 
2.19). An increasing concentration of 0.5, 1.0, 2.0, 3.0, 4.0 and 5.0mM ATP was used in a final 
reaction volume of 50μl containing PCNA from the monoQ fractions. Binding was carried out at 
room temperature for 30 minutes after which it was washed 3X before being boiled in 2X 
Laemmli buffer and run on a SDS-PAGE gel and transferred onto a nitro-cellulose membrane for 
western analysis.  
 
2.21 Time dependent binding 
The in vitro binding experiment was carried out, this time keeping the level of ATP constant and 
varying the time interval for binding. The protocol was the same as before, the ATP levels were 
kept constant at 2.0mM and binding carried out for 10min, 20min, 30min, 45min, 60min, 90min 
at room temperature.  
 
2.22 Cell staining 
2.22.1 Staining of Hsc70-PCNA 
5 SV40 cells were plated onto cover slips (18X18 mm) in a 6 well NUNC plate. The cells were 
fixed with 2% paraformaldehyde for 10 minutes. Cells were washed 2X with PBS for 5 minutes 
each, then with 50mM glycine. They were treated with 2N HCl /0.1% triton-X in water for 10 
minutes and rinsed with PBS. 50mM glycine was added to neutralize the acid and was rinsed 
with PBS as before. They were then fixed in 3.7% paraformaldehyde for 10 minutes and rinsed 
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3X with PBS and 1X with 0.1% triton-X/PBS. Cells were blocked with 10% sheep serum in 
0.1% triton-X and PBS for 10 minutes. 1μg of Hsc70 mAb (Oncogenescience, USA) and 2.5μg 
of PCNA pAb in 1% triton-X/PBS was used for staining overnight at 4°C. Anti mouse fluoresein 
(1/50 dilution) and Cy3 anti rabbit (1/100 dilution) in 1% triton-X/PBS was used as secondary 
antibodies for 1 hour in the dark at room temperature (all secondary anti bodies were from Sigma 
Chemicals, USA).  Cells were then stained with Hoechst 33342 (10μl of a 10 mg/ml stock in 
100ml PBS). The slides were mounted with PermaFluor (Lipshaw Immunon, USA) and viewed 
under oil immersion using a fluorescence microscope (Axioplan PO1, with MC100 camera from 
Zeiss, Germany).  
2.22.2 Staining of transfected DNMT1 and Hsc70 
All transfection were carried out using Superfect according to the manufacturer’s protocols 
(Qiagen, Germany). The cells were fixed with 3.7% paraformaldehyde for 10 minutes, rinsed 3X 
with PBS and 1X with 0.1% triton-X/PBS. Cells were blocked with 10% sheep serum in 0.1% 
triton-X and PBS for 10 minutes. 1μg of Hsc70 mAb (Oncogenescience, USA) and 2.5μg of anti-
GST pAb (F1.1) in 1% triton-X/PBS was used for staining overnight at 4°C. Remaining 
procedures were the same as above. 
2.22.3 Staining of DNMT1 and YY1 
Staining was carried out with CaSki cells treated with 25 or 100mM TSA for 6 and 24 hours. The 
cells were fixed with 3.7% paraformaldehyde for 10 minutes, rinsed 3X with PBS and 1X with 
0.1% triton-X/PBS. Cells were blocked with 10% sheep serum in 0.1% triton-X and PBS for 10 
minutes. 7μl of DNMT1 mAb D12 (Courtesy Koh TW (IMCB, Singapore)) and 0.6μg of YY1 
pAb (SantaCruz Antibodies) in 1% triton-X/PBS was used for staining overnight at 4°C. 
Remaining procedures were the same mentioned above. 
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2.22.4 Staining of DNMT1 and Hsp70 in 5AzadC treated MRC5SV40 and MCF7 cells 
Cells treated with 4μM 5AzadC for 3, 6 and 24 hours were fixed in 3.7% paraformaldehyde for 
10 minutes, rinsed 3X with PBS and 1X with 0.1% triton-X/PBS. Cells were blocked with 10% 
sheep serum in 0.1% triton-X and PBS for 10 minutes. 2.5μg of Hsp70 mAb (Stressgen, USA) 
and 0.4μl of DNMT1 pAb 3G5 (Courtesy Chuang LS) in 1% triton-X/PBS was used for staining 
overnight at 4°C. Remaining procedures were the same mentioned above. 
 
2.23 ATPase assay 
The fractions assayed for their activity were that from the gel filtration and monoQ elutions. 32P 
αATP was diluted 1/400X with 10μM cold ATP. 25μl of 4X ATPase activity buffer (Tris pH7.0, 
20mM NaCl) was added to 10μl of each sample of either gel filtration or monoQ. 20μl of the hot 
diluted ATP was added to each mix and topped up to 100μl. The mixture was incubated at 37°C 
for 30 minutes and the quenched with 2μl of 0.5 EDTA, 50μl of which was used for the assay. 
The samples were loaded onto a monoQ column for separation using a 2-40% salt gradient. 
Radioactivity was detected using a Radiomatic Flo-one beta Flow Scintillation analyzer 500TR. 
The same protocol was used to measure the effect of PCNA on the ATPase activity of Hsc70.  
 
2.24 Immunoprecipitation (IP) 
MRC5.SV40 cell line was used for the IP. The cells were lysed by sonication in 2X packed cell 
volumes of 50mM Tris.HCl pH7.5, 0.3M NaCl, 1mM EDTA, 1mM DTT, 50mM NaF and 1mM 




2.24.1 PCNA IP 
500μg of cell extract was added to 250μl of Hsc70 IP buffer 1(50mM Tris pH8.0, 3% glycerol, 
0.02%NP40, 0.1M KCl, 3mM MgCl2 ) and Hsc70 IP buffer 2 (50mM Tris pH8.0, 3% glycerol, 
0.02%NP40). The two different buffers were used to test the effect of Magnesium on 
Immunoprecipitation. Since the cell extract contains 0.3M salt, once mixed with the IP buffer, 
the salt concentration was adjusted to a final concentration of 0.15M with NaCl. 4μg of PCNA 
mouse mAb PC10 (Santacruz, USA) was used and mixed by inversion over-night at 4°C. The 
extracts were added to 20μl of anti mouse IgG beads which were pre-washed with Hsc70 IP 
buffer 1 and 2 with an additional 0.15M NaCl and mixed by inversion for another hour at 4°C. 
The beads were washed 3X with their respective before being boiled in 2X Laemmli buffer for 5 
minutes and run on a SDS-PAGE gel for western analysis. 
2.24.2 Hsc70 IP 
500μg of 5 SV40 cell extract was used for this IP. It was added to 250μl of Hsc70 IP buffer 2 
along with 20μg of mouse Hsc70 monoclonal antibody (Oncogenescience, USA). The remaining 
protocol was the same as above. 
 
2.25 Purification of Hsp40 
Hsp40 cDNA was cloned into pET vector using the NdeI and BamHI cloning site. They were 
transformed into BL21 DE3 (pLyse -) for expression of the protein. The pellets were lysed in 
lysis buffer (50mM Tris pH 7.5, 0.5M NaCl, 3% Glycerol) by sonication with 4 pulses of 10s at 
30% output power after which they were centrifuged from 10 min at 14,000 rpm at 4°C. The cell 
lysate was added to Ni-NTA Agarose beads (Qiagen) pre-washed in Equilibrium Buffer (50mM 
Hepes 7.9, 300mM NaCl, 10% Glycerol). The lysate was bound for 30 min at 4°C after which 
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the beads were centrifuged and washed twice in the Equilibrium Buffer. The beads were then 
washed for 5 min each with 5, 10 and 20mM imidazole to remove the impurities. The bound 
protein was eluted using 100 and 500mM imidazole for 30 min each at 4°C. The eluted proteins 
were dialyzed in ATP Buffer (50mM Tris.HCl 7.0, 20mM NaCl, 2mM MgCl2) for 1 hour.      
  
2.26 p21Waf peptide competition assay 
DNMT1 constructs tagged with GST was pre-bound to glutathione sepharose beads. A mixture 
of recombinant Hsc70, Hsp40 (Purified according to 2.25), PCNA( MonoQ fraction), 2mM ATP 
in binding buffer (0.1M KCl, 3mM MgCl2,10mM HEPES pH 7.5, 10% glycerol, 0.02% NP40, 
20mM Sodium Molybdate) was added to the beads and competed with 0.5, 1.0 and 5 μM p21 
peptide for 30 min at 4°C. The beads were washed three times with the binding buffer before 
running on an SDS-PAGE gel and transferred onto a nitro-cellulose membrane for western 







    




CHAPTER 3  RESULTS 
HPV genomes are approximately 7,900 bp in size with GC content close to 40%. Therefore, the 
frequency of finding CpG sites in the HPV genome would number close to 400. The common 
papillomavirus types of HPV-6, -11, -16, -18, -31 and -45 contain 160, 155, 112, 172, 122 and 
154 CpG sites which are much less than the expected number of 400, suggesting a function for 
CpG sites in the biology of genital HPVs. Although, the in situ methylation status of 
carcinogenic HPV genomes have never been studied in detail. The only evidence for a possible 
role comes from the experiment where in-vitro methylated HPV-16 genomes were 
transcriptionally incompetent after transfection into culture cells (Rosl et al., 1993). Here our aim 
is to study the role of methylation in cervical carcinoma cell lines with integrated HPV-16 
genomes.  
 
3.1 Role of methylation in HPV  
3.1.1 Copy number quantification of SiHa and CaSki cell lines 
The two most commonly studied HPV-16 cervical carcinoma cell lines are SiHa and CaSki. They 
are characterised by the fact that SiHa has one to two copies of the HPV-16 genome while CaSki 
is known to contain around 500 copies (Yee et al., 1985) integrated into the host chromosomes. 
This was confirmed in our studies where we used the E6 ORF region to quantitate the copy 
numbers in the two cell lines through semi quantitative PCR. β−globin gene was used as an 
internal marker to quantitate the amount of DNA used for the PCR reaction (Fig 1A). PCR of the 
E6 ORF region from CaSki cells show a significantly higher copy number than in SiHa cells (Fig 
1A). To obtain an estimate as to the number of folds of increase, the input DNA for SiHa was 
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increased by 10 and 100 times and compared with that of CaSki with 1 and 1/10 diluted template 
by PCR using the E6 ORF as the region to be amplified. 
  
Fig 1: Genomic copy number quantitation and RT-PCR of HPV-16 genes in SiHa and 
CaSki cell lines.  
A. Genomic PCR of the E6-ORF region in SiHa and CaSki depicting the copy number difference 
of the HPV-16 genome present in the 2 cell lines, β-globin served as the cellular control. 
B. Titration of the copy number difference between the two cell lines. 
C. RT-PCR confirms that similar amounts of the early genes E6, E7 and E1 are transcribed in the 
two cell lines. The transcription of the late genes is present only in CaSki cells. GAPDH was 
used to normalise the cDNA used for the RT-PCR.      
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Indeed, even a 100-fold increase in SiHa template did not match the levels of CaSki, thus 
confirming that the ratio of the copy numbers in both cells differ by a factor of a few 100 copies. 
RT-PCR of the respective mRNAs for the two cell lines are shown in Fig 1C. SiHa cells are 
know to be integrated such that they are interrupted in the E2, E4 and E5 genes (Baker et al., 
1987; Yee et al., 1985). Hence, no gene transcripts were observed for the three genes. Yet, the 
difference in the copy numbers did not translate into a similar increase in the transcription of the 
early genes E6, E7 and E1. In fact, the level of transcription of E6 and E1 genes was similar for 
both the cells lines, although E7 was slightly more for CaSki cells than SiHa. There was no 
expression of the late genes observed in SiHa cells. This difference in the levels of transcripts as 
compared to their copy numbers suggested a possible silencing mechanism (e.g. Methylation) in 
CaSki cells for most of its copies as well as the silencing of the late genes in SiHa cells.  
 
3.1.2 Methylation status of HPV-16 and HPV-18 genomes  
To study the methylation status of HPV-16 and HPV-18 genomes, the GTP dependent 
methylation sensitive restriction endonuclease McrBc was used as the preferred tool. This 
enzyme was chosen based on the work done by Tan HH and Chuang LS.  McrBc cuts close to 
the sequence purine methylated C (PumeC) in the context of a second PumeC about 40 to 2000 
bp apart (Stewart and Raleigh, 1998; Sutherland et al., 1992; Yee et al., 1985). After McrBc 
digestion, a PCR product indicates unmethylated DNA, which is of similar intensity to mock 
treated DNA. However, if the PCR product is weaker or absent when compared with the control, 
then the original DNA was methylated (Fig 2). 
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Fig 2: McrBc digestion and PCR analysis technique. McrBc digestion depends on the 
recognition of two PumeC half sites. After restriction digestion, a particular region of interest is 
amplified by PCR to detect the methylation status. A drop in the intensity of the digested PCR 
product or the absence of the amplicon in comparison with the control-undigested sample 
denotes a region, which is methylated.    
 
Since the methylation of Cytosines in the mammalian systems mainly occurs in the context of 
CpG dinucleotides, the digestion by McrBc would then be a useful tool to detect methylated 
CpGs. The drawback would be that, PumeCpAs and PumeCpTs can act, as potential recognition 
sites that would not be distinguished as well as potentially crucial PymeCpGs would not be 
recognised.    
 
3.1.2a HPV-16 methylation status 
 In the HPV-16 genome, 81 of the 112 CpGs (73%) are PuCpG. Therefore, they constitute 
potential targets for cleavage by McrBc. The CpG as well as PuCpG sites are distributed evenly 
throughout the whole genome (Fig 3) making the use of McrBc a viable option to study the 




Fig 3: Linearized map of HPV-16 genome. The relative position of the HPV-16 genes and 
amplicons G1 to G9 are shown in the top panel. The bottom three panels depict the distribution 
of the 112 CpG sites present in the genome as well as the positions of the 81 PuCG sites (McrBc 
recognition sites) and the 5 HpaII/MspI sites.       
 
To establish an overall picture of the methylation status throughout the HPV-16 genome in SiHa 
and CaSki cells, we used McrBc to digest their respective genomic DNAs and amplified PCR 
fragments of about 1Kb to span the entire genome. 
                                 
Fig 4: Circular genomic map of HPV-16. Inner circle shows the genome organization with 
relative location of the HPV-16 genes. Outer circle shows the position of PCR primers and 
relative location of amplicons G1 to G9. The numbers between the amplicons indicate the 5’ 





         
Fig 5: McrBc cleavage of the HPV-16 genomes in CaSki and SiHa cells. PCR amplification 
of G1 to G9 sets of primers with the cleavage of amplicons (McrBc, right lane of each set) 
indicating methylation, compared with the uncleaved controls (C, left lane of each pair). The 
cleavage pattern indicates hypermethylation throughout the CaSki genome and the late genes of 
SiHa genome (G5, G6, and G7). The LCR region and the early genes in SiHa remain 
unmethylated (G8, G9, G1, G2). G3 and G4 amplicons in SiHa are disrupted during integration.     
 
0.25μg of genomic DNA from SiHa and CaSki DNA were digested with McrBc for 1 hour at 
37°C and heat inactivated. The restriction digested genomic DNA from CaSki cells were diluted 
100 fold so as to have similar intensity upon PCR amplification as the SiHa DNA. Primer sets 
G1-G9 (See section 2.7 Table i) were used to amplify the DNA. Most of the amplicons were 
completely digested in CaSki cells, thus indicating extensive methylation throughout the genome. 
In SiHa the amplicons G8, G9, G1 and G2 (7145-122, 7850-556, 515-1528, 1501-2526 
respectively) which correspond to the LCR, promoter and coding region for E6 E7 and E1 were 
not digested indicative of the fact that these regions were not methylated. Regions G3 and G4 
(2501-3501, 3471-4472) were not amplified in SiHa as expected from the disruption of the E2 
gene during integration (el Awady et al., 1987a). Interestingly the late regions which correspond 
to the amplicons G5, G6 and G7 ( 4402-5402, 5367-6370, 6348-7173) in SiHa were digested 
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similar to CaSki DNA suggesting that these regions  comprising of the late genes L2 and L1 in 
the single copy of SiHa were targeted by methylation machinery and hence could be silenced. 
This methylation pattern would then co-relate with the expression levels of the HPV-16 genes in 
these two cell lines as most of the copies in the CaSki genomes are methylated and hence 
silenced. The one or two copies that are probably active were not seen in this initial screen and 
could be observed in further studies (See Fig 11).   
Thus, it showed that HPV-16 DNA could be methylated and that methylation may play a role in 
the silencing of the majority of HPV-16 copies in the CaSki genome. The methylation of the late 
genes in SiHa could also explain the lack of transcription of the genes observed in Fig 1C.  
Since there was a lack of amplification of the G3 and G4 regions from SiHa genomic DNA, we 
wanted to investigate the precise integration region of the HPV-16 genome in these cells. 
Another observation was that the G3 amplicon contained part of the E1 gene, yet the disruption 
of the region did not have an effect on the transcription of E1 as SiHa cells have an equivalent 
level of E1 compared to CaSki cells (See Fig 1C). This suggested that the integration site could 
be further downstream from the start site of the G3 amplicon (nt 2501).  
Therefore the G3 and G4 amplicons were further dissected into 6 smaller fragments; 3.1 (2501-
2804), 3.2 (2758-3160), 3.3 (3117-3501), 4.1 (3471-3840), 4.2 (3771-4250), 4.3 (4111-4472) of 








       
B. 
 
Fig 6: Deciphering the integration region in SiHa cells. 
A. Map of the dissection of the G3 and G4 regions to 6 smaller amplicon with the start and end 
sites for each primer set denoted. 
B. Diluted HPV-16 plasmid and CaSki genomic DNA are used as a control for PCR efficiency of 
the primers. Failure to amplify the 3.2, 3.3 and 4.1 amplicons in the SiHa genome denotes the 
region disrupted during integration.   
 
As a measure of the PCR efficiency, the HPV-16 plasmid and CaSki genomic DNA were used in 
diluted amounts comparable to that of the single copy SiHa genomic DNA. Fig 6B shows that the 
region corresponding to amplicons 3.2, 3.3 and 4.1 spanning bp 2758-3840 were not amplified 
and hence disrupted in SiHa cells. From our RT-PCR data (Fig1C), we know that the E1 gene in 
SiHa is expressed. Since the amplicon 3.1 ends proximal to the end of the coding region of the 
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E1 gene (position 2814 bp), the results we see would coincide with the data obtained. Thus, the 
disruption would be mainly in the E2 coding region as the amplicons missing (2758-3840 bp) 
coincide with that for the coding region of E2 (2756-3853 bp), explaining the lack of the E2 
expression in SiHa cells. Conversely, the late regions are intact, yet not expressed. Since the 
amplicons G5, G6 and G7 were found to be methylated from our McrBc digestion studies (See 
Fig 5), the role of methylation could come into play in switching off the late genes. 
 
3.1.2b HPV-18 methylation status 
A strategy similar to that of HPV-16 was used to study the methylation status of the HPV-18 
genome. This study was carried out in collaboration with Chuang LSH and Badal S. The HPV-18 
genome is 7857 bp and was divided into 8 amplicons; G1 (7019-56), G2 (37-930), G3 (876-
1890), G4 (1763-2818), G5 (2802-3797), G6 (3730-4784), G7 (4721-5918) and G8 (5830-7038). 
Each amplicon was designed to amplify a PCR product of about 1Kb in size (Fig 7A). The 
organization of the genome is very similar to that of HPV-16 in that the transcription of the early 
genes starts counter-clockwise at a promoter located the genomic position 105. Four different 
HPV-18 cell lines were used for this experiment, three of which were derivatives of the HeLa 
cell line. HeLa is widely used cell line with about 50 genomic copies of HPV-18 integrated 
within the host cellular genome (Schwarz et al., 1985).  
Here we use three different HeLa cell lines. HeLa CCl2 a typical representative of the widely 
used wildtype HeLa clone, D98 a HGPRT negative mutant strain of HeLa (Bengtsson et al., 
1975) and HeLa 444 a fusion cell between HeLa D98 and fibroblasts (Srivatsan et al., 1986). C4-
1 is unrelated to HeLa, but is another widely used cell line derived from a cervical cancer which 




                                            
B. 
                            
 Fig 7: McrBc cleavage and PCR amplification of the HPV-18 genomes. 
A. Inner circle shows the genome organization with relative location of the HPV-18 genes. Outer 
circle shows the position of PCR primers and relative location of amplicons G1 to G8 
 B. McrBc cleavage of Hela CCl2, D98, 444 and C4-1 where the figure documents lack of 
cleavage denoting lack of methylation in amplicons G1-G4 and  deletion of amplicons G5-G7 in 
all four cell lines. There is a partial (CCl2) or complete cleavage (D98, 444, C4-1) of the 
amplicon G8 which overlaps with the L1 gene denoting partial or complete methylation of the 
respective regions.   
 
 72
While we could amplify the amplicons G1 to G4 and G8 from all four clones, no amplicons 
could be generated for G5, G6, and G7. Through McrBc digestion of the genomic DNA of the 
four cell types (Fig 7B), we found no digestion in the G1 amplicon in HeLa CCl2, but a slight 
digestion in HeLa D98 and 444 as well as in C4-1. This may indicate that the G1 region, which 
contains the enhancer, promoter and replication origin of HPV-18, is not methylated in HeLa 
CCl2, but that possibly some of the 50 genomes in HeLa D98, HeLa 444 were methylated. The 
amplicons G2, G3, and G4, with the early genes E6, E7, and E1, are not digested, i.e. not 
methylated in all four cell lines. The PCR product for amplicon G8 is slightly digested in HeLa 
CCl2 and completely digested in the other three DNA preparations. This shows that the L1 gene, 
most of which is included in amplicon G8 is methylated in Hela D98, 444 and C4-1 cells. The 
finding that regions G5, G6 and G7 could not be amplified were expected, as a 2-3 kb deletion 
within HPV-18 of HeLa had been reported (Schwarz et al., 1985).  
Although our studies suggest a direct link between the methylation of HPV-16 in CaSki and 
silencing of the multiple copies, a similar co-relation could not be made with that of the HPV-18 
cell lines. This was because the multiple copies of the HPV-18 genomes in Hela D98 and 444 
showed a very similar methylation pattern to that of the single copy C4-1 in amplicons G1 and 
G8.   
Hence, we decided on further examining the role of methylation on the LCR and promoter 







3.1.3 Study of promoter methylation status in HPV-16 SiHa and CaSki cell lines 
3.1.3a HpaII/MspI  
 
                       
Fig 8: HpaII/MspI digestion and PCR analysis technique. The two enzymes are isochizomers 
that recognize a CCGG site wherein MspI cleaves the site regardless of the methylation status of 
the CpG. HpaII digests when the CpG is unmethylated and resistance to cleavage denotes a 
methylated site. After restriction digestion, a particular region containing the restriction sites is 
amplified by PCR to detect its methylation status.  
 
In addition to McrBc, methylated CpGs can be detected with the restriction enzymes HpaII and 
MspI. Both enzymes cleave the sequence CCGG. Methylation of the CpG within the recognition 
site inhibits the cleavage by HpaII, whereas MspI is unaffected (Fig 8). After digestion with the 
two restriction enzymes, PCR reactions were carried out to detect regions containing the 
HpaII/MspI recognition sites. In the case of HPV-16 the frequency of these sites are very low and 
are present only in five positions throughout the whole genome (Fig 3) at nt positions 57, 502, 
700, 3495 and 5377. Nevertheless, the presence of two sites at positions 57 and 502 does provide 
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the opportunity to study the methylation status of the two CpGs in the promoter and E6 ORF 
respectively (Fig 9). 
            
Fig 9: HpaII/MspI digests of SiHa and CaSki DNA. The two HpaII/MspI sites at position 57 
and 502 are denoted by two (*) and overlap with the p97 promoter and 3’ region of the E6 gene 
respectively. Genomic DNA of SiHa and CaSki was not cut (CT, control) or cleaved with the one 
of the two enzymes (H, HpaII; M, MspI) and PCR amplified to generate the amplicons P2, P5 
and P11. None of the three amplicons could be generated with either of the two enzymes in the 
case of SiHa cells, indicating lack of methylated CCGG sequences. In CaSki cells, most of the 
DNA was resistant to HpaII digestion but readily cleaved by MspI, indicating methylation of 
these two sites in most of the 500 HPV-16 copies in CaSki cells.    
 
Genomic DNA isolated from SiHa and CaSki cells were digested with HpaII and MspI and 
amplicons corresponding to the LCR region (P2: 7145-122), the E6 ORF (P5: 99-559) and p97 
promoter (P11: 7850-122) were amplified by PCR reaction. In the case of SiHa DNA, these 
amplicons could not be amplified after the cleavage with either of the two enzymes (Fig 9). This 
suggested that the three regions were not methylated. In the case of CaSki cells, most of the DNA 
were resistant to HpaII digestion but was readily cleaved by MspI (Fig 9). This indicated that the 
promoter and the E6 ORF contained a methylated cytosine in most of its copies at nt 58 and 503. 
 75
3.1.3b McrBc  
As seen earlier (Fig 3), McrBc is a more efficient tool to study methylation, as the number and 
distribution of the potential sites are far greater than the other enzymes. 
            
 
Fig 10: Distribution of CpG sites in the LCR, p97 and E6 ORF region of HPV-16. The 
position of each CpG site is represented by (*). A (*) denotes a PuCpG site (McrBc recognition 
site). The binding sites of transcriptional regulators AP1, NF1, Sp1 and E2 are denoted by the 
boxes.     
  
There are 27 CpGs present in the LCR, promoter and E6 ORF region of which 13 are PuCpGs 
(Fig 10, represented by *) and hence potential McrBc sites. This is in comparison with just two 
sites for HpaII/MspI. To study the methylation status of the different regions in the LCR, 
promoter and E6 ORF of the HPV-16 genome in SiHa and CaSki cells, amplification of 6 
different PCR products were investigated (See Fig 11A). 
 The methylation status of the LCR and p97 promoter region was studied using amplicons P1, P2 
and P3. P1 (7145-559) contained all three regions with 12 potential McrBc sites instead of 13 as 
one of the sites would be included in the primer sequence. P2 (7145-122) contained seven and P3 
(7145-7560) four sites respectively (Fig 11A). Three more amplicons P4 (7850-559) with five 
sites, P5 (99-559) with four sites and P6 (232-559) with one site were used to study the 
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methylation status of the promoter and E6 ORF regions. CaSki genomic DNA was diluted 100 
fold to have a similar intensity upon PCR amplification as the SiHa DNA.   
In the case of SiHa cells, none of the six amplicons showed any change in the intensity when 
compared to the undigested controls after McrBc digests, suggesting that none of the CpGs in the 
LCR, promoter or E6 ORF were methylated (Fig 11B). Therefore, the one or two copies of HPV-
16 in SiHa cell line were able to transcribe the early genes un-hindered by methylation as 
observed in Fig 1C if indeed methylation does regulate the transcription of HPV-16 genes.  
For CaSki cells amplicons P1, P2 and P4 showed complete digestion with McrBc whereas P3, P5 
and P6 showed a residual amount of DNA that is not digested by the enzyme, which could 
correspond to the unmethylated copies. The intensity of the residual band in the three amplicons 
P3, P5 and P6 was about 20% of the undigested control. This indicated that there were probably 
only a few copies of unmethylated HPV-16 DNA in the CaSki genome, which would explain the 
similar levels of transcription of the HPV genes seen in the two cell lines in Fig 1C. Interestingly 
the residual bands are not observed for all the six amplicons. This suggested that the methylation 
pattern was not uniform throughout the LCR, promoter and E6 ORF regions. 
Since P5 and P6 correspond to the E6 ORF, it is possible that more copies of the CaSki genome 
are unmethylated in this region as compared to P4, which also includes the promoter. Similarly, 
amplicon P3 that is further away from the promoter region had a residual band indicative of 
unmethylated CpGs. P1 and P2, which included the promoter region showed complete digestion. 
Therefore, it can be concluded that the 5’ region of the LCR and 3’ region of the E6 ORF, are 











Fig 11: McrBc digests of the LCR, p97 and E6 ORF region in SiHa and CaSki DNA. A. Top 
panel represents the LCR, p97 and E6 ORF region in HPV-16 with the PuCpG sites marked in 
(*). Bottom panel shows the mapping of the six amplicons (P1 to P6) generated to detect the 
methylation status of the particular region. 
B. PCR of the six amplicons after McrBc digestion of the SiHa and CaSki DNA. The PCR 
product of the digested samples (McrBc) is compared with the control uncut product (Ctr). 
Absence of or a decrease in the intensity of the PCR product in comparison with the control 





McrBc is therefore efficient in identifying gross methylation status over a large region of 
genomic DNA. However, it does have limitations in identifying precise methylated CpG sites, or 
non-PuCpGs sites unless amplicons are limited to one known CpG site. This can be 
supplemented by the well-established bisulphite based genomic sequencing.  
 
3.1.3c Bi-sulphite analysis 
Bi-sulphite modification takes advantage of the fact that it converts cytosine residue to uracil 
effectively, with the 5-methylcytosine residue remaining unaltered.                                    
Thus, the sequence of the treated DNA would differ based on the methylation status of the 
original genomic template. The modified DNA can be amplified by a PCR reaction with primers 
specific for sequences based upon these chemically induced differences.  
The McrBc restriction digestion technique was used to pinpoint regions of interest that were 
found to be methylated. The bisulphite technique was used to analyse in detail the status of 
methylation of the individual CpGs within these regions. The first region was between genomic 
positions 7498 and 161. This segment contains 11 CpGs at positions 7535, 7554, 7677, 7683, 
7695, 7862, 31, 37, 43, 52, and 58 (Fig 7). The first 5 of these CpGs are in close proximity to the 
AP1 and NF1 sites (Fig 10) of the HPV-16 enhancer (Chong et al., 1990). The last five CpGs ( 
7862, 31, 37, 43 and 52) overlap with a Sp1 and two E2 binding sites (Fig 10), which regulate the 
transcription start at position 97 (Gloss and Bernard, 1990; Tan et al., 1994). A second segment 
was chosen to act as a control which contained the L2 gene (4322-4946) methylated in both SiHa 
and CaSki cells as observed by McrBc restriction digestion.   
After the bi-sulphite treatment, primers specific to the two regions Msp3 (4322-4970) and Msp4 
(7498-161) (See section 2.7 Table iv) were used for amplification by PCR. Care was taken to 
ensure that the primer sequences themselves did not contain any CpGs. This was to ensure that 
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the PCR products were not selectively amplified for a particular methylated status of certain CpG 
sites. As a control, unmodified DNA (SiHa CT, CaSki CT) was used for the PCR reaction to 
show that the primers were specific towards only the bi-sulphite treated DNA (Fig 12). The 
bands were extracted and purified for sequencing.  
Fig 13 shows the sequencing results for the region 7534-106, which includes the 11 CpG sites in 
the region amplified by the primer set Msp4. The control sequence in black represents the normal 
genomic sequence for HPV-16 (from database ftp://ftp-t10.lanl.gov/pub/papilloma/GenBank-
files/Human-papilloma/HPV16R.gb).  
                                  
                      
Fig 12: PCR of the bi-sulphite treated SiHa and CaSki DNA. PCR with primers specific for 
bi-sulphite treated DNA for CaSki (CaSki Bis) and SiHa (SiHa Bis) in the 2 regions Msp3 ( L2 
region, 4322-4970) and Msp4 ( LCR, p97 region, 7948-161). Lack of PCR products using 
untreated DNA as a control (CaSki CT, SiHa CT) shows the specificity of the primers. The PCR 
products were excised, purified and sequenced.   
 
Unmethylated cytosines are modified to a thymidine, while methylated cytosines remain 
unaltered. All 11 CpG sites in the CaSki genomic DNA (boxed in red) remain unchanged and 
hence methylated, while that of SiHa cells were deaminated to thymine residues and therefore 
not methylated. 
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The control L2 region was amplified by the primer set Msp3 (Fig 12). The sequencing results 
here are shown for both the sense and antisense strands as all the CpGs could not be read through 
either one of them alone. The sense strand was similar to what was observed before with the 
cytosines in the non-CpG sequence being converted to tymines. In the region of 4352-4532, there 
were 3 CpG sites and all three of them were un-modified for both CaSki and SiHa cells (Fig 14A 
boxed in red), therefore they were methylated. These PCR products were generated using the 
same template as that for the LCR and promoter region using the primer set Msp4.  
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 Fig 13: Sequence results of the bi-sulphite treated CaSki and SiHa DNA using Msp4 
primer. The sequence results were read from nt 7534-7906 and 1-106. Control (in black) refers 
to the original HPV-16 sequence; CaSki (in red) and SiHa (in blue) are bi-sulphite treated DNA 
sequence. The 11 red boxes represent the CpG sites in the region. All 11 CpGs in CaSki 
remained unaltered and hence were methylated while all 11 cytosines in SiHa were converted to 








B.      
Fig 14: Sequence results of the bi-sulphite treated CaSki and SiHa DNA using Msp3 primer. 
Control (in black) refers to the original HPV-16 sequence; CaSki (in red) and SiHa (in blue) are bi-
sulphite treated DNA sequence  
A. 3 CpG sites were read in the sense direction (nt 4352-4532)  
B. 6 CpGs read in the antisense direction (nt 4929-4869, 4449-4389). The sequencing results 






The antisense sequence in Fig 14B shows that the three CpGs in the region 4929-4869 as well as 




Table 1: Methylation status of CpGs in SiHa and CaSki DNA from the Msp3 and Msp4 bi-
sulphite PCR and sequencing. (+) denotes a methylated CpG, while a (-) denotes an 
unmethylated CpG. All the 6 CpGs in SiHa and CaSki in the L2 region were methylated (4322-
4970) while only the CpGs in the CaSki DNA from the LCR and p97 region were methylated 
(7498-161).       
 
Taken together these results illustrate that the methylation status of the SiHa genomic DNA was 
different in the two regions that we examined. Therefore, in SiHa cells the CpGs in the LCR and 
promoter region are not methylated (Fig 13, Table 1) whereas those in the late regions are 
targeted for by methylation and hence silenced (Fig 14, Table 1). The bi-sulphite reaction also 
corroborates the data obtained with the McrBc digestion in Fig 5. In the case of CaSki cells, since 
most of their 500 copies are methylated, the unmethylated, hence transcriptionally active copy of 
one or few HPV-16 genomes would not have been detectable in this experiment. Another point 
to note is that the CpGs analysed in Table 1 exclude those, which had a higher tendency to be 
unmethylated when studied using the P3, P5 and P6 amplicons by McrBc digestion. However, 
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considering the number of copies that were unmethylated even in these regions was very few, it 
cannot be said for sure if they would have been picked up in the bi-sulphite analysis.   
The two techniques in combination form a very powerful analytical strategy wherein, McrBc 
digestion could be used to determine the gross methylation status of particular regions of 
genomic DNA. Once a region of interest is established, bi-sulphite analysis could then be used to 
decipher the methylation status of individual CpGs.  
 
3.1.4 Clinical analysis of HPV-16 infected clinical samples 
 
With the strong correlation of the promoter methylation states (Fig 11) and its silencing found in 
the data obtained in the two HPV-16 cell lines SiHa and CaSki, we decided to see if a similar 
pattern could be detected in normal and cancerous clinical samples infected with HPV-16.  
To this end, we screened 81 clinical samples (normal or cancerous) which were positive for only 
HPV-16 from two cohorts. 33 were obtained from Luisa Villa (Ludwig Institute of Cancer 
Research, Sao Paulo, Brazil) and 48 from Cosette Wheeler (University of New Mexico, 
Albuquerque).  The second cohort was further sub-classified as normal, CINI, CINIII or invasive 
cancer stages of cervical cancer. The classification of the samples for the second set was not 








3.1.4a Mapping of meCpG by McrBc digestion of the HPV-16 promoter 
To investigate the significance of methylation in HPV-16 cervical samples, we choose the region 
corresponding to the primer set P4 (7850-559) as this could provide the methylation status of the 
p97 promoter, which drives the expression of the E6 and E7 oncogenes. 
To make sure that our PCR reactions were sensitive enough, optimization experiments were 
carried out using CaSki and SiHa DNA as control standards. 
Serial dilution of SiHa (150ng-15pg) and CaSki (15ng-1.5pg) genomic DNA were amplified 
using two enzymes: Taq (Promega) and AmpliTaq Gold DNA polymerase (Roche). As can be 
seen from Fig 15, the sensitivity of the Taq enzyme was only up to 1.5 ng for SiHa genomic 
DNA, while for CaSki it could detect up to 15 pg of genomic DNA.  
                                   
                                  
 
                                   
Fig 15: PCR optimization and sensitivity. Taq DNA polymerase (Promega) and AmpliTaq 
Gold (Roche) were used to test the sensitivity of the PCR reaction. AmpliTaq Gold could detect 
PCR with as little as 1.5pg of the multiple copies CaSki DNA and 150 pg of the single copy SiHa 




The sensitivity was 100 fold more for CaSki because they contain about 500 copies as opposed to 
the single copy in SiHa. However, Tag Gold increased the sensitivity by a further 10 fold as we 
could detect up to 150 pg of SiHa and 1.5 pg of CaSki DNA. 
Therefore, the two enzymes were used appropriately in our experiments depending on the 
sensitivity required as asymptomatic samples were generally known to contain lower 
concentration of DNA and hence a more sensitive enzyme was required to analyse them.    
Fig 16 shows the McrBc digests from the Brazilian cohort. The DNA was digested with McrBc 
followed by a PCR amplification using the P4 primer, which included part of the LCR, the p97 
promoter and the E6 ORF (nt 7850-559) (Fig 11). Among them 8 of the 14 asymptomatic smears 
were digested by McrBc completely or partially. As can be seen from the Fig 16, asymptomatic 
samples BN3, BN4, BN7 and BN14 showed almost complete digestion, whereas BN2, BN5, 
BN6, and BN10 show partial digestion of the promoter region. Therefore, the promoter region in 
these samples was considered to be methylated.  The remaining six asymptomatic samples were 
not cleaved by McrBc and hence thought to be unmethylated. Hence, within these samples the 
extent to which the promoter is methylated could vary. As for the invasive carcinomas only 2 
(BT7 and BT10) of the 16 samples were cleaved by McrBc and hence methylated.   
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Fig 16: McrBc digests to detect the methylation status of the Brazilian samples in the P4 
amplicon (7850-559). (BN1-14) refers to normal asymptomatic samples and (BT1-16) tumour 
samples. 8 (labelled in blue) of 16 normal samples demonstrated partial or complete cleavage 
with McrBc indicating the presence of methylation, while only 2 (labelled in blue) of the 16 
tumour samples were methylated 
  
 
Therefore, for the Brazilian samples 57.1% (8 of 14) of HPV-16 genomes from asymptomatic 
smears and 12.5% (2 of 16) carcinomas contained methylated promoter (Table 2). 
We received three samples with DNA in the episomal form classified as CIN-I. The McrBc 
digests of which are shown in Fig 18 (BCI-1, BCI-2, BCI-3). The G8 amplicon, which includes 
the LCR, promoter and the E6 ORF regions, could not be amplified due to a limited amount of 
DNA provided. Since none of the other amplifiable regions in the samples were digested by 
McrBc, hence unmethylated, the three samples were classified as being unmethylated for the 
promoter region as well in Table 2.  
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Fig 17: McrBc digests to detect the methylation status of the samples from New Mexico in 
the P4 amplicon. Normal (AN1-4), CIN I (ACI1-4), CIN III (ACIII1-4) and tumour (AT1-4) 




    
Table 2: Methylation of the LCR and E6 gene of HPV-16 in clinical samples from Brazil 
and New Mexico. CpG methylation was determined by cleavage of the DNA preparations with 
the restriction enzyme McrBc and subsequent PCR amplification of a genomic segment of the 
HPV-16 corresponding to the promoter and the E6 gene (P4). Data from both cohorts were 
combined in the bottom table.    
 
As for the cohort from New Mexico(Albuquerque), under similar experimental conditions 5 of 
11 asymptomatic smears (AN2, AN3, AN4, AN8, AN11), 3 of the 10 CIN I lesions (ACI-3, 
ACI-5, ACI-8 ), 2 out of 10 CIN III (ACIII-1, ACIII-6) lesions and none among the 17 cancers 
contained methylated HPV-16 promoters. The different stages and classifications of the above 
samples were revealed to us only after the experiments were carried out. Therefore, in the second 
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batch of samples we found a similar pattern for the frequency of occurrence of methylation in the 
HPV-16 promoter region. 46% of asymptomatic smears, 30% of CIN I lesions, 20% of CIN III 
lesions and 0% of cancers showed methylation of their promoter (Table 2). A point of caution is 
that some of the invasive cancer samples had a high concentration of DNA (AT1, AT5, AT6 and 
AT8). Therefore, care has to be taken to ensure efficient digestion using controls like the CaSki 
genomic DNA, which has multiple copies of the HPV-16 genome, concurrently with the analysis 
of the samples.  
Combining the results of the two cohorts together, 13 of 25 (52%) of HPV-16 genomes from 
asymptomatic smears, 5 of 23 (21.7%) of those from precursor lesions (CIN I and CIN III) and 
only 2 of 33 (6.1%) of those from carcinomas contained methylated p97 promoter. This indicated 
that the methylation of the LCR, promoter and E6 gene decreased with increased tumourigenesis 
(Table 2).  
An important point to note in this study is that the P4 region amplified after digestion with 
McrBc contains 13 CpGs of which 4 are PuCpGs and hence recognition sites for the enzyme (Fig 
10). Therefore, there could be a possible under-representation of the methylation status if an 
uneven distribution of methylation of the CpGs existed wherein; non-PuCpGs were preferentially 
methylated. This could be overcome by using the bi- sulphite analysis to decipher the 








3.1.4b Mapping of meCpG by McrBc digestion of the HPV-16 genome 
 
To examine whether one could find a similar distribution of McrBc cleavage as found in SiHa 
and CaSki cells (See Fig 5), we analysed the methylation status of the HPV-16 genomic DNA 
from a few samples. The primers used were similar to what has been mentioned before (G1-9) 
(Fig 4) used to detect the distribution of methylation in SiHa and CaSki cells. However, in the 
current analysis the final set of primers G8 (7145-122) and G9 (7850-559) were combined and 
labelled as G8 (7145-559) (Fig 18A).  
The amplification of all the primers were limited by the amount of DNA and the efficiency of 
PCR amplification of certain primer sets hence; a few of the amplicons could not be detected. In 
asymptomatic sample AN3 the G8 primer which now includes the LCR, promoter and E6 ORF, 
was methylated. The distribution of methylation was not specific to only the promoter or early 
genes but was spread throughout the genome. Hypermethylation was observed mainly in G8 and 
G1 amplicons corresponding to the promoter and E6 ORF regions. Comparatively G4 and G5 
regions corresponding to the E2 gene were hypomethylated. 
In the 3 CIN I samples analysed (ACI-5, ACI-8,ACI-10 ), there seems to be a gradual loss of 
methylation of the genome with ACI-5 showing heavy methylation of most regions and ACI-10 
showing no methylation in the regions that could be amplified. Again, the least methylated 
regions were that in G4 and G5 for all 3 samples. For the 2 CIN III samples, there was no 
detectable methylation in any of the amplifiable regions for ACIII-3 while G6, G7 and G8 were 






    B.                                   
 
Fig 18: McrBc cleavage of segments of HPV-16 genomes in clinical samples.  
A. Genomic map of HPV-16 and the relative locations of amplicons G1-G8.  
B. Cleavage of amplicons G1-G8 by McrBc (McrBc, right lane of each pair) indicates 
methylation, compared with uncleaved controls (CT, left lane of each pair). The clinical 
specimens used were the Normal (AN3), CINI (ACI-5, ACI-8, ACI-10, BCI-1, BCI-2, and BCI-
3), CINIII (ACIII-1, ACIII-3) and tumour (BT4, BT7) samples.          
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As explained earlier in Section 3.1.4a, the 3 samples from the Brazilian cohort with episomal 
copies of HPV-16 were considered as CIN-1 samples. There was no detectable methylation in 
any of the amplifiable regions in all three samples (BCI 1-3).   
In the case of the two invasive samples from the Brazilian cohort analysed, BT7 showed a similar 
pattern to CaSki in that, almost all the regions were targeted by methylation. On the other hand, 
BT4 was unmethylated throughout its genome except for the G2 amplicon. 
 
Comparing the genome wide methylation status with that obtained for the P4 amplicon in Fig 16 
and Fig 17 suggests that, in samples AN3, ACI-5, ACI-8 and BT-7 a methylated promoter was 
indicative of the HPV-16 being targeted by methylation throughout its genome but to varying 
degrees in the regions that could be amplified in Fig 18.      
Conversely, ACI-10, ACIII-3 and BT-4, which were not methylated in the P4 amplicon (Fig 17, 
16), were seen to be unmethylated in the other regions that were amplified in Fig 18. Therefore, 
the methylation of the promoter region could be indicative of the methylation status throughout 











3.1.4c Mapping of meCpGs of the HPV-16 promoter by bisulphite modification 
This technique requires a considerable amount of DNA and hence was carried out on only 15 
samples with a distribution of them being 5 asymptomatic smears, 2 CIN I lesions, 1 CIN III 
lesion and 7 cancers. The primer Msp4 (nt 7498-161) used earlier to study the methylation status 
of HPV-16 genome in SiHa and CaSki cells (Fig 12) was used to amplify the treated DNA and 
the resulting PCR was purified and sequenced.  
The sequence results are depicted in a table form (Table 3) with the methylation status of the 
individual CpGs denoted by either a (+) for methylated, (-) for unmethylated and (+/-) for a 
mixture methylated and unmethylated CpGs. The CpGs whose methylation status could not be 
read are denoted by (?).       
In Table 3, all eleven CpGs of the five asymptomatic smears (N1-5) were methylated. This 
suggested that the samples chosen for analysis were similar to the 52% bracket in Table 2, which 
was found to be methylated. This is comparable to the methylation pattern observed in CaSki, 
where it represented the majority of the copies that are silenced. 
In the two CIN I samples (CI-1 and CI-2), four and three, respectively, of the five CpGs at the 
promoter were not methylated, while all CpGs of the enhancer were methylated in one sample 
and two in the other one. Co-incidentally, the CpG at nt 31 that was methylated in the two 
samples is a PuCpG and hence, in the McrBc analysis it could have been digested and classified 
as a methylated sample.     
A CIN III (CIII-1) sample and two tumour samples (T1 and T4) were methylated at all CpGs of 
the enhancer and promoter, while the remaining five other tumours had heterogeneous 
methylation patterns. Yet, in all the ten CIN and invasive cancers, the CpG at nt 7862 remained 
unmethylated. This site is the only CpG dinucleotide between two specifically positioned 
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nucleosomes and close to an AP-1 site essential for transcriptional activation during epithelial 
differentiation (Bernard, 2002; Stunkel and Bernard, 1999).   
 
Table 3: Methylation of 11 CpGs in the LCR of HPV-16 in two cell lines and 15 clinical 
samples. (+) methylated, (-) unmethylated, (-/+) both methylated and unmethylated residues in 
the same sample, (?) unknown. Results shown are for Asymptomatic (N1-5), CIN-I (CI-1, CI-2), 
CIN-III (CIII-1) and tumour samples (T 1-6).    
CpGs between position 7535 and 7695 are close to the cis-responsive elements of the viral 
enhancer; the CpGs between position 31 and 58 overlap with promoter elements; and the CpG at 
position 7862 is located between the borders of two specifically positioned nucleosomes.      
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Nevertheless, there exists some discrepancy between the results obtained in Table 2 and that of 
the methylation status of the invasive cancer samples as observed by bi-sulphite sequencing in 
Table 3. It has to be noted that analysing the methylation status by bi-sulphide sequencing 
involves PCR amplification of the particular fragment after modification, followed by excising 
the product before it is sequenced. Therefore, the stringency required to avoid any cross 
contamination is much higher and could result in a few inaccurate representation. The direct 
sequencing method used in this experiment would represent the majority of the copies. 
Therefore, it is advisable to analyse the sequences by cloning and scoring for the methylation 
status of the CpG sites in the various clones.      
In contrast, the McrBc digestion technique involves digestion by the enzyme, which has been 
shown to be very efficient (Fig 11) followed by PCR amplification. This makes it a more viable 
option in studying the methylation status of a particular region. Yet, care has to be taken that the 
region studied can be efficiently digested since the enzyme would only recognise the PuCpGs. 
Therefore, a more effective and accurate method of analysis could use overlapping regions to 












HPV-16 genomic DNA in both SiHa and CaSki cells were targeted by the DNA methylation 
machinery. In SiHa, this is restricted to the regions coding for the late genes (Fig 5: amplicons 
G5, G6 and G7), while the rest of the HPV-16 genome remains unmethylated. In contrast, the 
HPV-16 genome is heavily methylated (Fig 5) in CaSki cells. The methylation of the p97 
promoter in most of the copies in CaSki DNA would explain the comparative levels of the early 
gene transcription seen in Fig 1C between the two cell lines. This would also explain the lack of 
expression of the late genes in SiHa cells (Fig 1C) as they corresponded to the regions that were 
methylated. The methylation status of the HPV-16 genome of the two cell lines were further 
confirmed using the bisulphite analysis (Fig 13, 14 and Table1) which corroborated with what we 
had observed using the methylation sensitive restriction digestion. Therefore, our data provides a 
link between DNA methylation and its effect on HPV-16 biology.             
The recognition of the HPV-16 DNA does not seem to be based on a single physical property. 
The HPV-16 genome can be targeted as an episome, since we observed methylation in the 
asymptomatic smears (52% of samples tested, Table 2), which is considered to harbour episomal 
forms of the virus. This could be due to the host defence mechanism where, foreign or parasitic  
DNA is targeted for methylation, a line of thinking championed by Bestor (Bestor, 1998). Yet, 
the three CINI samples ( BCI-1, BCI-2 and BCI-3) which also harbour an episomal form  seem 
to be completely unmethylated in the regions that were amplified (Fig18).     
However, since we detected methylation in some tumours and in the cell lines with integrated 
HPV-16 DNA, they could be targeted due to being repeated sequences (Yoder et al., 1997) like 
in CaSki cells or due to a recombination event (Doerfler et al., 2001).  
We showed that the methylation of the HPV-16 LCR did not follow a simple pattern as the 
methylation status of individual CpGs could vary from one sample to another (Table 3, CIN and 
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tumour). Yet there could be a slight discrepancy in samples such as T1 and T4 (Table 3) which 
show methylation of all but one site. However, CpG methylation does not affect the binding of 
the E6 promoter factor Sp1 (Harrington et al., 1988), while it displaces the negative regulator E2 
protein from the promoter (Thain et al., 1996).  
Therefore, methylation status of the CpG at nt 7862 could play a vital role in these samples. This 
CpG site is located between the borders of two specifically positioned nucleosomes, one which 
overlaps with the enhancer and the other with that of the promoter (Bernard, 2002; Stunkel and 
Bernard, 1999).  If the site were to remain unmethylated, it could be speculated that the promoter 
region could be left free from the recruitment of the nucleosome complex. Thus even if the 
promoter were to be methylated, it would remain in an open structure where factors such as Sp1 
could bind and initiate transcription. Therefore, the loss of methylation of a few sites as observed 
in T1-7 (Table 3) could prove crucial enough to lift the repression on the promoter. It is not clear 
though that demethylation of the CpG site at 7862 alone is sufficient, or this holds true for any 
one of the CpG sites present in the promoter region. As discussed earlier, we did not see the 
presence of methylation in most of the tumour samples using the McrBc digestion technique 
(Table 3). Hence, it is possible that the methylation status of a few CpG sites by bisulphite 
sequencing could be misrepresented due to the human error. Our analysis of asymptomatic 
samples (Table 3, N1-5), suggests that for an effective silencing of the promoter, probably all the 
CpGs would have to be methylated. In either case, the results obtained by bisulphite sequencing 
have to be confirmed with a study involving a bigger sample size to obtain a definitive answer.     
A way to verify the co-relation of methylation of the promoter with oncogenesis would be to use 
samples from which RNA levels of the E6 and E7 oncogenes could be correlated to the 
methylation status of the CpGs in the HPV-16 promoter. Unfortunately, this could not be 
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achieved in the current study all the samples obtained were paraffin embedded from which RNA 
could not be extracted.      
The finding from the McrBc analysis demonstrated that the genomic hypomethylation of the 
promoter region could correlated with carcinogenic progression (Table 2). The technique could 
be used as a tool to detect the risk involved for patients in developing cervical cancer once 
infected with the HPV-16 virus.  
Current detection of cervical cancer is through the Pap smear test. The disadvantage of which is 
the fact that it can only detect cervical cancer once it shows a difference in the morphology of the 
cells but would not be able to asses the risk of developing it if infected with the HPV virus. With 
the general opinion that around 70% of all sexually active women are infected with the virus, yet 
the incidence of cervical cancer is around 500,000 world wide of which 290,000 cases are fatal. 
The ability to asses the risk involved in such people to develop cancerous growth is very vital. 
The only commercially available in vitro diagnostic test for HPV DNA only detects the presence 
of the high risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) or the low risk HPV 
types (6, 11, 42, 43, 44). This in itself does not provide any information as to the risk of 
developing cervical cancer. Of all the cases of cervical cancer, 50% of them are accounted for by 
the HPV-16. 
Our findings have demonstrated that a possible change in the methylation pattern of the LCR and 
promoter region in HPV-16 infected patients could trigger the transformation from the latent 
HPV-16 virus in most women to the transformed state that could lead to tumourigenesis. For this 
to be used as a commercially viable test to determine the risk a patient has in developing cervical 
cancer if they are HPV-16 positive, needs further validation.  
Firstly, a more quantitative approach using real time PCR to detect the change in the intensity of 
the PCR product after McrBc digestion is essential for the clinical samples. This would then 
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allow for an exact valuation as to the level of methylation present in a particular sample. 
Secondly since only around 55% of asymptomatic patients were methylated (Section 3.1.4a, 
Table 2) a study has to be carried out to see if the remaining 45% of patients are more susceptible 
to developing CIN I kind of lesions over a period of time. This could be achieved by analysing 
samples collected from the same patient over successive visits whose infection progresses from 
the asymptomatic to CIN lesions. The same study could also be used to test the hypothesis 
where, the loss of methylation over time of the different CIN lesions could lead to a more 
tumourigenic phenotype and hence to invasive cancer.  
The technology of detecting the change in methylation pattern once validated has the potential to 
be an add on test along with Pap smear and HPV DNA detection. This could lead to predicting 
the possible predisposition a person has towards developing cervical cancer as well as the 
chances the patient has of a benign tumour progressing to a more aggressive cancer once infected 













3.2 Effect of 5AzadC on DNMT1 in HPV-16 cell lines 
The results thus far suggested that the expression of HPV-16 genes may be affected by the 
methylation of the p97 promoter as seen in SiHa and CaSki cell lines (Fig 1C, 5, 11). Clinical 
studies (Section 3.1.4a, Table 2) suggested that there could be a direct relationship between the 
increased expression of the E6 and E7 oncogenes and hypomethylation of the p97 promoter as 
seen from the progression in tumourigenesis and progressive loss of methylation.  
5AzadC is a well know inhibitor of DNMT1 and hence a common drug used in relieving the 
methylation dependent repression of tumour suppressor genes. Here we show the effects of 
5AzadC on the HPV-16 cell lines. (The experiments were carried out together with Chuang LS, 
Yeo WL, Tan HH). 
 
 
3.2.1 Effect of 5AzadC on CaSki cell line from ATCC 
 
3.2.1a Protein expression levels and flow cytometric analysis 
CaSki cell line obtained from ATCC was treated with increasing concentrations of 5AzadC (0.1, 
0.25, 0.5, 1.0 and 4.0 µM)   in a time course experiment for 3, 6, 12, 24 and 48 hours Fig 19. The 
expression levels of DNMT1 seemed to remain unaltered after 3 hours of treatment. However, at 
6 and 12 hours post treatment, DNMT1 protein levels decreased with concentrations higher that 
0.25µM 5AzadC. By 24 hours there is a significant loss of DNMT1, even with concentrations as 
low as 0.1µM 5AzadC. Interestingly (See Fig 19, 48 hours) there is a recovery in the expression 
levels of DNMT1 at the lower concentration. To see if the decrease in the expression levels of 
DNMT1 led to an effect on their cell cycle profile, flow cytometric analysis was carried out for 
all the samples Fig 20. 
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Fig 19: CaSki ATCC cells are sensitive to 5AzadC. CaSki ATCC cells were treated with 
increasing concentration of 5AzadC for the stated lengths of time. The cells were lysed using the 
RIPA lysis method and analysed by Western blot using 2E10, a MAb specific for DNMT1. A 
drop in the expression levels of DNMT1 by western analysis is observed after 24 hours with a 
slight recovery of the expression at lower concentrations of the drug after 48 hours.     
 
 
However, even with a significant loss of DNMT1 after 24 hours of treatment there does not seem 
to be any significant effect on their cell cycle profiles, although a slower growth rate was 
observed for cells treated with higher doses of 5AzadC. To test if this hypothesis were true, the 
number of cells at each time point were counted using the flow cytometric counter since all 
plates were initially seeded with the same number of cells. The number of cells would then 
provide an analysis of the growth pattern of the cells.  
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Fig 20: Flow cytometric analysis of CaSki cells treated with increasing concentration of 
5AzadC over different time points.  
 
 
                         
Fig 21: Growth analysis for CaSki ATCC treated with 5AzadC. Cells treated with no drug 
(ct), 0.1 μM (0.1A) and 4μM 5AzadC (4A) for the various time points were counted in the flow 
cytometric analysis counter for 30s. The number of cells was plotted as a bar chart that illustrates 





















































Fig 21 shows the number of cells counted for Control, 0.1 µM and 4.0 µM 5AzadC for all the 5 
time points. It can be observed that for 0.1 µM 5AzadC there was no adverse effect in their 
ability to multiply as their cell numbers and hence their growth was the same as the control cells. 
For 4 µM 5AzadC the cells showed a similar growth rate as the control cells until the 24 hour 
time point. There was a complete lack of growth thereon as the cell numbers do not increase for 
the 48 hour time point, as opposed to the control and 0.1 µM 5AzadC cells. Therefore, even 
though the flow cytometric analysis did not show a significant cell cycle arrest at any particular 
phase, there definitely seems to be lack of growth for cells treated with higher concentration of 
5AzadC. 
                      
Fig 22: Western analysis of CaSki ATCC cells treated with varying concentrations of 
5AzadC for 24h. Total cell lysates were prepared and immunoblotted with antibodies for 
DNMT1 (mAb, 2E10), p53 (mAb, DO-1), PCNA (mAb, PC10), Hsp70 (SPA-820) and p21. 
Actin served as the cellular control for equal protein loading. Loss of DNMT1 expression leads 
to an induction of p53 and p21 Waf1/Cip1 proteins.     
 
To test if the growth retardation was due to an induction of cell cycle inhibitor proteins, western 
blots were carried out using antibodies for p21Waf1/Cip1 and p53. Fig 22 shows inductions of both 
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p53 and p21Waf1/Cip1 at 24 hours post treatment but only at concentrations higher than 0.5 µM 
5AzadC. This would explain why we saw cell growth for 0.1 µM and not 4 µM 5AzadC by 48 
hours (Fig 21). No change was observed in Actin, PCNA and Hsp70 proteins.  
 
3.2.1b Transcriptional and genomic analysis 
 
To see if the decrease in DNMT1 levels led to changes in the transcription of the HPV-16 genes, 
RNA was extracted from cells after 24h treatment and compared with the mock treated cells. 
Using an Oligo dT primer, cDNA was prepared from the RNA. A semi quantitative RT-PCR was 
carried out for the various HPV-16 genes.  
Fig 23 shows the expression pattern of the various mRNA. Low doses of 5AzadC did not seem to 
significantly affect the early gene expression of E6, E7, E1 and E4; with a slight decrease 
observed only with 4 µM 5AzadC. Nevertheless, expression levels of the late genes E2, L1, and 
L2 are induced for all concentrations of cells treated with 5AzadC in a dosage dependent manner.  
To check if the increase in the RNA expression levels is due to the loss of DNMT1 and 
subsequent demethylation of the HPV-16 genome, genomic DNA was prepared from the 5AzadC 
treated cells and the methylation pattern was analysed using restriction digestion with McrBc. 




                                           
Fig 23: 5AzadC leads to an upregulation of the late genes in CaSki ATCC cells. Semi-
quantitative RT-PCR of the mRNA levels of the HPV-16 genes for the 24h CaSki ATCC cells 
treated with 5AzadC resulted in an increase in the transcription of the late genes L1, L2 and E2 
and a slight decrease in the early genes only at 4 µM drug concentrations. GAPDH served as the 
cellular control transcript.       
 
Fig 24 shows the change in the methylation profile for 4 µM 5AzadC as compared with the 
control untreated cells. Demethylation was observed specifically in regions amplified by primers 
G2, G5, G7 and G9 (boxed in red).There was no change observed in the other regions of the 
HPV-16 genome. The bar chart representation of the level of demethylation in Fig 24 shows that 
a significant level of demethylation occurred in the region amplified by primer G2. This 
corresponded to the end of the E1 ORF and possibly the start of the late UTR. Demethylation of 
this region could contribute to an up-regulation of the late genes. However, the demethylation of 
the promoter region G9 did not correspond with an expected result of an increase in the 
transcription of the early genes. In fact there was possibly a repressive effect at 4.0μM 5AzadC, 
which was contrary to what was expected (Fig 23). The possible explanation for which will be 
discussed in Section 3.2.3.  
 107
 
                     
Fig 24: HPV-16 genomic DNA of 5AzadC treated CaSki ATCC cells undergoes 
demethylation of specific regions. The McrBc cleaved DNA was amplified using the G1-G9 
primers. The regions that underwent demethylation are boxed in red. The bottom panel is the bar 
chart for the ratio of the intensity of the McrBc digested bands in comparison with the undigested 
control (Ct). The ratio for the control cells in blue and that of 5AzadC treated cells in maroon for 
the 9 amplicon are plotted together for each amplicon. Demethylation is mainly observed in the 












3.2.2 Recovery of CaSki ATCC cells treated with 5AzadC 
5AzadC caused the depletion of DNMT1 protein expression levels that led to demethylation of 
specific region of the HPV-16 genome in CaSki ATCC cells. It would be interesting to know if 
removal of DNMT1 inhibition would also lead to reversal of the expression pattern of the 
proteins and subsequently the return of the original methylation pattern of the HPV-16 genome. 
 
3.2.2a Protein expression levels and flow cytometric analysis 
To address this question, CaSki ATCC cells was treated with 0.1 and 4.0 µM 5AzadC with the 
untreated cells acting as control. After 24 hours one set of these cells were collected. The drug 
was replaced with fresh media to let the cells recover. Cells were then harvested after 24, 48 and 
72 hours of recovery. Western analysis was carried out using monoclonal antibodies raised 
against DNMT1, p53 and p21Waf1/Cip1 proteins Fig 25A. 
As observed before (Fig 22), there is an almost complete loss of DNMT1 after 24h of treatment 
with 5AzadC with as low as 0.1 µM concentration of the drug. 24h after removal of the drug, 
DNMT1 protein levels were restored to almost pre-treatment levels for the lower drug 
concentration of 0.1 µM but not for cells treated with 4 µM of the drug. 
This remains the case even after 72h although a slight recovery for the expression levels of 
DNMT1 is observed only after 96h for the 4 µM treated cells. In comparison, p53 and 
p21Waf1/Cip1 proteins are induced by 24h of treatment and remained induced for the duration of the 
experiment (96h). In fact the induction is further enhanced after 48h for both concentrations of 
the drug and remains high even at the 96h time point. Flow cytometric analysis in Fig 25B shows 
that with 0.1 µM 5AzadC, the cells undergo a slight S-G2 arrest after 48 hours of treatment 
probably due to the removal of the media, but recover by 72 hours despite the high levels of p53 
and p21Waf1/Cip1 proteins. 
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 Fig 25: Western and flow cytometric analysis of the recovery of CaSki ATCC cells treated 
with 5AzadC.  
A. Recovery of DNMT1 expression is seen after 48h for 0.1 µM and after 96h for 4 µM 5AzadC 
treated cells.  
B. Only the cells treated with 4 µM 5AzadC show signs of cell cycle arrest.   
 
This high level expression of the two proteins is similar to what is observed for the 48 hour cells 
treated with 4 µM 5AzadC and hence could probably account for a similar cell cycle profile of 
the 72 hour 0.1 µM and 48 hour 4 µM 5AzadC treated cells.  
In contrast the cells treated with 4 µM 5AzadC do show a similar cell cycle profile as the 0.1 µM 
at the 48 hour time point but the cells sustain the cell cycle arrest through to 96 hours. This was 
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probably due to the high induction of p53 and p21Waf1/Cip1 proteins in the case of 4 µM, which 
was higher than for that observed for 01.µM 5AzadC treated cells.   
 
3.2.2b Transcriptional and genomic analysis 
To investigate if the induction of p53 protein seen in Fig 25 was due to the loss of transcription 
of E6, the RNA from the CaSki ATCC cells was extracted using the Qiagen RNA extraction 
protocol and cDNA prepared using an oligo dT primer. A semi quantitative RT-PCR was carried 
out to ascertain the mRNA expression of all the HPV-16 genes. 
Fig 26 shows the expression levels of the various HPV-16 genes. The intensity of the bands were 
quantitated using a gel quantitative software and the ratios obtained showed a decrease in 
expression of E6 and E7 as well as the increase in the expression of E2 which are generally 
indicative of the trend for the early and late genes respectively. They are similar to the results 
observed earlier (See Fig 23) in the case of the treatment with 5AzadC without recovery where 
the early genes are inhibited for 4 µM 5AzadC and there is an increase in the transcription of the 
late genes. 
With 0.1 µM 5AzadC there is around 20% decrease in the level of E6 transcription after 24 and 
48 hours (Fig 27, maroon). A further decrease of around 20% was observed by the 72 hour time 
point. However, the level of E6 then recovers close to normal levels by 96 hours. Therefore, the 




Fig 26: Semi-quantitative RT-PCT for 5AzadC treated CaSki ATCC recovery cells. mRNA 
levels of the HPV-16 genes show a significant induction in the transcription of the late genes (E5, 
E2, L1, L2) when treated with 4 µM 5AzadC, even after its removal after  
24h.     
 
 
          
         
Fig 27: Plotting of the intensity of mRNA expression levels. The intensity of the PCR products 
for E6, E7 and E2 for all four time points from Fig 26 was quantitated using the Gel Pro software 
and plotted as a bar chart. Control (blue), 0.1 µM (maroon) and 4 µM 5AzadC (yellow).    
 
 
Gel intensity Gel intensity Gel intensity 
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In the case of E7, the decrease in the levels could not be noticed as significantly as E6 because 
the PCR efficiency of the transcripts was far better and hence the subtle difference could not be 
elucidated. Nevertheless a decrease of about 20% was observed by the 72 hour time point. 
At the higher concentration of 4 µM 5AzadC the decrease in the levels of both E6 and E7 are 
significantly greater (Fig 27, yellow). E6 expression goes down by 30, 40 and 50% for the 24, 48 
and 72 hour time points respectively with E7 showing a similar trend. By 96 hours both the genes 
tend to recover similar to 0.1 µM 5AzadC but to a lesser extent. 
Analysis of the expression of the late gene E2 that is a repressor of the early promoter could 
explain the repression of the early genes. There is a gradual increase in the E2 transcription for 
the lower concentration of 5AzadC with a maximum transcription of 2 times the normal levels by 
96 hours. In the case of 4 µM 5AzadC there is a 2 fold increase by 24 hours, which drastically 
increases by 7, 8 and 9 folds the normal levels by 48 hours, 72 and 96 hours respectively. A 
similar trend is observed for all the late genes.  
A substantial increase in the E2 levels as observed in Fig 26 would be expected to suppress early 
genes completely, yet we still see a low level of expression of the early genes even at the 72 and 
96h time points. A possible explanation will be discussed in Section 3.2.3.  
To study the methylation status of the HPV-16 genome, genomic DNA was prepared using the 
Qiagen Blood Prep protocol and digested with the methylation sensitive restriction enzyme 
McrBc. The promoter region was amplified by PCR using the primer set P4 (nt 7850-556) for the 
four time points. The 24h untreated DNA was used as a control to compare the level of 






                                               









Fig 28: Reappearance of the methylation pattern in the demethylated 5AzadC treated 
CaSki ATCC cells upon recovery in the promoter region (P4). 
A. Genomic DNA was digested with McrBc and the P4 amplicon (p97 and E6 ORF: nt 7850-
556) was amplified by PCR. Demethylation was observed after 24h for 0.1 and 4 μM 5AzadC. 
Methylation of the promoter was observed for 0.1 μM after 48h and for 4 μM only after 96h.       
B. Plotting the intensity of demethylation for McrBc cleaved CaSki ATCC recovery DNA. The 
ratio of the McrBc digested bands for the 5AzadC treated digests (0.1 and 4 μM) against the 24h 
untreated control digest from Fig 28 was plotted as a bar chart for the different time points. An 
increase in the ratio denoted demethylation and a drop in the ratio at later time points denoted a 
relaying of the methylation pattern. 
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Fig 29: Growth analysis for CaSki ATCC cells upon recovery after treatment with 5AzadC. 
Cells treated with no drug (ct), 0.1 μM (0.1A) and 4μM 5AzadC (4A) for 24 hours and allowed 
to recover by removal of the drug after 48h. The cells from Fig 25 counted in the flow cytometric 




Fig 28(A) shows that by 24 hours both 0.1 µM and 4 µM 5AzadC demethylate the promoter 
region, which is augmented with an increase in the concentration of 5AzadC. Fig 28(B) shows 
the ratios of demethylation quantitated using Gel Pro software. By 48 hours, which corresponds 
to 24 hours of recovery after drug removal, the methylation status of the promoter region treated 
with 0.1 µM 5AzadC reverts back to ~75% of control levels. The methylation status then remains 
the same over the next two time points. The reversal of the methylation pattern coincided with 
the return of the DNMT1 protein levels by the 48 hour time point (Fig 25A). Through the cell 
count method (Fig 29) it was seen that the cells treated with 0.1 µM 5AzadC displayed a gradual 
cell growth from the 48 hour time point in comparison with 4 µM treated cells which only 
recovered by 96 hours with the re-expression of DNMT1.     
This, however, was not the case for the CaSki ATCC cells treated with 4 µM 5AzadC as their 
HPV-16 genomic DNA remain demethylated for the 48 and 72 hours similar to the 24 hour time 
Cell Count 
 115
point (Fig 28B). The methylation status reverts back to ~50% of controls levels by 96 hours. The 
re-establishment of the methylation pattern coincided with the re-expression of DNMT1 only 
after 96 hours when treated with 4µM 5AzadC (Fig 25A). 
Analysis of the HPV-16 genome wide methylation status by PCR of the McrBc digested 24 and 
72 hour time point genomic DNA using the G1-9 primers showed a similar trend. Demethylation 
was observed at the 24 hour time point with a remethylation occurring by 72 hours for the 0.1 
µM 5AzadC treated DNA but not for the 4 µM treated DNA (Fig 30). 
 
    
Fig 30: McrBc cleavage of the control, 0.1 and 4 µM 5AzadC treated CaSki recovery DNA 
for 24h and 72h. Top panel illustrates the linear map of the regions covered by the G1-G9 
primers used to amplify the McrBc cleaved DNA. Demethylation was observed after 24h for the 
treated cells in selected regions (G2, G5, G7, G9) of the HPV-16 genome. By 72h there is 
remethylation of the G7 and G9 regions for the 0.1 µM treated DNA, while 4 µM treated DNA 
remains demethylated.     
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However, this recovery was not seen throughout the HPV-16 genome. In the case of 0.1 µM 
5AzadC treated genomic DNA, the p97 promoter in the amplicon G9 as well as the L1 region in 
amplicon G7 are seen to have returned to ~ 75% of the control methylation levels at the 72 hour 
time point in comparison with its 24 hour counterpart. Nevertheless, this appears to be a partial 
remethylation of the HPV-16 genome as amplicons G2 and G5 remain demethylated even after 
72 hours at 0.1 µM 5AzadC. At the higher concentration of 4 µM 5AzadC after 72 hours, 
demethylation persists at amplicons G4, G5, G8 and G9 as all show an increase in the ratio of the 
McrBc digested band in comparison with the control undigested bands, which points to further 
demethylation. 
   
Therefore, a down regulation of DNMT1 by 5AzadC in CaSki cells leads to the demethylation of 
the integrated HPV-16 genome and this in turn leads to the up regulation of the late genes 
transcription. On removal of the drug, remethylation of the HPV-16 genome does occur but the 
methylation pattern does not fully revert back to normal during the duration of our experiments.      
  
3.2.3 Discussion 
5AzadC is a potent inhibitor of DNMT1. Since we showed that the HPV-16 genome is targeted 
by the methylation machinery both in cell lines and in clinical samples, it was interesting to see 
what the effect of depleting DNMT1 would be on CaSki cells. As would be expected the 
expression levels of DNMT1 decreased by more than 50% by 24 hours of treatment with as low 
as 0.1 µM of 5AzadC and the expression was far lower for the higher concentrations. This effect 
though was seen to be reversible as the expression levels of DNMT1 seem to return to normal 
levels by 48 hours for the lower concentrations. Apart from depletion of DNMT1, agents such as 
5AzadC frequently act through the mechanism of DNA damage pathway (Zhu et al., 2004). p53 
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plays an important role in the induction of cell cycle arrest and apoptosis in response to such 
stimuli (Karpf et al., 2001). This in turn would activate the expression of p21Waf1/Cip1, leading to 
the inhibition of cell proliferation.  
Fig 22 clearly shows that there was an induction of the p53 response pathway with an induction 
of p21Waf1/Cip1. Yet the Flow cytometric profile in Fig 20 does not show a very clear cell cycle 
arrest, though it could be argued that a slight G1 arrest was observed for all concentrations at the 
24 hour time point. Since re-expression of DNMT1 was observed by 48 hours, the cell cycle 
profile for all the treated cells except for those treated with 4 µM does seem to have returned to 
normal. A slight G1 arrest was observed for the 4 µM 5AzadC treated cell even after 48 hours of 
treatment (Fig 20). This would then explain the loss of growth observed through the cell count 
method in Fig 21 at the higher concentration but not at 0.1 µM, which showed a similar growth 
pattern as the control cells. Increased expression of p21Waf1/Cip1 due to exposure to 5AzadC has 
been reported (Chuang et al., 1997; Zhu et al., 2004). The ability for p53 to induce cell cycle 
arrest in the G1 phase in response to DNA damage is largely dependent on the expression of its 
downstream effector p21Waf1/Cip1 (Lakin and Jackson, 1999). Therefore, in the case of 5AzadC 
treatment of CaSki cells, a similar DNA damage response could be involved in the cell cycle 
arrest or the transient arrest at higher concentrations of the drug. This p53/ p21Waf1/Cip1 pathway 
would then allow the cells sufficient time to repair the DNA and ensure progression of the cell 
cycle. 
The induction of the p53/ p21Waf1/Cip1 (seen in Fig 25) pathway could also be due to the loss of E6 
transcription (Fig 26). Since E6 is known to degrade p53 (Scheffner et al., 1990), an inhibition of 
its transcription leads to an accumulation of the p53 protein. This in turn could lead to the 
induction of p21Waf1/Cip1, leading to a transient cell cycle arrest.  
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Loss of DNMT1 due to treatment with 5AzadC is known to demethylate genes and allow the re-
expression of the silenced genes (Brown and Plumb, 2004). In the case of CaSki cells, 5AzadC 
leads to the de-methylation of specific regions of the HPV-16 genome, which in turn lead to the 
up regulation of only the late genes E2, L1 and L2. The region with the highest de-methylation 
corresponds to the amplicon G2. In the BPV system the promoter that initiated E2 transcription 
was located at nt 2443 (Spalholz et al., 1991) which would be located in the G2 region of the 
HPV-16 genome. Therefore, considering the fact that the re-expression was mainly in the late 
genes and the transcripts in the HPV system tend to be poly-cistronic, the possibility of a late 
gene promoter being in the G2 region cannot be ruled out. The other regions that undergo de-
methylation were the amplicons in the G5 and G7 regions, which correspond to the late genes L2  
and L1. So de-methylation of a potential late gene promoter as well the ORFs of the late genes 
could account for the up regulation of E2, L1 and L2 gene transcripts. Further promoter activity 
assay using the G2 amplicon region has to be carried out to confirm the hypothesis.   
This raises another question as to why the up regulation of E2, which is a negative inhibitor of 
the p97 promoter, did not inhibit the early gene transcription to a greater extent in Fig 23, which 
has a significant induction of the E2 transcript. This could probably be explained due to the 
property of E2 which is unable to bind to methylated DNA (Kim et al., 2003b). Two of the four 
E2 binding sites are located in the amplicon G8 that was completely digested by McrBc (Fig 24) 








                 
 B.                     
                  
Fig 31: Illustration of the effect of 5AzadC on the HPV-16 genome in CaSki ATCC cells.  
A. 5AzadC causes demethylation of the G2, G5, G7 and G9 regions. This demethylation could 
lead to the activation of possible late gene promoter P2443 and PL. The green lollipop indicates 
methylated DNA.  
B. Illustration of the LCR, p97 and E6 ORF region with the four E2 binding sites indicated by 
red boxes. The green circles represent methylated CpGs. An increase in the E2 expression due to 
5AzadC leads to demethylation of the promoter (G9) but not LCR (G8) regions, hence inhibiting 
the binding of E2 to its binding sites.  
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Therefore, even though there was an induction of E2, its effect is negated by the fact that not all 
its binding sites were demethylated, hence, it cannot bind to the LCR region to act as an inhibitor 
of the early gene promoter (Fig 31). This could be verified in the future by a ChIP for each of the 
E2 binding sites, but could not be performed due to lack of suitable antibodies against the 
protein. 
It is yet unclear as to how the few copies of unmethylated HPV-16 DNA remain unaffected by 
the induction of E2. As observed in the Table 3 and discussed in section 3.1.5 it is possible that 
not all the CpGs have to remain unmethylated to have an active promoter. Hence, it could be 
hypothesised that the few copies of HPV-16 DNA in the CaSki genome that are active are not 
completely demethylated. If methylation persists in the E2 binding sites in the LCR region then, 
an induction of E2 transcription has no effect on the p97 promoter in such copies. The 
methylation pattern of the few active copies in CaSki cels could not be ascertained by bi-sulphite 
sequencing in Table 1 as they could not be differentiated from the majority of copies, which are 
fully methylated and hence silenced.  
In results obtained in Fig 26 and 28, we see an inhibition of the E6 and E7 along with an 
induction of E2 for the 24 hour cells treated with 4μM without any observable demethylation of 
the G8 region for the same sample (Fig31). Therefore, it is possible that in this experimental 
system the inhibitory effect observed was on the few copies of the HPV-16 genome which 
remain active at all times and the change in their methylation pattern especially of their E2 
binding sites could not be noticed by McrBc digestion. 
Since we had established that the HPV-16 genome in CaSki could be demethylated in response to 
the down regulation of DNMT1 by 5AzadC, it was interesting to see if the methylation pattern 
could be re-established once the drug was removed and the cells were allowed to recover. At 0.1 
µM 5AzadC DNMT1 proteins levels returned to normal levels 24 hours after drug removal (Fig 
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25), but this could not be attributed to the removal of the drug alone as, a re-expression of 
DNMT1 is observed at the 48h time point even when the drug was not removed (Fig 19) . This 
might be accounted for by the general half life of the drug, which becomes less effective after 24 
hours.   
However, the re-expression of DNMT1 protein 24 hours after removal of the drug did coincide 
with the re-emergence of methylation of the p97 promoter for 0.1 µM 5AzadC (Fig 28). This, 
however, was delayed in the case of 4 µM 5AzadC treatment as the expression of DNMT1 only 
occurs 72 hours after drug removal. It was observed that at lower concentration, the re-
expression of DNMT1 allows for the re-methylation of the p97 promoter. Hence, both 
demethylation and the re-emergence of the methylation pattern were seen to be tightly linked 
with the expression of DNMT1 protein. Yet a complete recovery of the methylation status of the 
promoter as compared with the control is not achieved in the course of our experiment and 
further passages have to be analysed if they completely revert back to the original methylation 
pattern, or if some amount of hypomethylation in a few copies remain.  
By studying the genome wide methylation status in Fig 30 it was observed that the re-
methylation at 0.1 µM 5AzadC after 72 hours occurs in a selective manner as some regions 
remain demethylated. This probably explains why an increase in late gene expression is seen in 
all the time points.  
It is not very clear as to why some regions are more prone to the differential state of methylation. 
It has been shown that the reprogramming of DNA methylation in the various repetitive 
sequences works independently in a region specific manner during early embryonic development 
in mice (Kim et al., 2004). A similar situation could possibly be in play in the reprogramming of 
the HPV-16 genome in the artificially induced demethylation by 5AzadC. Another possible 
reason is from the observation by Liang et al where in the murine system they found that in 
 122
addition to Dnmt1, Dnmt3a/3b were required for methylation of a select class of sequences 
which included abundant murine LINE-1 promoters (Liang et al., 2002). They also showed that 
Dnmt3a and/or -3b could restore methylation of these sequences to pre-treatment levels 
following transient exposure of cells to 5AzadC, whereas Dnmt1 by itself could not. This 
suggested a possible co-operative effect of the Dnmts where Dnmt3a/3b could compensates for 
inefficient maintenance methylation by Dnmt1. It would be interesting to see in the future if this 
applies to HPV system used in our experiments.         


















3.3 Effect of 5AzadC on CaSki variants  
 
3.3.1 6h and 24h treatment of 5AzadC on 4 CaSki cell lines   
Four stocks of the CaSki cell lines based on their age after the number of passages were used to 
test the effect of 5AzadC. CaSki ATCC obtained from ATCC was considered the youngest with 
the least number of passages. CaSki 87 originated from the laboratory of H.zur Hausen where 
they were frozen in 1986 and freshly thawed for this study. Two more cell lines CaSki VB and 
CaSki old were long term cultures thawed from the same batch, with CaSki old being passaged 
the most and hence considered as the oldest among the four cell lines. Their “ages” depending on 
the number of passages are as follows CaSki ATCC< 87< VB< old.   
Time course experiments were carried out with 2 different concentration of 5AzadC over the 
time period of 6 hours and 24hours. The concentrations used were 0.1µM and 4µM 5AzadC. The 
experiments were carried out together with Chuang LS, Yeo WL, Tan HH. The cells were lysed 
and 50µg and 100µg of extract were electrophoresed on a 6.9% and 13.5% gels respectively.  
Fig 32 shows the western analysis of the cells collected after the two time points.  The left panel 
consists of the western with the monoclonal antibody 2E10 for DNMT1, which shows that by 6h 
there is a decrease in the level of DNMT1 for the cell lines CaSki ATCC, 87 and VB at 0.1µM 
concentration of 5AzadC while there was no change for CaSki old. At a concentration of 4µM 
5AzadC there was a decrease in the DNMT1 levels for all four cell lines, with the highest being 
for CaSki ATCC and the lowest being for CaSki old. The decrease in the levels of DNMT1 was 
slightly more at 4µM than 0.1µM for the other two cell lines as well.  
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Fig 32: Sensitivity of the CaSki variants when treated with 5AzadC (0.1 and 4 µM) for 6 
and 24h. Western analysis of total cell lysates was probed with DNMT1, p53 and p21 
antibodies. Loss of DNMT1 expression is seen for both concentrations of CaSki ATCC and for 4 
µM 5AzadC treated CaSki 87 and VB cells after 24h. CaSki Old is resistant to both 
concentration of 5AzadC. A drop in DNMT1 is accompanied by an induction of p53 and to a 
lesser extent p21Waf1/Cip1 proteins.        
 
Western analysis for the cell cycle inhibitors p53 and p21Waf1/Cip1 did not show a difference or 
induction at the 6h time points for CaSki ATCC, 87 and VB. However, the levels of basal p53 
are the same for the 3 cell lines, the levels of p21Waf1/Cip1 is much higher for CaSki ATCC. In 
comparison with these cell lines, CaSki old has a very small trace amount of both proteins and is 
not induced by 5AzadC at the 6h time point. 
24h post treatment, 5AzadC shows a stark contrast between the cell lines. For CaSki ATCC, the 
levels of DNMT1 have been completely depleted even at 0.1µM drug concentrations. For CaSki 
87 and VB, there is a decrease of up to 50% for 0.1µM and a complete loss of DNMT1 
expression at 4µM 5AzadC. With a decrease in the levels of DNMT1, there is an induction of 
p53 in all three cell lines with the induction in each case being of similar ratios with CaSki 87 
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having a slightly higher induction. The same was the case for p21Waf1/Cip1 protein expression, 
which followed the levels of its activator protein p53. 
However, in the case of CaSki old, treatment with 5AzadC even after 24 hours did not lead to a 
reduction of DNMT1 levels at 0.1µM. The drop for 4µM was similar to that at 6hours of 
treatment. No induction of p53 and p21Waf1/Cip1 was observed even after 24h of treatment for 
either concentrations of the drug. 
Thus, there seems to be a form of resistance towards the DNMT1 inhibitor 5AzadC in the CaSki 
cells as they are passaged over time. In our study, we found that the CaSki ATCC was very 
sensitive to 5AzadC while CaSki 87 and VB had acquired some amount of resistance towards the 
drug, with this effect being very pronounced in the case of CaSki old cells         
 
3.3.2 Genomic methylation analysis of the CaSki variants treated with 5AzadC   
Since DNA methylation could play a role in the transcription of the HPV-16 genes as seen from 
our results in the previous sections, the methylation pattern for the 4 CaSki cell lines were 
analysed using the methylation sensitive restriction enzyme McrBc. Genomic DNA was prepared 
and subjected to the same restriction enzyme digestion protocol. Two regions of the HPV-16 
genomic DNA were analysed to observe if any difference existed in the methylation pattern of 
the 4 variants. The region chosen for the study were: the G9 amplicon representing the p97 
promoter and the G2 amplicon, which was found to be, demethylated the most in the earlier 
experiments with CaSki ATCC. The three CaSki cell lines ATCC, 87 and VB which were shown 
to be sensitive to 5AzadC and led to a depletion of DNMT1 (Fig 32), do undergo demethylation 
of their integrated HPV-16 genome. Fig 33 shows that for the 24 hour treated samples 
demethylation occurs in both the regions analysed (G2 and G9). 
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                      A.                                            B. 
                       
Fig 33: McrBc cleavage of CaSki variants DNA treated with 5AzadC for 24h.  
A. PCR of the G9 amplicon indicates that there was a demethylation of the region for CaSki 
ATCC, 87 and VB but not for CaSki Old when treated with 4 µM 5AzadC.   
B. PCR of the G2 amplicon indicates that there was a demethylation of the region for CaSki 
ATCC, 87 and VB but not for CaSki Old when treated with 0.1 and 4µM 5AzadC. 
Demethylation was greater in 4µM than 0.1µM 5AzadC treated DNA.         
 
 
Demethylation is observed at 0.1 µM 5AzadC in the G2 region with it increasing at the higher 
concentration of 4 µM 5AzadC. As for CaSki Old, which was resistant to 5AzadC and did not 
show any significant loss of DNMT1 expression, there was no change in the methylation status 
and the two regions (G2 and G9) remained methylated. This confirmed what we had observed 
earlier (See Fig 24, 29) that the 5AzadC dependent depletion of DNMT1 lead to a direct effect on 
the methylation status of the HPV-16 genome.     
 
                
 
 127
3.3.3 Effect of high dose of 5AzadC on CaSki Old cell line 
 
3.3.3a Protein expression levels and flow cytometric analysis  
Since we established that the CaSki Old cell line was resistant to 5AzadC up to a concentration 
of 4 µM, we wanted to see if a similar effect of depletion of DNMT1 and demethylation of the 
HPV-16 genome would occur at higher concentrations. The CaSki Old cell line was treated with 
concentrations of 4, 10, 25 and 50 µM of the drug for 6, 24 and 48 hours. The experiments were 
carried out together with Chuang LS, Yeo WL.     
Western analysis using DNMT1 specific monoclonal antibody 2E10 shows that after 6 hours of 
treatment only at a concentration of 50 µM do we see a reduction in the protein expression levels 
of DNMT1. By 24 hours there is a concentration dependent inhibition of DNMT1 similar to what 
was seen with CaSki ATCC (See Fig 19) but at lower concentrations of the drug. This decrease is 
accompanied by a steady increase in the levels of p53 protein expression. Again, by 48 hours we 
did see a recovery in the expression of DNMT1, yet the p53 levels were still induced to 
significantly higher levels compared with the control cells Fig 34 (A); suggesting a possible 
induction of p21Waf1/Cip1. 
Flow cytometric analysis Fig 34 (B) shows that by 6 hours there is an S phase arrest at all 
concentrations of 5AzadC. The arrest is sustained after 24 hours. For 50 µM 5AzadC the cells 
were arrested at S/G2 phase as the number of G1 cells decrease. By 48 hours, at 4 and 10 µM 
5AzadC a slight G1 arrest was observed with the higher concentration showing pre-G1 DNA 











                                                             
    
                
 













                            
 
Fig 34: CaSki Old cells are sensitive to high doses of 5AzadC.   
A. Western analysis demonstrates that for 24 and 48h time points, treatment with 25 and 50µM 
5AzadC leads to a decrease in the protein expression levels of DNMT1 with an increase in p53 
levels.  
B. Flow cytometric analysis of CaSki Old cells treated with high dosage of 5AzadC undergoes 
cell cycle arrest at different phases depending on the concentration of the drug.  
C. Slower growth of the treated cells is observed after 24h by cell counting.   
 
 
Cell counting using the flow cytometric counter in Fig 34 (C) suggests that, in the initial 24 hours 
irrespective of the concentration of the 5AzadC, the cells went through one cell division and 
double in number. But by 48 hours, since the cells were arrested, the doubling rate was affected, 
even for 4 µM 5AzadC as seen before in Fig 21.  








3.3.3b Transcriptional and genomic analysis 
A.                                                                              B.  
          
Fig 35: High dose of 5AzadC causes upregulation of late genes and suppression of early 
genes. RNA was extracted from the 24 hour treated samples and reverse transcribed using the 
oligo dT primers as before. RT-PCR was carried out for all 8 HPV-16 gene transcripts Fig 35(A). 
The bands were quantitated using the Gel Pro analyser software and relative intensities plotted as 
a bar chart.  
A. Semi-quantitative RT-PCR of HPV-16 genes; GAPDH used as a cellular control.   
B. Intensity of the PCR products quantitated using Gel Pro. The early genes (in blue) are 
downregulated while the late genes (in maroon) are upregulated in a concentration dependent 
manner by 5AzadC.  
 
The effect of 5AzadC as seen in the earlier experiments was the down-regulation of the early 
genes, again due to the increased transcription of the late genes especially E2 as seen from the 
quantitated intensity of the E2 transcription in Fig 35(B). In the case of the CaSki old cells 
treated with high doses of 5AzadC, there was a 2 fold increase in the expression of the late genes 
E2 and E5 for 25 and 50 µM 5AzadC, which corresponds to the decrease in the early genes E6 
and E7. Similar increases were observed for L1 and L2 transcription. However, the down-
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regulation of E1 and E4 seems to be higher than E6 and E7 transcripts. Considering the fact that 
the transcripts are generally transcribed from the same polycistronic p97 promoter, the slight 
difference in the ratios could be due to different efficiencies of the primers used to amplify the 
products. None the less, the general trend remains the same for CaSki old with the early genes 
being down-regulated and the late genes being up-regulated. 
To analyse if the reduction in DNMT1 levels led to a change in the methylation pattern of the 
HPV-16 genome, the genomic DNA from the 50 µM 5AzadC CaSki old cells were digested with 
the methylation sensitive restriction enzyme McrBc. 
 
                 
                                                               
Fig 36: HPV-16 genomic DNA of the 5AzadC treated CaSki old cells undergoes a general 
demethylation. The McrBc cleaved DNA was amplified using the G1-G9 primers. The bottom 
panel is the bar chart for the ratio of the intensity of the McrBc digested bands in comparison 
with the undigested control (Ct). The ratio for the control cells in blue and that of 5AzadC treated 
cells in maroon for the 9 amplicon are plotted together for each amplicon.  
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Similar to what was done in Fig 24, the gel intensity ratios of the McrBc digested bands after 
PCR amplification of the 9 amplicons for the control and 50 µM 5AzadC treated cells were 
plotted to see the change in the methylation pattern. 
Fig 36 shows that an increased demethylation occurred in amplicons G2, G5 and G9, similar to 
what was observed in Fig 24. Unlike in the earlier experiment, demethylation was also observed 
in the remaining 6 amplicons as well. 
Therefore, CaSki old cells that were resistant to 5AzadC at lower concentrations were shown to 
be sensitive when much higher concentrations of the drug were used. This resulted in the 
demethylation of the CaSki old genome, which in turn contributed to the up-regulation of the late 




Treatment with 5AzadC on the CaSki cell lines of various ages, depending on their long term 
culture status, proved that they were prone to becoming resistant to chemotherapeutic drugs such 
as 5AzadC, as observed by the inability of the drug in depleting DNMT1 protein levels in these 
cells. As seen from Fig 32, CaSki ATCC was the most sensitive, followed by CaSki 87 and VB, 
which were cultured for a longer period of time, and the least sensitive was CaSki old, in culture 
for the longest period. All three sensitive cell lines (ATCC, 87, VB) displayed common features 
as observed earlier in CaSki ATCC alone (See Section 3.2.1) in that, the loss of DNMT1 led to a 
demethylation of their respective CaSki genomes (see Fig 33). In the case of CaSki old, the 
failure to deplete DNMT1 sufficiently resulted in an unaltered state of the methylation pattern of 
the CaSki genome.  
 133
The resistant cells (CaSki Old) could be shown to be able to deplete DNMT1 at a higher dosage 
of the drug (Fig 34). The loss of DNMT1 expression resulted in the demethylation of the CaSki 
genome (Fig 36) as well as the upregulation of the late genes and suppression of the early genes 
(Fig 35). This suggested that the E2Bs present in the LCR and p97 promoter regions were 
sufficiently demethylated for E2 to bind and inhibit the transcription of the early genes. This was 
in contrast to what was observed earlier with CaSki ATCC cells, where the induction of the late 
genes did not suppress the early gene transcription (Fig 23). This suggested that the higher 


















3.4 Effect of alkylating agent MMS on DNMT1 in HPV-16 cell lines 
DNA methylation in HPV-16 biology appears to be able to help maintain the virus in its latent 
episomal state. Yet through the course of infection and progression of tumourigenesis (See 
section 3.1.4a, table 2), the virus tends to get progressively demethylated and hence probably 
lead to tumorigenesis. The question remains as to the possible trigger that induces the 
demethylation event. People are continuously exposed to varying amounts of chemicals that have 
been shown to have carcinogenic or mutagenic properties in experimental systems (Rosenkranz, 
2003). Exposure can occur exogenously when these agents are present in food, air or water, and 
also endogenously when they are products of metabolism (Turesky, 2004). One such agent is the 
sulfonate-derived alkylating agent MMS which has the ability to produce alkylation lesions and 
single and double stranded breakage in the DNA (Schwartz, 1989). MMS was also shown to be a 
potent inhibitor of DNMT1 (Chuang et al., 2002).  Therefore, it would be interesting to see if 
carcinogens such as MMS which can inhibit DNMT1, could have an effect on the HPV-16 
genome.        
 
3.4.1 MMS depletes DNMT1 in SiHa and CaSki old cells 
3.4.1a CaSki old is more sensitive to MMS than SiHa  
Time course experiments were carried out with SiHa and CaSki old cell lines treated with 
varying concentration of MMS (50, 100, 200, 350, 500 µM)  for 3, 6, 12, 24, 36, 48 and 72 
hours. Western analysis was carried out as shown in Fig 37 with monoclonal anti bodies for 
DNMT1 (2E10) and p53 (DO-1). Western and flow cytometric analysis was obtained from work 
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Fig 37: CaSki Old cells are more sensitive to MMS than SiHa cells. 
A. Western analysis shows that the DNMT1 expression levels are more sensitive to being down 
regulated in CaSki old cells in comparison with SiHa cells. The induction of p53 levels are 
sustained only in CaSki old but not SiHa cells. 
B. Flow cytometric analysis confirms that the sustained induction of p53 leads to cell death in 
CaSki old, while SiHa cells undergo cell cycle arrest and slowly recover back to normal. 
The data was obtained from work done by Chuang LS and Tan HH   
 
DNMT1 expression levels decreases by 24 hours for both the cell lines at MMS concentrations of 
350 µM and above. In SiHa cells DNMT1 protein levels return to control levels by 36 hours even 
for cells treated with higher concentration of MMS. In CaSki old cells, there is no re-expression 
of DNMT1 when treated with 350 and 500 µM MMS even after 72 hours Fig 37(A).  
The expression pattern of p53 provides some clues as to why this could be the case Fig 37(A). In 
SiHa cells, there is an induction of p53 by 6 hours in a concentration dependent manner. The 
expression levels peaked at 24 hours post treatment. By 36 hours the p53 levels decrease 
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significantly and by 48 hours the expression levels are back to that seen in control cells. CaSki 
old cells on the other hand induce p53 in a similar fashion, with an induction seen after 12 hours 
in a concentration dependent manner. The difference being that the strong induction of p53 is 
sustained for cells treated with 200, 350 and 500 µM MMS through to the 72 hour time point and 
do not revert back to the normal expression levels during the course of the experiment. 
 
3.4.1b MMS leads to cell death in CaSki old but not SiHa cells 
Flow cytometric profile of SiHa cells (Fig 37B, right panel) shows that at 3 hours of treatment a 
slightly higher proportion of the cells are at G1 compared with the control cells. By 6 and 12 
hour time points a clear G1/ G2-M arrest is observed when treated with 350 and 500 µM MMS. 
The cell cycle arrest coincided with the induction of p53 expression. 24 hours onwards, the 
cellular response varies with the different concentrations of MMS.  
In the case of SiHa cells treated with 350 µM MMS 24 hours post treatment, an accumulation of 
cells in the G1 and G2 phase was observed. This could be accounted for by the progression of a 
population of G1 cells to the G2 phase. This is confirmed in future time points (36 and 48 hours) 
where the cells are release from G1 but arrested in the G2/M phase. Majority of the cells undergo 
a G2 arrest by 48 hours, and are released from arrest after 72 hours.  When treated with 500 µM 
the cell cycle profile varies from that of 350 µM MMS treated cells. After 24 hours majority of 
the cells are arrested S phase. After 36 and 48 hours there seems to be a late S phase arrest rather 
than a G2 arrest as seen earlier with the 350 µM MMS. By 72 hours, there is no significant cell 
cycle arrest for the 350 µM treated cells and they revert back to normal.  
There is no significant change in the cell cycle profile for the CaSki old cells (Fig 37B, left 
panel) after 3 hour of treatment with 350 and 500 µM MMS due to the lack of induction of p53. 
By 6 hours, with a slight induction of p53 a G1/S arrest is observed, which becomes more 
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apparent by 12 hours. Unlike in SiHa cells the induction of a high level p53 is sustained from the 
24 hour time point onwards leading to a probable p53 induced apoptosis. This was observed by 
the pre-G1 peak indicative of dying cells for both concentration of 350 and 500 µM MMS in the 
cell cycle profile.  
The effect of an alkylating agent such as MMS was therefore shown to have a very different 
effect on the HPV-16 transformed cell lines SiHa and CaSki.    
        
 
3.4.2 Loss of DNMT1 leads to extensive demethylation of HPV genome in CaSki old cells 
 
 
3.4.2a McrBc scanning of the genome 
 
Genomic DNA was prepared for both SiHa and CaSki old cells for all 5 concentrations of MMS 
along with the control untreated cells. They were then digested with the methylation sensitive 
McrBc restriction enzyme and amplified by PCR using the 9 sets of primers G1-G9. Fig 38 
shows the methylation pattern of the HPV-16 genome for the two cell lines. In SiHa cells since 
G1, G2, G8 and G9 are not sensitive to McrBc digestion (See section 3.1.2a Fig 5) and this was 
co-related to being not methylated by the bisulphite studies (See section 3.1.3c) in normal cells, 
no change was expected in the pattern. However, the regions G5, G6 and G7, which are 
methylated in control cells, maintain their methylation status as there was no difference in 
intensities of the digested PCR products. Hence, MMS did not induce demethylation of the late 
regions at any concentration of the drug (Fig 38, right panel). This suggested that either the 
residual DNMT1 expression present is sufficient to maintain the methylation pattern of the HPV-
16 late regions in SiHa, or that a DNMT other than DNMT1 could play a role.   
 






































Fig 38: MMS causes genome wide demethylation of CaSki old DNA but has no effect on the 
methylation status of SiHa DNA. CaSki old and SiHa DNA treated with MMS were cleaved by 
McrBc and PCR amplified using the G1-G9 primers (Top panel is a map illustrating the regions 
covered by the primer sets). Genome wide demethylation is observed in CaSki old cells treated 
with 200mM and higher concentration of MMS. There is no change in the methylation status in 
SiHa DNA even in the hypermethylated late regions.  
Bottom panel is the ratios of the McrBc cleaved DNA from CaSki old and SiHa cells plotted 
against their uncut controls. The intensity of the McrBc digests from the control cells are plotted 
in blue and the cells treated with MMS in black.     
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In the case of CaSki old genome, demethylation to a certain extent is observed throughout the 
genome when treated with 200 µM MMS. This becomes more apparent with 350 and 500 µM 
MMS Fig 38 (left panel) corresponding to the depletion of DNMT1 protein expression (Fig 37). 
A comparison of the level of methylation between the control and 500 µM MMS treated cells are 
seen in the bar chart in Fig 38, which corresponded to the loss of DNMT1 expression seen in Fig 
37. The intensity of the McrBc digest product was quantitated using the Gel Pro software and 
plotted as a bar chart. It is clear from the bar chart that the gross demethylation of the HPV 
genome due to MMS occurred throughout the genome. This is similar to the treatment of CaSki 
old cells with high dose of 5AzadC (Fig 36) where demethylation was observed throughout the 
genome.    
 
3.4.2b Bi-sulphite analysis of the CaSki old genome after MMS treatment 
To check the methylation status of individual CpGs in the CaSki old genome, the bi-sulphite 
modification technique was used for the control, 350 µM and 500 µM MMS treated cells. Msp4 
primer (nt 7498-161, Section 2.7, Table iv) was used to amplify the treated DNA and sequenced. 
Fig 39 shows a representative sample of the sequencing results for the 3 treated samples. In the 
result below 3 CpGs at nt 7677, 7683 and 7695 was analysed. In the control sample, all the CpGs 
are clearly methylated as they remained as cytosine residues (blue peak) and the background 
thymidine residue (red peak) is negligible. 
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Fig 39: Raw sequence data illustrating the demethylation of CpGs after MMS treatment in 
CaSki old cells. Control, 350μM and 500μM bisulphite treated DNA were directly sequenced 
and analysed for the conversions of the cytosines.   
 
 
In the case of the 350 µM treated DNA the CpGs at nt 7677 and 7683 show a mixed population 
as the thymidine peak is significantly higher compared to the control untreated DNA. In fact the 
CpG at nt 7683 has a higher thymidine peak than cytosine, indicative of more copies being 
demethylated. As for the nt 7695 for the 350 µM treated DNA, it is completely demethylated as a 
thymidine residue has replaced the original cytosine residue. Therefore even within the 3 CpGs 
seen from the same sample DNA, there seems to be a differential amount of demethylation in 
each individual CpG sites. 
In the case of the 500 µM treated DNA, the 3 CpG sites were completely demethylated as all the 
cytosines were replaced by thymidine residues. This corresponded with what was observed 
earlier in the McrBc analysis (Fig 38) which showed increased demethylation for the same 
samples. Thus the bi-sulphite result confirms what we had earlier been observed with the McrBc 
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digestion (Fig 38) and shows that both techniques were comparable and demethylation of the 
HPV-16 genome occurred in a dose dependent manner when treated with MMS. 
 
3.4.3 De-methylation leads to an up-regulation of the late genes 
 
As in the previous experiments with 5AzadC we wanted to see if the demethylation of the HPV-
16 genome correlated with its gene expression (Fig 23, 27). RNA was prepared from cells treated 
with MMS for 24 hours. They were reverse transcribed using an oligo dT primer and each gene 
transcript amplified by RT-PCR. There is a significant suppression of the early gene transcription 
of E6, E7, E1 and E4, when treated with 200 µM MMS or more (Fig 40). The transcripts are 
almost undetectable when treated with 350 and 500 µM MMS. Concurrently there is an increase 
in the late gene expression. There is slight increase in the transcription of the E2, E5, L1 and L2 
for cells treated with 200 µM MMS with a significant increase when treated with 350 and 500 
µM. GAP was used as an internal control for the PCR reactions. Therefore the decrease in the 
transcription of the early genes and the increase of the late genes coincide at the 200 µM MMS 
concentration, which probably is a threshold point for demethylation to occur as observed in Fig 
38.    
In comparison with the data obtained with the treatment of 5AzadC (Fig 23), MMS leads to a 
prominent suppression of the early genes, even though the transcription of the late genes are 
comparable. This difference could be accounted for by the fact that the HPV-16 genomic DNA 
underwent demethylation to a greater extent when treated with MMS (Fig 38) than with 5AzadC 
(Fig 23). This would enable the binding of E2 to its recognition sites and shut down the early 
gene promoter.     
  
 142
                                                           
 
Fig 40: MMS causes severe inhibition of the transcription of the early genes in CaSki old 
cells. Semi-quantitative RT-PCR of the HPV-16 genes show an inhibition of early genes when 
treated with concentrations of 200μM MMS or more with an increase in the expression of late 
genes.      
 
3.4.4 Demethylation leads to possible instability of the HPV-16 genome 
Hypomethylation of genomic DNA has been shown to promote chromosomal instability and 
tumours (Eden et al., 2003; Feinberg, 2004). In the Arabidopsis system repeated DNA sequences 
are subjected to DNA methylation, hypomethylation of which leads to genes becoming 
transcriptionally and transpositionally active (Hirochika et al., 2000). In the case of the MMS 
treated CaSki old cells, hypomethylation of the repeated HPV-16 genome was observed.  
Therefore, it was a logical question to ask if this hypomethylation lead to chromosomal 
instability in the repeated sequences of the integrated HPV-16 genome, which are reportedly 
arranged as tandem repeats in the CaSki old cell line.   
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To study possibility of chromosomal instability, the change in the copy numbers of the CaSki old 
genome was investigated. The loss of a genomic fragment from its genome would then indicate a 
possible chromosomal instability factor induced due to hypomethylation by MMS. For this 
purpose, the genomic DNA for the 24 hour time point for the control and MMS treated samples 
were standardised using the β-globin gene as seen in Fig 41 and the gel intensity quantitated 
















Fig 41: Loss of copy numbers of the G7 amplicon in CaSki old cells treated with MMS 
indicates a possible instability of the HPV-16 genome. Intensity of the PCR products was 
quantitated with Gel Pro software (right panel). There is a drop in the PCR product of G7 
amplicon in a concentration dependent manner. β-globin PCR of a similar size served as an 
internal cellular control for equal template loading.  
  
The normalised DNA was used to amplify the G7 amplicon ((6348-7293) of the CaSki old HPV-
16 genome. The intensity of the bands were quantitated and plotted as a bar chart (Fig 41). A 
40% decrease in the copy numbers of the G7 fragment was observed when cells were treated 
with 200 µM MMS. This correlated with the commencement of demethylation of the HPV-16 
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genome in CaSki old cells (Fig 38). There is a similar loss of 40% and 60% of the G7 amplicon 
in the 350 and 500 µM MMS treated samples respectively.  
Therefore, there seems to be a correlation between the hypomethylation of the HPV-16 genome 
in the CaSki old with an increase in transcription of the late genes (Section 3.4.3) as well as a 
possible instability of certain copies of the HPV-16 genome. 
 
3.4.5 Discussion    
MMS was shown to be a potent inhibitor of DNMT1 in most cells (Chuang et al., 2002) and we 
show that it can also deplete the DNMT1 protein levels in both CaSki old and SiHa cells. Yet the 
downstream effects of the depletion of DNMT1 by the drug are not the same in the two cell lines. 
In the case of CaSki old cells, there is a sustained induction of p53 which causes apoptosis 
whereas in SiHa cells p53 induction decreases after 36 hours Fig 37. The initial induction of p53 
in both the cell lines is probably due to the response from the DNA damage pathway by the cells, 
in reaction to the alkylating damage caused by MMS. Therefore, the cells respond in arresting the 
cell cycle at the G1-S phase to allow DNA repair to take place. This happens along with the loss 
of DNMT1 expression. In the CaSki old cells this loss of DNMT1 expression leads to the 
demethylation of its genome whereas it had no effect on the methylation status in SiHa cells (Fig 
38). This could be because CaSki old cells were more sensitive to MMS as the levels of DNMT1 
did not recover after the 24 hour time points at concentrations of MMS higher than 200 µM (Fig 
37). This was not the case in SiHa cells where a re-expression of DNMT1 is observed for 350 
and 500 µM MMS concentrations by 48 hours. This loss of DNMT1 expression, which led to the 
demethylation CaSki old genome, resulted in the up-regulation of the late genes (Fig 40). Since 
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CaSki old genome has intact copies of the E2 gene, the expression of this repressor lead to an 
immediate shut down of the p97 promoter controlling the early gene transcription (Fig 40).               
The transition point or critical MMS concentration for demethylation to occur was 200 µM (Fig 
38). At this concentration we saw a down-regulation of all the early genes transcription (Fig 40). 
Even though we did not see a significant increase in the level of E2 transcription, the basal 
expression could be sufficient to suppress the p97 promoter if the E2Bs were demethylated.  
 
     
 
Fig 42: Illustration of an E2 dependent mechanism to down regulate the early gene 
promoter in CaSki cells treated with MMS. The upregulation of the transcription of E2 (red 
circle) due to the demethylation caused by MMS allows it to bind to the four E2 binding sites 
(red boxes) thus displacing the transcription factors Sp1 and TFIID, hence shutting off the early 
gene promoter. 
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As discussed earlier (Section 3.2.3) the increase in the E2 concentration alone is not sufficient to 
repress the p97 promoter as it is unable to bind DNA that is methylated (Thain et al., 1996). A 
differentially methylated promoter could be transcriptionally active as the transcription factor 
controlling the p97 promoter Sp1 is unaffected by the methylation state of the promoter 
(Harrington et al., 1988). 
Therefore, the difference between the effects of increase an in E2 transcription when the cells are 
treated with 5AzadC and MMS is that, in the case of 5AzadC the increase in E2 does not affect 
the transcription of the early genes. This was because demethylation was specific to a certain 
regions only and the LCR region is still methylated and hence inhibits its binding. In the case of 
MMS since the whole genome is equally demethylated, E2 could bind to its binding sites in the 
LCR thus repressing the promoter completely.  
The inhibition could function as postulated in Fig 42. In the control cells the one to two copies of 
active promoter is uninhibited as; either the E2 binding sites remain methylated or the level of E2 
is insufficient to inhibit the promoter. With the demethylation of the genome due to a loss of 
DNMT1, there could be an increase in the transcription of all the genes, but an increase in E2 
along with the demethylation allows it bind to the E2Bs in the LCR and promoter region and 
inhibit the early genes transcribed from the polycistronic p97 promoter. The loss of E6 would 
then explain the sustained expression of p53 protein in CaSki old cells, which leads it to cell 
death (Fig 37).  
As expected, in the case of SiHa there is no E2 transcript as the gene is disrupted during 
integration (el Awady et al., 1987b). Moreover, the expression of the early genes is not under the 
control of methylation (3.1.3b, 3.1.3c). Therefore, the initial increase in p53 due to DNA damage 
is compensated for by the E6 transcription that brings the level back to normal after 36 hours of 
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treatment. Hence allowing the cells to recover and revert to normal expression levels of the 
proteins. 
In the case of CaSki old cells, demethylation throughout the HPV-16 genome could activate a 
specific late gene promoter, which leads to the induction of E2 and late genes, thus inhibiting the 
p97 promoter. Therefore, the hypothesis in Fig 42 could be tested by a ChIP to see if E2 indeed is 
the reason for the inhibition of the p97 promoter. This could not be carried out in the current 
study due to a lack of suitable antibodies against the E2 protein.    
Demethylation induced due to the effects of high dose of 5AzadC and MMS of the HPV-16 
genome in CaSki old cells have one similar feature in that, they both induce the late genes. 
Therefore, apart from controlling the promoter activity of the HPV-16 genome, methylation 
could also play a crucial role in the regulation of the late gene promoter and their expression. It 
could be the molecular switch required for the expression of the late genes. Transcription of E2 
would inhibit the early genes that are not required by the virus during the late stages. As seen 
from results in Fig 41, demethylation could also lead to instability of the HPV-16 genome 
allowing it to be extruded out to be packaged by the late genes L1 and L2.  
Therefore, methylation could play a very crucial part in first controlling the expression of the 
onco-genes E6 and E7 while suppressing the late genes since, an over expression due to an 
increased copy numbers could also be detrimental to the viability of the cell. In the event that the 
cell encounters carcinogens or alkylating agents affecting its viability, its genome undergoes 
hypomethylation inducing the late genes, at the same time allowing for the genome to be 
extruded out due to loss of chromosomal stability. This provides the virus with a mechanism to 
package the DNA and leave the cell before it encounters cell death. A way to confirm this 
observation would be to use electron microscopy to identify the presence of viral particles after 
the cells are treated with MMS.                
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3.5 Effect of TSA on HPV-16 cell lines 
 
In the previous chapters, it was shown that the p97 promoter of HPV-16 was a target for 
methylation and in clinical samples hypomethylation was shown to correlate with tumour 
progression (Section 3.1.5). Therefore, we surmised that the methylated promoter could be 
packaged into nucleosomes by the recruitment of HDACs and hence silenced. In W12 cells 
which harbour HPV-16 in the episomal form, it was shown that the addition of the HDAC 
inhibitor TSA augmented the transcription of E6 and E7 within 4 hours, thus showing that the 
HPV-16 minichromosomes were in a relatively closed state (Bechtold et al., 2003). This 
however, did not lead to an increase in the late genes, an observation similar to that found in 
HPV-31b where only the early genes were up-regulated in undifferentiated cells with the addition 
of TSA (Mar Pena and Laimins, 2001). This demonstrated that there was no indiscriminate effect 
of TSA on all the HPV-16 promoters. In contrast, when S12 cells, which have integrated HPV-16 
genome, was treated with TSA, repression of the p97 promoter and a down regulation of E6 and 
E7 genes was observed. This was also shown by Finzer et al (Finzer et al., 2002) in HeLa cells 
treated with TSA. To see if this was the case in the CaSki and SiHa cells, the effect of TSA was 









3.5.1 TSA transiently down-regulates HPV-16 transcription in CaSki but not SiHa cells  
CaSki and SiHa cells were treated with varying concentrations of TSA (25, 50, 100, 200mM) in a 
time course experiment. The RNA was extracted using the Qiagen RNA extraction protocol and 
cDNA prepared using the oligo dT primer. A semi-quantitative PCR was carried out to see the 
effect of the TSA on the transcription of the E6 and E7 genes. GAPDH was used as an internal 
control.     
In CaSki cells (Fig 43A), TSA led to the inhibition of E6 and E7 transcription within 6 hours of 
treatment. No such effect was however found in SiHa cells (Fig 43B). This inhibition of E6 and 
E7 mRNA in CaSki cells is reversible as these RNAs returned to steady state levels within 12 
hours post treatment for 25mM and 24 hours post treatment for 50mM TSA. As this inhibition 
did not have the same effect on the house keeping gene GAPDH, this suppression was selectively 
directed towards the virus specific transcription.   
Western analysis showed that the loss of E6 and E7 expression in CaSki cells led to a an increase 
in the expression of p53 and to a lesser extent that of Rb by 6 hours (Fig 44A). The change in 
p53 levels did not result in any significant alteration the flow cytometry profiles of CaSki cells 
(Fig 43A) at the 6 hour time point. Nevertheless, it appeared that there was an early S phase 
arrest, which became more apparent at the 12 hour time point with all concentrations of TSA. 
This arrest was is in spite of the fact that the E6 and E7 expression for the 25mM TSA was 
reverting back to normal levels by 12 hours.  
A similar trend was seen with that of 50mM TSA at the 24 hour time point by which time the 
cells treated with 25mM TSA have reverted back to their normal levels of E6 with a decrease in 
p53 levels.  
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Fig 43: TSA causes the suppression of early genes in CaSki cells with no effect on SiHa 
cells. Semi-quantitative RT-PCR was carried out to study the mRNA levels in CaSki and SiHa 
cells after treatment with increasing concentrations of TSA. GAPDH served as a internal cellular 
control. 
A. RT-PCR of CaSki cells show a severe inhibition of the E6 and E7 genes by 6h whose 
expression then begins to recover by 12 and 24h at lower concentrations of TSA and by 48h for 
100mM TSA.     
B. TSA has no effect on the transcription of E6 and E7 genes in SiHa cells. 
C. RT-PCR of E1 and E2 genes in CaSki cells treated with TSA show that the effect of the 
inhibition is only on the early genes and that the late genes were not affected. This also showed 
that the suppression of the early genes was E2 independent as no induction of E2 was observed.  
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Fig 44: Western analysis of CaSki and SiHa cells treated with TSA 
A. An induction of p53 and p21 and a slight drop in DNMT1 expression is observed in CaSki 
cells treated with TSA.  
B. A drop in the p53 expression along with an induction of p21 is observed in SiHa cells treated 
with TSA.  
 
               CaSki                    SiHa 
 
         
Fig 45: TSA leads to cell death in CaSki cells but not in SiHa cells. 
A. Flow cytometric analysis of CaSki cells shows a G1-S phase arrest after 12h followed by cell 
death at 100 and 200mM TSA concentrations after 24h.   
B. Flow cytometric analysis of SiHa cells indicates a G1 arrest at higher concentrations of TSA 
after 24h and no cell death.   
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Since it is known that p53 induction leads to an up-regulation of p21Waf1/Cip1, we monitored its 
expression through western analysis and found that p21Waf1/Cip1 was induced 24 hours after 
treatment with TSA at higher concentrations (Fig 44A).  
This repression of transcription was observed only for the early genes and the late genes were not 
affected. There was no induction of the E2 gene transcript (Fig 43C) observed.  This was in 
contrast to what was observed earlier where, CaSki cells treated with MMS resulted in an 
inhibition of the early genes due to an induction of E2 (Fig 40).     
 
Interestingly after 24 hours of treatment with 100mM and 200mM TSA, the repression of E6 and 
E7 was not released and the cells maintained a high level of p53. Flow cytometric analysis 
showed that these cells had undergone cell cycle arrest with a population undergoing apoptosis as 
seen from the pre G1 peak (Fig 45A).     
After 24hours of treatment, these cells start to undergo apoptosis despite the re expression of E6 
and E7 which led to a decrease in the p53 and p21Waf1/Cip1 protein levels.  
 
TSA had little or no effect on the expression levels of DNMT1 except at the 24hours. A drop in 
the levels of DNMT1 did not induce de-methylation for the 24 hour samples (Fig 46). 
 
E6 and E7 in CaSki and SiHa cells are driven by the same p97 promoter; yet, the response to 
TSA was drastically different in SiHa cells. There was no change in the levels of E6 and E7 
mRNA (Fig 43B). Very interestingly, western analysis showed a decrease in the levels of p53 
along with an induction of p21Waf1/Cip1 (Fig 44B).   
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Fig 46: TSA does not affect the methylation pattern of CaSki genomic DNA.  
The ratio of the McrBc digested PCR bands against the uncut control for the 6 and 24h CaSki 
cells treated with increasing concentrations of TSA was quantitated using the Gel Pro software 
and plotted as a bar chart. There is no demethylation observed at any concentration of TSA for 
either of the time points.     
    
 
The induction of p21Waf1/Cip1 also led to a G1 arrest in the SiHa cells at the 24hour time point for 
the 100mM and 200mM TSA concentrations as seen from the flow cytometric analysis (Fig 
45B).  
Even though the early genes in both CaSki and SiHa cells are under the control of the p97 
promoter, the dramatically different effect of TSA as seen from our results suggests a role of 
unknown transcription factors, which preferentially associate with the enhancer-promoter regions 
in CaSki but not SiHa thus, leading to a suppression of the promoter.                    
A possible candidate for this effect is the transcription factor YY1. It has a bi-functional nature 
where it can either activate or repress the LCR of HPV-16 and 18. It binds to a specific DNA 
sequence (CGCCATNTT), located at 5 sites in the LCR of HPV-16 (Fig 46, Top panel). YY1 
contains two repression domains, one embedded within the residues 170 to 200 and the other 
overlapping with the C terminal zinc finger DNA binding domain. YY1 is also known to have its 
activator domain at the N terminus (Bushmeyer et al., 1995). Interestingly acetylation of YY1 at 
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residues 170 to 200 could activate its repressor function by interacting more effectively to 
HDACs (Yao et al., 2001).  
                                                                
Fig 47: Detection of a 38bp deletion in the HPV-16 genome of SiHa cells. Size difference 
between the PCR products of CaSki and SiHa genomic DNA of the same region, which has a 
YY1 binding site, reiterates the deletion of the 38bp between nt 7756-7793 in SiHa genomic 
DNA.   
  
Another interesting fact is that the HPV genome in SiHa cells has a 38bp deletion at nt 7756-
7793 that overlaps with the one for the binding sites of YY1 as seen from the PCR comparison 
between CaSki and SiHa cells (Fig 47). This deletion has been reported in an earlier work done 
by Kozuka et al (Kozuka et al., 2000). 
 
3.5.2 Association of YY1, DNMT1 and HDAC1 with p97 increases with TSA 
To address the question as to what factors bind to the p97 promoter preferentially after treatment 
with TSA in CaSki cells, we carried out chromatin immunoprecipitation (ChIP) analysis with 
antibodies specific to YY1, DNMT1 and HDAC1. This study was through collaborative work 
with Chuang LS and Yeo WL.  
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Fig 48: ChIP showed that a possible complex of YY1, DNMT1 and HDAC1 could be 
involved in TSA mediated suppression of the p97 promoter. Top panel illustrates the regions 
amplified by the primers used in the ChIP. The 5 green circles represent YY1 binding sites, red 
boxes indicate E2 binding sites, two dark blue boxes represent Sp1 binding sites and the light 
blue box represents the 38bp deletion in SiHa DNA. The intensity of the PCR products measured 
against its control was quantitated using the Gel Pro software and plotted as a bar chart above 
each ChIP result. 
A. ChIP using YY1 pAb showed a specific increase in the immunoprecipitation of the V1, V2 
and V3 regions when treated with 100mM TSA.  
B. ChIP using DNMT1 pAb with the same extract as in 54A showed a specific increase in the 
immunoprecipitation of the same V1, V2 and V3 regions when treated with 100mM TSA.  
C. ChIP using YY1 pAb showed a specific increase in the immunoprecipitation of the V3 and P7 
regions when treated with both 25 and 100mM TSA. 
D. ChIP using HDAC1 mAb with the same extract as in 54C showed a similar increase in the 
immunoprecipitation of the V3 and P7 regions when treated with both 25 and 100mM TSA.PCR 
of the E4 region, which shows no change, is used as a negative control in all the experiments 
along with the beads alone that bound no DNA. 
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The data in Fig 48(A) shows that after 6 hours of treatment with 100mM TSA the association of 
YY1 to the HPV-16 LCR region containing the YY1 binding sites increased 3 fold in the region 
V1(7727-7870) and V2 (7850-122) compared to the control untreated cells. This increase was 2 
fold for the region V3 (7727-122)   
As a negative control a region of the HPV-16 genome with no YY1 binding sites was used. The 
level of association of this region E4 (3343-3620) after TSA treatment was similar to that under 
the control non-treated conditions. This binding was considered as the background produced by 
the antibody. This suggested that the increased association of YY1 to the LCR region after 
treatment with TSA was a very specific interaction. 
Similarly, an increase in binding to the LCR region was found for DNMT1 in cells treated with 
100mM TSA for 6 hours (Fig 48 B). The increase in association was slightly lower than that of 
YY1 but significantly more than the control untreated cells. This increase was about 2.5 folds in 
the V2 region and close to 2 folds with regions V1 and V3 (the intensities of which were 
quantitated by Gel Pro software). Again E4 region was used as a negative control showed no 
differential binding for treated or untreated cells.  
This again proved that similar to the association of YY1, the antibody 3G5 towards DNMT1 
specifically precipitated the LCR and p97 region in CaSki cells after treatment with TSA. 
We compared the association profile for DNMT1 throughout the HPV-16 genome in CaSki cells 
before and after treatment with TSA. Fig 49 illustrates the results wherein the precipitation of 
only the G9 (lane 10) region which contains the promoter (p97, lane 1) is high for untreated cells 
and this specifically increases upon treatment with TSA (the intensities of the PCR products were 
quantitated using the Gel Pro software). Therefore, the interaction of DNMT1 was specific to the 
HPV-16 promoter region.       
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Fig 49: Association of DNMT1 is specific to the p97 region in CaSki genome. ChIP using 
DNMT1 pAb (3G5) and primers specific to region G1-G9 were used to see the association 
specificity of DNMT1 before (CT, blue bar) and after treatment (100mM, maroon bar) with TSA. 
The intensity of the PCR products were quantitated and represented as a bar chart.      
 
YY1 and DNMT1 are not known to interact directly with one another. IP with either of the two 
antibodies to see if a direct interaction exists proved negative. 
Immuno staining with the two antibodies showed no co-localization. Nonetheless, it was 
interesting to note that 6h of treatment with TSA at 25mM TSA led to the formation YY1 foci 
(Fig 50) which diminished in numbers after 24 hours.  By then, the cells had recovered from the 
effects of TSA with re-expression of the early genes. In contrast, the foci remained after 24hours 
for the 100mM TSA treated cells. Though we did not see any DNMT1 foci similar to the YY1, 
we did see in a particular instance that DNMT1 did form very distinct foci that co-localised with 













                 
Fig 50: Immunostaining of CaSki cells treated with TSA using YY1 pAb (red) and DNMT1 
mAb (green). The nuclei were stained using Hoescht 33342 (DAPI).    
 
Even though the two proteins may not interact directly, they do share a common interacting 
partner in HDAC1 (Fuks et al., 2000a; Yao et al., 2001). To address the question if HDAC1 
played a role in the inhibition of the p97 promoter, antibodies specific towards it were included 
in the ChIP experiment. HDAC1 antibody precipitated the LCR region containing the YY1 
 159
binding sites with fold increments roughly comparable to those observed with YY1 (Fig 48 C, D) 
for CaSki cells treated with increasing concentrations of TSA (25mM, 100mM) for 6 hours. 
The E4 region used as a negative control showed no differential binding for treated or untreated 
cells similar to what was observed with YY1 and DNMT1 antibodies. 
ChIP assay therefore provides evidence that after treatment with TSA there is an increased 
recruitment of the YY1, DNMT1 and HDAC1 complex onto the LCR region of HPV-16 in 
CaSki cells.  
ChIP with SiHa cells using the same antibodies did not precipitate any of the regions studied 
with the above primers.             
        
3.5.3 Discussion 
YY1 is a multifunctional transcription factor with dual potential as it is involved in both 
transcriptional activation and repression of a variety of genes (Thomas and Seto, 1999) including 
HPV-16 and 18 genes controlled by the LCR. Time course experiments with HPV-16 positive 
cervical carcinoma cells CaSki and SiHa in the presence of TSA led to a transient suppression of 
the p97 promoter in CaSki but not SiHa cells. Earlier reports suggest that this initial down 
regulation is most probably at the transcriptional level as the same pattern was observed with that 
of actinomycin D, which is a known non specific inhibitor of RNA polymerase transcription 
(Finzer et al., 2002). However the viral oncogene expression was inhibited only in CaSki cells, 
this suggested the role for a transcription factor that specifically bound to the LCR of only CaSki 
cells. A likely candidate would be YY1 as the LCR region of SiHa genomic DNA has a 38bp 
deletion corresponding to one of the YY1 binding sites (Fig 47) (Kozuka et al., 2000). It has 
been shown that the mutation of any one of the five YY1 binding sites in the LCR region led to 
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the abrogation of its suppressor function (O'Connor et al., 1996). Hence, the integrity of the five 
sites is crucial for the inhibitory function of YY1 on the p97 promoter of HPV-16. 
ChIP assay demonstrate that with increasing concentration of TSA, there is an increase in the 
binding of YY1 to the LCR, thus probably resulting in the subsequent inhibiting of E6 and E7 
transcription. In CaSki cells there are only a few HPV-16 copies that are transcriptionally active 
and not methylated (Fig 11). YY1 binding site contains a CpG whose methylation status dictates 
if YY1 can bind to the DNA. If the CpG is methylated, YY1 binding is abrogated (Kim et al., 
2003a). Hence, YY1 does not play a role in the copies of CaSki cells that are methylated. 
However, it does so in the case of the copies that is not silenced by methylation.  
ChIP with antibodies specific to DNMT1 and HDAC1 also showed that along with an increased 
binding of YY1, there was an increased precipitation of DNMT1 and HDAC1 when CaSki cells 
were treated with TSA. Since we could not show any evidence of a direct interaction of DNMT1 
and YY1, it is possible that the two probably form a complex with their common interacting 
partner HDAC1.  
If the recruitment of YY1, DNMT1 and HDAC1 complex were involved in the TSA mediated 
inhibition of the promoter, this would be contrary to what is known about the function of TSA as 
an inhibitor of HDAC. YY1’s repressor function is activated through a complex feedback 
mechanism. It was demonstrated that acetylation of YY1 at its HDAC binding domain 
(comprising residues 170 to 200) by p300 and PCAF not only increased its effectiveness as a 
transcriptional repressor but also HDAC binding activity. The binding of HDACs to the 
acetylated residues result in active deacetylation of this region, possibly resulting in a negative 
feedback loop (Yao et al., 2001).This would then explain how TSA in effect augmented the 




Fig 51: Illustration of YY1, DNMT1 and HDAC1 dependent mechanism to down regulate 
the early gene promoter in CaSki cells treated with TSA. Recruitment of YY1, DNMT1 and 
HDAC1 in CaSki cell upon treatment with TSA leads to an inhibition of the p97 promoter. The 
deletion of one the YY1 binding site in SiHa fails to recruit the complex and hence is unaffected 
by TSA.   
 
 
This in turn has two possible outcomes, one of which is that the HDACs would in turn recruit 
DNMT1 which could result in the region becoming methylated; and the other being that the 
HDACs recruit the nucleosome complex onto the LCR region (Stunkel and Bernard, 1999). Both 
scenarios would then inhibit the p97 promoter and hence the transcription of E6 and E7. 
Treatment with TSA did not induce E2 (Fig 43C), hence, the inhibition of the E6 and E7 was 
independent of E2.   
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From our experiments (Fig 46) we observed that there was no change in the methylation status of 
the promoter, hence it is possibly not the mechanism involved in the transient TSA induced 
inhibition of the promoter. Therefore, a possible mechanism could be through the recruitment of 
the nucleosome complex through YY1 and HDAC1 that leads to the observed inhibitory effect 
on the p97 promoter in CaSki cells. Since part of this region is deleted in SiHa, it is unaffected by 
the addition of TSA. 
Thus, in CaSki cells E6 mediated p53 degradation is inhibited with a down regulation of E6. This 
in-turn leads to a p53 dependent induction of p21Waf1/Cip1 (Fig 43A, 50A) which causes the cells 
to arrest at the early G1-S phase (Fig 45A). Beyond the 24 hour stage, the accumulation of p53 at 
higher concentrations of TSA (100mM and 200mM) induces apoptosis, even with the re-
expression of E6 after 48 hours at 100mM (See Fig 45 and 49).   
In the case of SiHa cells, even though there was no apparent change in the levels of E6 (Fig 
43B), there was reduced p53 expression (Fig 44B). A probable cause could be explained by the 
recent finding that demonstrated YY1 to be a negative regulator of p53 (Sui et al., 2004) and 
functions by inhibiting its interaction with its co-activator p300 and by enhancing its interaction 
with the negative regulator Mdm2 (Gronroos et al., 2004).  
As for the induction of p21Waf1/Cip1 in the same cells, it has been known for sometime now that 
the TSA induced histone acetylation at Sp1 sites on the p21Waf1/Cip1 promoter led to an up-
regulation of its gene expression in a p53 independent manner (Sowa et al., 1999).  
In HeLa cells it was shown TSA causes a down regulation of C-Myc, which is known to control 
the expression of p21Waf1/Cip1 by binding directly to its promoter and inhibiting it. Therefore TSA 
allows for the suppression of p21Waf1/Cip1 to be relieved (Li and Wu, 2004). A definitive answer to 
the p21Waf1/Cip1 expression could be obtained in the future by ChIP assay of its promoter for the 
binding of C-Myc before and after TSA treatment in the SiHa cells.  
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Our data demonstrates that YY1 could be the factor that regulates the suppression of the p97 
promoter in a TSA induced manner through the recruitment of HDAC1, DNMT1 and the 
nucleosome complex. It also opens the door towards an interesting idea in that, YY1 along with 
factors such as HDAC1 could be involved in recruiting DNMT1 to the LCR region thus enabling 
a more permanent silencing of the oncogenic promoter. This silencing would be crucial to the 
host cells as a sustained E6 and E7 expression is required for the virus to transform the cells 



















3.6 An interacting partner of PCNA: Hsc70 
DNMT1 interacts with PCNA and they are co-localized at the replication foci (Chuang et al., 
1997). Our aim was to see if there were any other cellular factors which interact with either or 
both of these proteins and play a part in either DNA replication or DNA methylation. 
 In a work started by Koh TW (IMCB,Singapore), it was shown that the transcription factor 
CBF1 could interact with DNMT1 (Personal communication, Koh TW). He went on to test that 
the heat shock proteins which are known to interact with transcription factors such HSF and 
steroid receptors (Abravaya et al., 1992; DeFranco et al., 1998) could possibly interact with 
DNMT1 and CBF1.     
  
3.6.1 Purification of recombinant PCNA: Gel filtration 
Concurrent with experiments conducted by Koh TW (IMCB,Singapore) on CBF-DNMT1 
interaction, PCNA expressed in the bacterial system was subjected to purification by Gel 
filtration according the procedure described in Section 2.16. PCNA elutes out from fractions 31-
40 (Fig 52A) along with impurities. Although Gel filtration is not the most effective method to 
obtain pure protein, macro molecular complexes of the protein could be obtained. Therefore 
PCNA could be co-purified with interacting proteins from the bacterial host. 
Western analysis of fractions 30-42 (1μl) from gel filtration after separation on a 12% SDS-
PAGE gel in Fig 52(B) shows that PCNA elution profile extended into few more fractions and 
peaks at fraction 36. When the same filters were analyzed with antibody for DnaK, the bacterial 
homolog of Hsc70, the recombinant PCNA was shown to co-elute with DnaK Fig 52 (C).    
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Fig 52: Purification of hPCNA by Gel filtration 
A. Superose-6 Gel filtration of 65% ammonium sulphate precipitate. Only fractions 30-42 which 
contained the PCNA eluate stained by Coomassie Brilliant Blue are shown in the figure.     
B. Western analysis of fractions 30-42 using Hsc70 pAb, showing the elution profile of DnaK. 
C. Western analysis of fraction 30-42 using PCNA mAb, showing the elution profile of PCNA. 
D. ATPase assay of fractions 30-42 with Bovine Hsc70 (Sigma, USA) as a control in lane 1 
 
 
Hsc70 has a weak intrinsic ATPase activity, similar to DnaK. Since DnaK eluted out along with 
PCNA, it was interesting to find out whether its ATPase activity could be altered. 
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The results from the ATPase activity of gel filtration fractions 30-42 of PCNA in Fig 52 (D) 
show that the activity peaks within fractions 34-42. Since all these fractions contained PCNA and 
the activity was uninhibited, PCNA definitely did not act as an inhibitor of the ATPase activity of 
DnaK. 
 
3.6.2 Mono Q fractionation of recombinant PCNA  
When PCNA was subjected to monoQ column purification (Procedure: Section 2.17), it eluted at 
fractions 30-37 (Fig 53 A) with much less impurities compared to the gel filtration fractions. 
Western analysis of the Mono Q fractions 21-38 shows that DnaK elutes within fractions 21-32 
and peaks at fraction 26, whereas PCNA elutes within fractions 25-37 and peaks at fraction 32 
and 33 Fig 53 (B,C). 
These results suggested that the positive charge on the monoQ matrix might enable binding to 
PCNA strongly and dislodge the interacting protein such as DnaK.  
The Mono Q fractions 21-38 were analyzed for its ATPase activity similar to what was carried 
out with the gel filtration fractions. Fraction 23 had the highest activity Fig 53 (D). The ATPase 
activity was quantitated by the amount of ATP converted to ADP and AMP. The assays for the 
monoQ fractions contained a 100 fold less concentrated amount of ATP than its gel filtration 
counterparts to avoid saturation of the system. Under such conditions only fraction 23 could 
completely hydrolyze ATP showing that the most active monoQ fraction was about a 100 fold 








Fig 53: MonoQ fraction of hPCNA from Superose-6 column 
A. 12% SDS-PAGE gel of MonoQ column chromatography (stained by Coomassie Brilliant Blue 
Dye) of fractions 12-38. 
B. Western analysis of fractions 12-38 using Hsc70 pAb, showing the elution profile of DnaK. 
C. Western analysis of fractions 12-38 using PCNA mAb, showing the elution profile of PCNA. 
D. ATPase assay of fractions 21-38 which correspond to the fraction in which DnaK and PCNA 







3.6.3 Co-localization of Hsc70 with PCNA at the replication foci 
 
MRC5 SV40 cell line generally has a significant amount of the constitutively expressed cognate 
Hsc70. As discussed in Section 1.5.1, the induced form of Hsp70 shares an 81% homology with 
Hsc70, which share similar properties in terms of binding to proteins. These proteins are the 
mammalian homolog of the bacterial DnaK.  
Since we observed that DnaK co-eluted with PCNA, the objective of our study was to see if its 
mammalian homolog Hsc70 could also interact with PCNA and hence play a part in DNA 
replication.  
We chose to study the interaction with Hsc70 as it was the constitutive form expressed under 
normal physiological conditions.  
A general staining of the cells was initially carried out with antibodies specific to Hsc70. Fig 54 
shows that there are at least 3 different staining pattern for Hsc70; completely nuclear, 
cytoplasmic and diffused throughout the cell. This staining pattern could be due to the fact that 
the cells were not synchronized and hence were at different stages of the cell cycle. 
Chuang et al had shown that in MRC5.SV40 cells, PCNA could form distinct nuclear speckles, 
which co-localized with BrdU staining at the early replication foci. Therefore co-staining of the 
cells with Hsc70 (in green) and PCNA (in red) was performed to study the co-localization of the 
two proteins in vivo (Procedure: Section 2.22.1). Fig 55 (A, B) showed that indeed both proteins 






A.     B. 
 
Fig 54: Differential staining pattern of Hsc70 observed in MRC5 SV40 cells. 
A. MRC5 SV40 cells stained with Hsc70 mAb (1μg/ml, Oncogene Science)   





Fig 55: Co-staining of MRC5SV40 cells with Hsc70 and PCNA. 
Co-localization of the endogenous Hsc70 with PCNA is observed at the replication sites in the 
MRC5SV40 cells. Panel (a) represents staining by Hsc70 mAb (1μg/ml) and panel (b) represents 
staining with PCNA pAb (2.5 μg/ml). DNA was stained with Hoescht 33342 in panel (c). 




3.6.4 Immuno-precipitation of Hsc70 and PCNA  
 
   
 
Fig 56: Co-immunoprecipitation of Hsc70 and PCNA from MRC5 SV40 cells. 
A. Western blot of IP with PCNA mAb. IP was carried out under Mg2+ and Mg free conditions 
and western blot analyzed with Hsc70 pAb. 
B. Western blot if IP with Hsc70 mAb. IP was carried out in Mg free buffer. Western blot 
analyzed with PCNA pAb. 
Anti-mouse IgG beads were used as control for both the experiments.     
 
The results obtained through the gel filtration as well as cell staining lead to the possibility that 
Hsc70 and PCNA could interact directly with each other. An immuno-precipitation (IP) was 
performed using the MRC5 SV40 cell extracts. Fig 56 (A, B) shows PCNA co-precipitated 
Hsc70 and inversely Hsc70 co-precipitated with PCNA. The IP was carried out in Mg free 
buffers as described in section 2.24. The control for both the experiments was the anti mouse IgG 
beads which on their own show poor binding to either protein. 
 
3.6.5 Discussion 
Gel filtration is used for purifying native macromolecular complexes based on their size. With 
the monoQ column, the separation of the proteins is by their charge. A salt gradient is often used 
 171
to elute the proteins by charge neutralization. This tends to prevent the formation of high 
molecular weight complexes if charge to charge interaction is involved in the complex formation. 
 The result in Fig 52 shows that PCNA co-elutes with DnaK during gel filtration. Since they elute 
out in fractions corresponding to the size 100-200 kD, the complex may consist of DnaK and the 
trimeric PCNA.   
In the case of the monoQ, DnaK was fractionated before PCNA. However, there are a few 
fractions in which DnaK elutes with PCNA (Fig 53B, fractions 26-31), suggesting that the 
proteins could be in a tight complex.   
DnaK is a weak ATPase that can be activated by DnaJ, which may have co-purifed with DnaK as 
seen from the 40kD band in Fig 52(A). However, the ATPase activity of DnaK does not increase 
with an increasing amount of DnaK (Fig 52D). This could be due to a saturation of the ATPase 
activity even though there is a varying level of DnaK present in the fractions, suggesting that the 
amount ATP added to the assay was limiting and had been completely hydrolyzed to ADP. 
Therefore, no conclusion could be made about the effect of PCNA has on the activity of DnaK. 
However, the monoQ fraction assay indicated a tremendous drop in the ATPase activity for 
DnaK, as the amount of ATP used in the assay was a 100 fold less than that used for the gel 
filtration fractions, yet it was not completely hydrolysed. Another point to note was that the 
ATPase activity of DnaK for fractions 24-27 which corresponded to its elution peak was the least 
active. Thus during the monoQ column purification, the DnaK complex may have been 
dissociated from one or more of its co-activators such as DnaJ by binding to the charged monoQ 
beads.  
With the results from the gel filtration and mono Q purification of PCNA, it was established that 
PCNA could interact with DnaK.  This suggested the possibility of PCNA interacting with the 
mammalian homologs of DnaK; Hsc/Hsp70. This was initially observed when Hsc70 co-
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localised with PCNA at the replication foci (Fig 55).These results suggested that Hsc70 may 
interact directly with PCNA.  
The IP experiments though not completely conclusive, suggested either a direct interaction (Fig 
56) of the two proteins or the possibility that they were part of the same protein complex. 
Surprisingly, the antibodies for the two proteins could pull down the other in a buffer lacking 
Mg. Since Mg is a crucial component in the ATPase activity of Hsc70, it could be that either the 
interaction is inhibited by the ATPase activity or that in the presence of Mg the interaction could 
be transient and hence the probability of the two proteins being able to be precipitated by the 
antibodies is lower. This may also explain the very weak immuno precipitation by either 
antibody as the cell extract used would contain intrinsic levels of Mg which cannot be depleted, 
hence making the interaction transient and difficult to immuno precipitate.    
 
 
3.7 Characterization of PCNA binding domain in Hsc70 
3.7.1 PCR cloning and expression of recombinant Hsc70 truncated proteins 
To study the direct interactions of Hsc70 and PCNA, the cDNA (1941bp) of Hsc70 was sub-
cloned into 6 different fragments by PCR (Fig 57) with help from Koh TW. 
Primers ATP-ss and CT-as were used to produce the Hsc-FL fragment corresponding to amino 
acid residues 1-647.  
















Fig 57: Hsc70 fragments obtained by PCR which were cloned into pMAL vectors for the 
expression of recombinant proteins. 
 
 
Primers Pep-ss and Pep-as were used for Hsc-Pep fragment corresponding to amino acid residues 
355-575. Primers CT-ss and CT-as were used to give Hsc-CT fragment corresponding to amino 
acid residues 540-647. Primers ATP-ss and Pep-as, Pep-ss and CT-as were used to produce Hsc-
ATPep and Hsc-Pep-CT fragments respectively corresponding to amino acid residues 1-575 and 
355-647. 
All fragments were cloned into pMAL vectors and expressed as maltose binding fusion proteins 
(MBP) Fig 56(A). Except for the clone expressing Hsc-PepCT, all the recombinant proteins were 
expressed and purified by amylose beads to produce a single recombinant protein band as 
observed by Coomassie Blue staining. The maltose binding protein was also purified to act as 









   Pep-CT
Hsc70 
Codon 
1 355 415 540 575 647 
FL 
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3.7.2 In-vitro binding of PCNA to Hsc70  
In-vitro binding experiments of Hsc70 with PCNA were carried out using the recombinant  
Hsc70 truncated proteins immobilized onto amylose beads (Procedure: Section 2.19). MBP beads 
were used as a control for the binding experiment. PCNA was tested for its binding to the 
recombinant Hsc70 proteins. Western analysis was carried out using a mAb specific for PCNA 
(PC10). Fig 58 (B) showed that PCNA could only bind to the ATPase and ATPep recombinant 
proteins of Hsc70. The binding of PCNA to the ATPep fragment was about 3-4 folds more than 
with the ATPase domain alone. There was no binding observed for any of the other domains 
making this interaction specific to the amino terminal of Hsc70.   
 
Fig 58: Mapping of PCNA binding domains in Hsc70. Recombinant PCNA was incubated 
with MBP-amylose immobilized beads bound to the different Hsc70 fragments. Bound PCNA 
was visualized by western analysis.  
A. SDS-PAGE gel of Hsc70 fusion proteins used for the in-vitro binding experiments detected by 
Coomassie Brilliant Blue staining. 
B. Immunoblot of PCNA showed that it bound specifically to the ATP and ATP-Pep domains of 





3.7.3 In-vitro binding of Hsc70 to PCNA 
 
                  
Fig 59: Concentration dependent in-vitro binding of Hsc70 to PCNA and vice-versa 
A. Increasing amounts of recombinant PCNA interacted with MBP-Hsc70 bound to amylase 
beads.       
B. Increasing amounts of Hsc70 (Sigma, USA) interacted with GST-PCNA bound to GSH beads. 
The respective bead with no bound protein was used as controls in both experiments. 
 
 
To see if the inverse relationship could be established in the in-vitro system, PCNA tagged with 
GST was immobilized onto glutathione sepharose beads to see if it could bind to recombinant 
Hsc70 (Sigma). An increasing amount of Hsc70 did not show a concentration dependent binding 
to PCNA (Fig 59 B). This could be because the system could have been limited by the amount of 
PCNA on the beads and binding reached saturation with 15µl of Hsc70. The glutathione beads 
alone acted as a negative control. Similarly, the binding of PCNA to Hsc70 on the beads was not 
entirely concentration dependent with an increase observed only for the two fold increase in 
PCNA concentration (Fig 59A).      
 
3.7.4 Effect of ATP on the interaction between PCNA and Hsc70 
Since the function of Hsc70 is dependent on its ATPase activity, its effect on binding to PCNA 
had to be elucidated. In vitro binding experiments were carried out as before using Hsc70 full 
length recombinant protein instead of the truncated proteins. The amount of Hsc70 and PCNA 
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were kept at a constant level and the amount of ATP added to the system was varied. The 
reactions were carried out at room temperature for 30 minutes as described in section 2.20.  
Fig 60 (A) shows that an increase in the ATP concentration from 0.5mM to 2.0mM increases the 
binding of PCNA to the recombinant full length heat shock protein (HscFL). However further 
increase in ATP causes a decrease in binding affinity.  
 On repeating the same experiment by keeping the ATP level constant at 2.0mM and varying the 
time intervals for binding, Fig 60 (B) shows that the binding gradually increases and reaches a 
saturation point at 60 minutes. 
Therefore the optimal in-vitro binding condition would be by binding PCNA to full length Hsc70 
for 30 minutes in the presence of 2mM ATP.   
 
                          
Fig 60: Effect of ATP and time on the binding of PCNA to MBP-Hsc70. PCNA bound to 
Hsc70 on amlyose beads were analyzed by western blotting with PCNA mAb.  
A. 2mM ATP concentration is the optimum for the binding of PCNA to MBP-Hsc70 at room 
temperature after 30 min. 
B. Optimum time for the binding of PCNA to MBP-Hsc70 at a constant concentration of 2mM 




3.7.5 Effect of PCNA on the ATPase activity of Hsc70 
 
Hsc70 belongs to a family of highly conserved ATPases. Its ATPase activity is activated by the J 
domain proteins such as Hsp40 in the mammalian system by binding to the ATPase domain of 
Hsc70 (Greene et al., 1998). In our studies we have found that PCNA could also bind to the 
ATPase domain (Fig 58). Through the ATPase activity assay from the Gel filtration and monoQ 
column purification, the role PCNA plays towards the activity of Hsc70 could not be elucidated. 
Therefore to test the function of PCNA’s binding to Hsc70, the ATPase activity (Fig 61C) was 
carried out using recombinant proteins of Hsc70 (Fig 61B), Hsp40 (Fig 61A) and PCNA 
(MonoQ fraction 34, Fig 53C). The activity for each set was measured at intervals of 10 minutes 
up to 50 minutes (Fig 61C) as described in section 2.23. 
Recombinant PCNA on its own had no ATPase activity. This basal activity was only slightly 
lower than that of Hsc70 on its own. When PCNA was added along with Hsc70 into the assay, 
the activity was the same as basal Hsc70. Thus PCNA on its own does not activate Hsc70. Hsp40 
as expected activated the ATPase activity with a linear increase for the first 30 minutes after 
which the activity reaches a steady state. A 5 fold increase in the activity was observed by 30 
minutes.  
When PCNA was added along with Hsp40 and Hsc70, there is a dramatic increase in the ATPase 
activity. After 10 minutes, there in an increase of 6.5 folds while with Hsp40 alone there was 
only a 1.8 fold increase. The activity then increased in a linear manner to 9 folds by 50 minutes. 
Therefore, even though PCNA on its own does not possess an activating property towards the 
ATPase activity of Hsc70, it nonetheless acts as a co-activator in the presence of Hsp40.  
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Fig 61: PCNA increases the ATPase activity of the Hsc70 activated by Hsp40.  
A. Coomassie Brilliant Blue staining of purification of Hsp40 in pET vector (His Tag). 
Impurities debound using 5, 10, 25 and 100 mM imidazole. Hsp40 debound from Ni-NTA 
Agarose beads using 500mM imidazole and dialysed.     
B. Coomassie Brilliant Blue staining of expression of Hsc70 full length clone in MBP vector 
C. ATPase activity of Hsc70 measured in a time dependent manner in the presence of different 
interacting proteins. The activity was measured by the hydrolysis of 32P αATP. A monoQ 
column using a 2-40% salt gradient was used for separation of the hydrolysed products.  
Radioactivity was detected using a Radiomatic Flo-one beta Flow Scintillation analyzer 500TR.   
  
A.  B. 
C. ATPase activity assay 
Activity 
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This data taken together with that in Fig 60 suggests that ATP is essential for the interaction of 
PCNA with Hsc70. Since we also observed that the addition of ATP levels above 3.0mM lead to 
a decrease in the binding affinity to Hsc70 (Fig 60A) and that PCNA in the presence of Hsp40 
could act as a co-activator of Hsc70 ATPase activity (Fig 61C), it can be assumed that the 
decrease in the affinity could be due to the hydrolysis of the ATP. Since the proteins used in the 
studies were from the bacterial systems, it cannot be excluded that they might have had 




From the in-vitro binding experiments it is apparent that PCNA binds to the ATPase domain of 
Hsc70. This binding is further enhanced by the inclusion of the peptide domain (Fig 58). The 
ATPase domain is the most conserved region among all heat shock proteins including DnaK. 
This would explain why PCNA could co-elute with DnaK during gel filtration fractions.  
The reaction cycle of Hsc70 in Fig 62 (modified from (Rassow et al., 1997b)) shows that ATP is 
required for the peptide-binding domain to attain an open conformation, for binding to new 
polypeptide. PCNA binds the to ATPase domain and as seen from our experiments, ATP is 
required for the optimum binding of PCNA to Hsc70 (Fig 60). Thus it suggests that Hsc70 has to 
be in the ATP bound conformation to interact with PCNA. With an increase in ATP above 
2.0mM, the equilibrium for the Hsc70 conformation shifts towards the ADP state due to the 
hydrolysis of ATP brought about by PCNA acting as a co-activator in the presence of DnaJ (Fig 
61C), which could have been co-purified as impurities during the purification of recombinant 
PCNA (Fig 52A). This in turn could de-stabilize the interaction of Hsc70 and PCNA (Fig 60A). 
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Hence 2.0mM ATP appears to be the optimum level for the overall binding of Hsc70 to PCNA as 
shown in Fig 60 (A) in our experimental system.  
Further results from the time dependent experiment Fig 60 (B) show that the optimal time is 60 
min for the maximum amount of PCNA to bind to Hsc70 in the presence of 2.0mM ATP. The 
binding remains stable up to 90 min. This indicates that the activation of the ATPase activity of 
Hsc70 in the current experimental system occurred with ATP levels above 2mM as within 30 
min at higher concentrations, the interaction is no longer stable (Fig 60A).    
With the ATPase activity assay using the recombinant proteins, it was elucidated that PCNA had 
no effect on the ATPase activity of Hsc70 even though it binds to its ATPase domain. But it acts 
as a co-activator in the presence of Hsp40 (Fig 61C).  
Since it is believed that the ATP hydrolysis step is the rate-limiting step for binding to substrates, 
it is possible that binding of PCNA, which acts as a co-activator of Hsc70 ATPase activity in the 
presence of Hsp40, could facilitate the binding of a particular substrate. Fig 62 depicts the 
possible reaction cycle where the binding of PCNA along with Hsp40 could lead to a more stable 
complex with a specific substrate due to the increased rate of hydrolysis of ATP.  
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Fig 62: Illustration of the possible role of PCNA in the Hsc70 reaction cycle. Binding of 
PCNA to the ATPase domain of Hsc70 acts as a co-activator in the presence of Hsp40. This 
increases the ATPase activity of Hsc70, allowing for tighter binding to a specific substrate.     
 
Since PCNA and Hsc70 interact directly and co-localize at the replication foci (Fig 55) and a 
similar property has been observed with PCNA and DNMT1 (Chuang et al., 1997), it would be 









3.8 Characterization of Hsc70 binding domain in DNMT1 
Since it was hypothesised that DNMT1 could probably be a part of the complex at the replication 
foci along with PCNA and Hsc70, in-vitro binding experiments were carried out using the 
truncated Hsc70 constructs. 
 
3.8.1 DNMT1 binding domain in Hsc70 
A DNMT1 construct containing residues 121-207 (AD1.4) tagged with GST was used to bind to 
the MBP tagged Hsc70 constructs Fig 58(A). The experimental system for the in-vitro binding 
was similar to that with PCNA (Section 2.19). The proteins bound were then analysed by western 
analysis with a DNMT1 specific antibody. DNMT1 binding to MBP beads alone was used as 
control. 
Fig 63 shows that DNMT1 binds specifically to the Pep-CT domain of Hsc70. However, 
DNMT1 is unable to bind to either Pep or the CT domain on its own, which means that both the 
domains are required together for the binding of DNMT1. Therefore, DNMT1 binds to the C-
terminus substrate-binding domain of Hsc70.  
Since PCNA binds to the N-terminus ATPase domain and DNMT1 binds to the C-terminus 
substrate-binding domain of Hsc70, it is possible that the three proteins could form a complex in 
vivo at the replication foci.  
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 Fig 63: Mapping of DNMT1 binding domain in Hsc70. Recombinant DNMT1 (aa121-207) 
was incubated with MBP-amylose immobilized beads bound to the different Hsc70 fragments. 
Bound DNMT1 was visualized by western analysis.  
A. SDS-PAGE gel of Hsc70 fusion proteins used for the in-vitro binding experiments detected by 
Coomassie Brilliant Blue staining. 
B. Immunoblot of DNMT1 showed that it bound specifically to the Pep-CT terminus of Hsc70.   
 
 
3.8.2 Co-localization of endogenous DNMT1 and Hsc70 
To see if endogenous DNMT1 and Hsc70 do co-localize in vivo, cell staining for the two 
proteins was carried out in MRC5-SV40 cells using a in polyclonal antibody for DNMT1 (3G5) 
along with a monoclonal Hsc70 antibody (Oncogenescience). DNMT1 (in red) in Fig 64 forms 
distinct foci which had been reported earlier to co-localize with PCNA (Chuang et al., 1997). 
Hsc70 (in green) as had been observed earlier in Fig 55 do co-localize to the replication foci as 
well. The merger of the two shows that DNMT1 and Hsc70 (yellow foci) co-localize with each 
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other and are targeted to the replication foci which are indicative of early S-phase. This also 
suggests that DNMT1, PCNA and Hsc70 could be part of a complex at the replication foci. 
  
Fig 64: Hsc70 co-localizes with DNMT1 at the replication foci in MRC5 SV40 cells.  
DNMT1 (red) was stained using pAb (3G5) while Hsc70 (green) was stained using mAb 
(Oncogenescience, 1μg/ml). The two staining were overlaid to show their co-localization (yellow 
dots). The nucleus was stained the DNA dye Hoescht 33342 (blue, DAPI). Pictures 
(magnification, ×40) shown are under constant exposure.     
 
3.8.3 Co-localization of transfected DNMT1 with Hsc70  
The in-vitro binding experiments which showed the direct interaction of DNMT1 and Hsc70 was 
carried out using a truncated N-terminal DNMT1 construct consisting of residues 121-207 
(AD1.4). This construct contains the PCNA binding domain as well as the nuclear localization 
signal (NLS). Since the full length endogenous DNMT1 could co-localize with Hsc70 Fig 64, it 
would be interesting to see if just the presence of the truncated construct AD1.4 could achieve 
this interaction in-vivo. 
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Therefore, AD1.4 was transfected into MRC5-SV40 cells. Results of the cell staining with the 
endogenous Hsc70 (in green) and the transfected AD1.4 (in red) are shown in Fig 65A. The 
nucleus is stained with DAPI (in blue). AD1.4 forms very distinct foci all of which co-localize 
precisely with Hsc70, indicative of what we observed in the in-vitro binding experiments 
suggesting that, the fragment AD1.4 alone could be sufficient for the interaction of DNMT1 with 
Hsc70.  Fig 65(B) is the staining of the endogenous PCNA (in green) with transfected AD1.4 (in 
red). It forms distinct foci which were shown to be sites of newly replicated DNA as reported by 
Chuang et al  as they co-localized with BrdU staining (Chuang et al., 1997). 
                
Fig 65: Transfection of MRC5 SV40 cells with mammalian expression vector coding for 
wild type GST-DNMT1 (AD1.4 aa-121-207).  
A. Distinct foci staining and co-localization of the GST-DNMT1 construct (red, GST pAb, 
10μg/ml) with endogenous Hsc70 (green, mAb, 1 μg/ml) was observed.  
B. Distinct foci staining and co-localization of the GST-DNMT1 construct (red, GST pAb, 
10μg/ml) with endogenous PCNA (green, mAb PC10, 10μg/ml) was observed. 
The nuclei were stained with the DNA dye Hoescht 33342 (blue). Pictures (magnification, ×60) 
shown are under constant exposure.           
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Therefore, the co-localization Hsc70 and AD1.4 that result in a similar staining pattern could be 
assumed to represent the replication foci.  
 
3.8.4 Hsc70 binding domain in DNMT1 
 
The region required for the binding of DNMT1 to Hsc70 was from residues 121-207 (AD1.4). 
The region was further truncated into five segments. F1 consisted of residues 121-148, F2: 
aa149-173, F3: aa174-207, F4: aa141-163 and F5: aa141- 173. All truncated products were 
expressed as GST tagged proteins. The amount of proteins used in the study was analysed by 
western analysis using an anti-GST antibody, shown in the Fig 66 (B).  
The truncated AD1.4 fragments were added to full length Hsc70 bound to MBP beads as before. 
The GST pull down protein fragments were analysed by western analysis (Fig 66A). 
From our in-vitro analysis, it was observed that F4 and F5 pulled down with Hsc70 indicating 
that these two regions within AD1.4 were sufficient for the direct interaction of the two proteins. 
Yet, the reason is unclear why the interaction of the F5 region to AD1.4 was less than that shown 
by the F4 construct. The regions F1 and F3 that border the F4 and F5 region do not show any 
interaction, thus indicating the specificity of the binding region. Even F2, which contains most of 
F4 and F5, shows very weak interaction suggesting the importance of the integrity of residues 
from 141-163. Therefore, through the subtraction pull down assay it was established that the 









                              
 
 
Fig 66: Codons 141-163 (F4) in human DNMT1 codes for an Hsc70 binding domain.  
A. Map of recombinant GST-DNMT1 proteins used to pinpoint the Hsc70 binding domain. F1 
codes for residues 121-148; F2: aa149-173; F3: aa174-207; F4: aa141-163; F5: aa141- 173 and 
AD1.4 121-209.    
B. In-vitro pull down assay demonstrates that only constructs F4 and F5 were able to bind to 
Hsc70. AD1.4 was used as a positive control.  
Bottom panel is a western analysis using GST pAb of the input amounts of the recombinant 




F4 domain of DNMT1 contains a PXPXP sequence which is similar to the proline rich PXXP 
domain know to act as the binding site for many protein-protein interactions like: the binding site 
of p300 in the p53 transactivation domain (Dornan et al., 2003) as well as the binding site of Src 





Fig 67: Point mutational analysis to determine the Hsc70 binding domain in DNMT1.  
Top panel illustrates the mutated Prolines in the AD1.4 construct (P1, P2, P3) as well as the 
constructs AD1.4 and F6 used as positive controls and F1 and F3 constructs used as negative 
controls. 
A. Input recombinant proteins quantitated by western analysis using a GST pAb.    






The substitution of the prolines at aa 148 and aa 152 to alanines individually in the clones P1 and 
P2 and a double substitution in P3 was carried out by Chuang LS and used in the current study. 
These clones were then studied for their ability to bind Hsc70 in a GST pull down assay.            
The pull down assay was carried out using the AD1.4 construct as a positive control; F1 and F3 
were the negative controls. A new construct F6 which was a combination of F1 and F2 (Fig 66) 
was used as a second positive control. The current experiment used the DNMT1 binding domain 
in Hsc70 (PepCT) instead of the full length Hsc70 construct. The input proteins for the 
experiments are shown in Fig 67 (A) with the experimental procedure same as before (Section 
2.19).  
As observed in Fig 66 AD1.4 as well as the F6 construct interacted with the recombinant Hsc70 
Fig 67 (B). Both F1 and F3 are unable to bind to Hsc70 as expected. The P1 construct (P148Æ 
A) does not seem to adversely affect the binding, while there was a slight decrease in the binding 
of P2 (P152Æ A). However, when both the prolines are substituted in construct P3, there is a 
complete loss of binding similar to that of the F1 and F3 constructs.   
Therefore, through the in-vitro experiments it was established that the PXPXP region in the N-
terminus of DNMT1 binds to the C- terminus substrate binding domain of Hsc70. 
 
3.8.5 In-vitro binding of DNMT1b to Hsc70 
DNMTs are known to be expressed as different isoforms. In the case of DNMT1 it has two more 
isoforms: the oocyte specific DNMT1o lacking the first 118 amino acids from the N-terminus 
(Mertineit et al., 1998) and DNMT1b which incorporates in-frame an additional 48 nt in the N 
terminus (Hsu et al., 1999). This leads to an addition of 17 amino acids next to the PXPXP 
sequence that was found to be crucial to bind to Hsc70 Fig 68.  
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Fig 68: Illustration of the 17aa insertion in DNMT1b. The insertion is next to the Hsc70 
binding domain PxPxP (in red)   
 
The abundance of Dnmt1b transcript as determined by quantitative RNase protection analysis 
was determined to range from 6% to 25% of Dnmt1 in human cells (Bonfils et al., 2000). 
However, antibodies raised against Dnmt1b epitopes demonstrated that Dnmt1b protein was 
present at approximately 2-5% of the level of DNMT1. 
Since the insertion was adjacent to the Hsc70 binding region, we went on to investigate if it had 
any effect on the binding of Hsc70 and hence see if DNMT1b is also another interacting partner. 
The DNMT1b fragment similar to DNMT1’s AD1.4 but including the 17 aa was constructed as a 
GST tagged protein (VA3) by Chuang LS (IMCB, Singapore). Similar constructs were created 
for the F4 and F5 regions but with DNMT1b as template (F4V and F5V).  
GST pull down assay was carried out using the full length Hsc70 bound to MBP beads. Earlier 
we had seen in Fig 66 that F4 and F5 for DNMT1 could interact with Hsc70. However, the same 
construct including the extra 17 aa in F4V and F5V from DNMT1b fails to interact with Hsc70. 
This is the same for the VA3 construct, which suggests that the splice variant DNMT1b does not 
bind to Hsc70. This was despite the fact that the DNMT1b constructs contained the PXPXP 
region shown to bind Hsc70 in DNMT1.  
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Fig 69: DNMT1b is unable to bind to Hsc70. 
Top panel illustrates the DNMT1b constructs. F4V and F5V are constructed similar to F4 and F5 
from Fig 66 using the DNMT1b as template, which includes an additional 17aa, spliced behind 
P148. VA3 is the corresponding construct of DNMT1b similar to AD1.4. 
Bottom panel shows the results of the in-vitro binding experiments where it is seen that none of 
the DNMT1b constructs bind to Hsc70. AD1.4 is used as a positive control.  
The inputs for the experiments were normalised by western analysis using a GST pAb.     
 
Therefore, this proved that the integrity of the F4 region from aa 141-152 was crucial for the 
binding of Hsc70 and not just the PXPXP region. Nonetheless, this also showed that there exists 
in-vivo an isoform of DNMT1 that cannot interact with Hsc70. 
 
3.8.6 Immuno staining of DNMT1b  
DNMT1 could co-localize with PCNA (Chuang et al., 1997) and Hsc70 in the replication foci in 
MRC5SV40 cells (Fig 64). The transfected AD1.4 fragment of DNMT1 was sufficient to see this 
interaction in-vivo through immuno staining (Fig 65). Since the construct VA3 is unable to bind 
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to Hsc70, immuno staining of VA3 transfected into MRC5SV40 cells was carried out to see if it 
could still co-localize at the replication foci with PCNA and Hsc70. 
Fig 70 (A) shows the co-localization of AD1.4 (in red) and PCNA (in green) at the replication 
foci. In the same experiment Fig 70 (B) when VA3 is transfected, PCNA (in green) is unhindered 
in its ability to form distinct foci in the nucleus, but unlike what was observed with AD1.4, VA3 
(in red) does not co-localize with PCNA at the foci and have a slightly more diffused staining 
throughout the nucleus. 
Fig 70: Transfection of MRC5 SV40 cells with mammalian expression vector coding for 
GST-DNMT1 (AD1.4) and DNMT1b (VA3).  
A. Distinct foci staining and co-localization of the GST-DNMT1 construct AD1.4 (red, GST 
pAb, 10μg/ml) with endogenous PCNA (green, mAb PC10, 10μg/ml) was observed. 
B. GST-DNMT1b construct VA3 (red, GST pAb, 10μg/ml) stains diffusely and no longer co-
localizes with PCNA at the replication foci. 
C. Distinct foci staining and co-localization of the GST-DNMT1 construct (red, GST pAb, 
10μg/ml) with endogenous Hsc70 (green, mAb, 1 μg/ml) was observed. 
D. Both Hsc70 and VA3 fail to stain distinct dots and are diffused throughout the nucleus.   
The nuclei were stained with the DNA dye Hoescht 33342 (blue). Pictures (magnification, ×40) 
shown are under constant exposure.           
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Fig 70 (D) shows a similar phenomenon with the staining of VA3 (in red) being completely 
diffused throughout the nuclei. In this case, we did not observe any distinct foci formation for 
Hsc70 either in the VA3 transfected cells.  
 
3.8.7 Function of Hsc70 interaction with DNMT1 and PCNA  
The interaction of DNMT1 with PCNA and Hsc70 was mainly observed in-vivo at the 
replication foci, through our immuno staining Fig (55, 64, and 65). Therefore, the function of the 
interaction between Hsc70 and the PCNA-DNMT1 complex could be related to their function 
during early replication. In earlier studies, it was also shown that p21Waf1/Cip1 could disrupt the 
interaction of DNMT1 and PCNA. Therefore the expression pattern of p21Waf1/Cip1 and DNMT1 
is inversely related (Chuang et al., 1997). However, in some cell lines like CaSki ATCC in 
comparison with CaSki old, the basal levels of p21Waf1/Cip1 could be high enough to hinder the 
normal interaction of PCNA and DNMT1 thus causing a barrier to the progression of the cell 
cycle.  
Since Hsc70 is involved in stabilizing protein complexes, it would be interesting to see if it 
performs a similar role in the case of DNMT1 and PCNA. 
To have a p21Waf1/Cip1 competition assay, the DNMT1 and DNMT1b fragments AD1.4 and VA3 
were immobilised onto GST beads. PCNA was then added to the beads in the presence of 
varying concentration of p21Waf1 peptide (0, 0.5, 1 and 5 µM). This competition assay was 
carried out in the presence or absence of recombinant Hsp70 (Sigma) and Hsp40 (See section 
2.25) along with ATP (2mM). The bound PCNA after the competition assay was visualised by 
Western analysis using a PCNA mAb (PC10). 
In the absence of the competitor (p21Waf1 peptide) the binding affinity of PCNA to AD1.4 (Fig 
71B, lane1) is similar to that of VA3 (Fig76C, lane1). Even though through immuno staining we 
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did not observe a co-localization of PCNA and VA3 (Fig 70), we see that in-vitro VA3 could 
bind PCNA. Hence, it can be speculated that DNMT1b could also interact with PCNA. 
In the absence of Hsp70/Hsp40, the binding of PCNA to AD1.4 decreases with an increase in 
concentration of the p21Waf1 peptide (Fig 71B, -Hsp70/40). However, the same amounts of 
p21Waf1 shows a greater inhibition towards the binding of PCNA to VA3 (Fig 71C, -Hsp70/40).  
 
 
Fig 71: Competition studies of DNMT1 (AD1.4) and DNMT1b (VA3) interaction with 
PCNA involving p21Waf1 peptide.  
A. The p21Waf peptide used in the competition assay 
B. The binding of PCNA to AD1.4 was competed by increasing concentrations of p21Waf1 
peptides, which was protected in the presence of Hsp70/Hsp40 and 2mM ATP. 
C. The binding of PCNA to and VA3 was more susceptible to attack from the p21Waf1 peptide 





In the presence of the Hsp70/Hsp40 along with 2mM ATP, the effect of p21Waf1/Cip1 competition 
is reduced significantly when PCNA binds AD1.4, mainly for the 0.5 and 1.0 μg of the peptide 
(Fig 71B, +Hsp70/40). This was not the case when the same experiment was carried out with 
VA3. p21Waf1 competed PCNA out of the complex to a similar extent as to when the binding 
assay was carried out without Hsp70/Hsp40 (Fig 71C, +Hsp70/40). Thus showing the inability of 
VA3 to interact with Hsc70 (Fig 69) could have been a contributing factor. 
 
3.8.8 Discussion 
DNMT1 was shown to be an interacting partner of Hsc70, binding to the C-terminal peptide 
binding domain. Since Hsc70 and DNMT1 were also seen to co-localize at the replication foci 
where DNMT1 interacts with PCNA, it was not surprising that the three proteins could interact 
with each other such that all three could probably co-exist as a complex at the same time. 
The N-terminal of DNMT1 contains a PXPXP region similar to the proline rich PXXP present in 
the SH3 domain of Src know to be a protein binding site (Jiang and Qiu, 2003). Through point 
mutations of the prolines at each end (Fig72), it was shown that this region in the case of 
DNMT1 also exhibited properties of protein-protein interaction where it bound Hsc70. Even 
though the PXPXP region was present in DNMT1b, the addition of the 17aa next to the site 
(Fig73) abrogated its binding to Hsc70. There are two possible explanations for the observed 
results. The addition of the 17aa could have led to a change in the structure of the protein so as to 
abrogate its binding or that the aa141-148 along with the PXPXP region constitutes the 
interaction region of DNMT1 to Hsc70. This demonstrated that the sequence and structural 
integrity of aa 141-152 in DNMT1 is necessary for its interaction with Hsc70. Further work with 
point mutations in the aa141-148 region has to be carried out to elucidate the crucial residues that 
are required for this interaction. 
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This then raises the question as to the significance of the interaction.  Hsc70 is known to play a 
role in many viral DNA replication systems, the first of which was the in the E.coli 
bacteriophage λ (Konieczny and Zylicz, 1999). In the case of HPV replication initiator E1 
helicase, Hsc70 and Hsp40 enhance the binding to DNA independently and additively. The 
interaction with Hsc70 was transient and required the hydrolysis of ATP (Liu et al., 1998a). In 
this system E2 protein recognises the origin of replication of the HPV genome and tethers the E1 
helicase to the origin DNA. The Hsc70 chaperone machinery enhances this assembly process 
significantly. The system seems to stabilize a dihexameric ring form of E1 probably to allow 
efficient DNA threading as observed from electron microscopy. In another more recent study, 
Hsc70 and Hsp40 proteins were shown to help in dissociating the E2 protein from the complex, 
thus removing its inhibition on the helicase activity of E1 protein (Lin et al., 2002).               
          
 
Fig 72: Illustration of the Hsc70 reaction cycle involving its interaction with PCNA and 
DNMT1.Binding of PCNA to the ATPase domain could act as a co-activator along with Hsp40 
to increase the ATP hydrolysis required to bind to DNMT1 in a tight conformation at its 
substrate binding domain. This then forms a very stable DNMT1, PCNA and Hsc70 complex.  
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In the mammalian system the Hsc70 and Hsp40 could perform a similar function as in viral DNA 
replication. Initially the binding of PCNA to the ATPase domain and DNMT1 to the substrate 
binding domain of Hsc70 in its ATP bound state, forms a low affinity complex. The binding of 
Hsp40 (activator) along with PCNA which acts a co-activator (as seen in Fig 61) increases the 
ATP hydrolysis. This increased hydrolysis changes Hsc70 to its ADP state wherein, a high 
affinity complex is achieved by the closing of the α-helical lid with respect to it binding with its 
substrate: DNMT1 (Fig 72). The change to the ADP state also allows the dissociation of PCNA 
from Hsc70. Since PCNA interacts with DNMT1 directly, it could still be a part of the complex, 
where it is indirectly bound to Hsc70 through DNMT1.nce our assays used recombinant PCNA, 
it can be assumed that they were in their monomeric state. Therefore similar to the E1 protein in 
the viral replication system, the Hsc70 complex could indirectly stabilize the ring structure of 
PCNA which is loaded onto the DNA by the RFC complex as a trimer in an ATP dependent 
manner (Majka and Burgers, 2004). Upon completion of the faithful transmission of the 
methylation pattern onto the newly synthesised DNA, binding of nucleotide exchange factors 
along with ATP to Hsc70 could facilitate the disassembly of the DNMT1-PCNA complex from 
the DNA. Thus, the Hsc70/40 system could act to stabilize the interaction during the methylation 
event and help in the disassembly from the DNA. 
Another function of this interaction could be its ability to protect the DNMT1/PCNA complex 
from the inhibition by p21Waf1/Cip1 as seen from the competition assay using p21Waf1 peptide (Fig 
71). This probably protects the cells from cell cycle arrest when the there is a high level of basal 
expression of p21Waf1/Cip1. Since p21Waf1/Cip1 is know to bind to PCNA with a 3:1 stoichiometry 
(Gulbis et al., 1996) the interaction with Hsc70 and DNMT1 would then prevent the binding and 
hence allow for replication and maintenance methylation to proceed unhindered. Only when the 
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cell encounters DNA damage where in the p21Waf1/Cip1 is induced, it binds to PCNA allowing for 
cell cycle arrest.          
This brings us to the question as to the role of DNMT1b in-vivo. Since there is no function 
associated with this isoform of DNMT1 and it probably makes up only 2-5% of the total DNMT1 
protein content (Bonfils et al., 2000), it is possible that the splice variant of DNMT1 has been 




















CHAPTER 4 CONCLUSION 
In summary we have demonstrated that Hsc70 binds to aa141-152, probably to the PXPXP 
region in the N-terminus of DNMT1 through it C-terminal substrate binding domain. This 
interaction could be strengthened by the increased ATPase activity caused by the association of 
PCNA along with Hsp40 to the ATPase domain of Hsc70. Hence, Hsc70 could facilitate a stable 
DNMT1 and PCNA complex at the replication fork during the S-phase of the cell cycle as well 
as a possible mechanism through which DNMT1 is unloaded from the DNA by the nucleotide 
exchange factors. 
The stability of this interaction as seen from its ability to protect against an attack from p21Waf 
peptides could play a role in cells exposed to low levels of DNA damage wherein the cell cycle 
arrest caused by an induction of p21Waf1/Cip1 could be circumvented. Alternatively, tumour cells 
invariably have high expression levels of Hsc70 accompanied by mutations in p53 that leads to 
low levels of p21Waf1/Cip1. This could result in hypermethylation of certain tumour suppressor 
genes and result in higher mutation rates due to the deamination of the 5-methylcytosines. Hence, 
it is yet unresolved as to the effect of the interaction of Hsc70 with PCNA and DNMT1 as either 
advantageous or detrimental to the cells.  
DNMT1 nevertheless plays a vital role in the virus related tumorigenesis as seen from our work 
on HPV-16 in clinical specimens, where genomic hypomethylation of the promoter controlling 
the E6 and E7 oncogenic expression correlated with carcinogenic progression (Table 2). A 
proposed hypothesis is illustrated in Fig 73. HPV-16 virus enters the host cell as single or 
multiple copies, and is methylated as a host defence mechanism. The silencing of the HPV-16 




Fig 73: Proposed hypothesis of the role of methylation in cervical cancer. 
A naked viral DNA entering the host cell is represented by the pink circle. The purple circle with 
yellow lollipops represents a fully methylated and hence silenced viral DNA. The red box is 
indicative of the p97 promoter while the blue box represents a possible promoter of E2. 
Slight demethylation of p97 promoter due to exposure to carcinogens and differentiation of the 
basal cells could lead to the onset of tumourigenesis (CINI), with low level expression of viral 
genes. Prolonged exposure to carcinogens and further differentiation leads to hypomethylation 
leading to higher viral gene expression, which supports DNA amplification (CINIII). Integration 
of the hypomethylated virus leads to the disruption of the E2 gene and a constitute expression of 






This would constitute the asymptomatic stage where the expression levels of the viral proteins 
are absent. Since in our studies only 52% of the asymptomatic samples were methylated, it could 
not be confirmed if the unmethylated promoters of the 48% of the remaining samples constituted 
a progression towards a CINI stage (Discussed in section 3.1.5). Exposure to alkylating agents 
such as MMS could lead to varying amounts of demethylation of the viral genome (Fig 38). This 
could result in the low level expression of the viral genes and a probable onset of tumorigenesis 
(CINI). The life cycle of HPVs is tied to the differentiation of its host cells within stratified 
squamous epithelia. Analysis of HPV-16 DNA harvested from a cervical epithelial cell line that 
was isolated from an HPV16-infected patient using bisulphite treatment demonstrated that the 
HPV-16 LCR was selectively hypomethylated in highly differentiated cell populations and 
hypermethylated in poorly differentiated basal cell-like cells (Kim et al., 2003b). A recent study 
has also demonstrated that there is an increase in the expression of HDAC1 and HDAC2 in 
cervical dysplasia and carcinoma with the expression levels correlating with the degree of 
dysplasia (Huang et al., 2005).   The expression levels of HDAC2 in these cells were shown to be 
inversely related to the expression of p21Waf1/Cip1. Therefore, a combination of factors such as 
differentiation of the epithelial cells and demethylation of the viral genome due to prolonged 
exposure to carcinogens as well as a possible silencing of tumour suppressor genes through the 
upregulation of HDACs could trigger the replication of the virus and progression of 
tumorigenesis (CINIII).  
Demethylation is therefore crucial in not only activating the transcription of the viral genes E1 
and E2 which helps propagate the replication of the viral genome, but in modulating the 
recruitment of E2-E1 complex to the origin of replication (Kim et al., 2003b). In agreement with 
our findings (Table 3), Kim et al also observed that the E2 binding site, which contained CpG at 
position 7862, was most frequently unmethylated in differentiated cells. 
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Binding of E2 to the demethylated promoter could result in the inhibition of the HPV-16 
oncogenes E6 and E7. Hence, there should exist a balance such that, the inhibitory effect of E2 
does not totally silence the p97 promoter. Further demethylation of the HPV-16 genome may 
trigger viral integration into the host genome disrupting the E2 gene, thus resulting in the 
constitutive expression of the p97 promoter and progression to invasive cancer.  
Methylation of the HPV-16 viral gene promoter could be a crucial mechanism, which perturbed 
could lead to the onset of cervical cancer. With further validation of the work presented here and 
discussed in section 3.1.5, the study of the methylation status of the promoter could be used as a 
marker to identify the risk potential patients’ possess when infected with the virus in developing 
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Infection with genital human papillomaviruses (HPVs) is the primary cause of cervical cancer. The infection
is widespread, and little is known about the secondary factors associated with progression from subclinical
infection to invasive carcinoma. Here we report that HPV genomes are efficiently targeted in vivo by CpG
methylation, a well-known mechanism of transcriptional repression. Indeed, it has been shown previously that
in vitro-methylated HPV type 16 (HPV-16) DNA is transcriptionally repressed after transfection into cell
cultures. By using a scan with the restriction enzyme McrBC, we observed a conserved profile of CpG hyper-
and hypomethylation throughout the HPV-16 genomes of the tumor-derived cell lines SiHa and CaSki.
Methylation is particularly high in genomic segments overlying the late genes, while the long control region
(LCR) and the oncogenes are unmethylated in the single HPV-16 copy in SiHa cells. In 81 patients from two
different cohorts, the LCR and the E6 gene of HPV-16 DNA were found to be hypermethylated in 52% of
asymptomatic smears, 21.7% of precursor lesions, and 6.1% of invasive carcinomas. This suggests that
neoplastic transformation may be suppressed by CpG methylation, while demethylation occurs as the cause of
or concomitant with neoplastic progression. These prevalences of hyper- and hypomethylation also indicate
that CpG methylation plays an important role in the papillomavirus life cycle, which takes place in asymp-
tomatic infections and precursor lesions but not in carcinomas. Bisulfite modification revealed that in most of
the HPV-16 genomes of CaSki cells and of asymptomatic patients, all 11 CpG dinucleotides that overlap with
the enhancer and the promoter were methylated, while in SiHa cells and cervical lesions, the same 11 or a
subset of CpGs remained unmethylated. Our report introduces papillomaviruses as models to study the
mechanism of CpG methylation, opens research on the importance of this mechanism during the viral life
cycle, and provides a marker relevant for the etiology and diagnosis of cervical cancer.
Human papillomavirus type 16 (HPV-16) and related HPV
types are carcinogenic, and persistent HPV, infection is a pre-
requisite in the etiology of most or even all cervical cancers (22,
38, 52). Most women become infected by HPVs, and while
some of these infections progress malignantly, most remain
subclinical or lead only to precursor lesions. The factors that
determine these outcomes are poorly understood. Transforma-
tion by HPVs depends on the oncoproteins E6 and E7, whose
transcription is modulated by numerous transcription factors
and epigenetic mechanisms (5, 18). Tumor progression may
result from stimulated oncoprotein expression through tran-
scriptional induction by steroids (10, 17), by deletion of tran-
scriptional silencers (25), or by integration of HPV genomes
into cellular DNA (3, 40, 43).
cis-responsive elements that regulate E6 and E7 oncogene
transcription are spread throughout the long control region
(LCR) of HPV-16, an 850-bp segment between the L1 and E6
genes. Transcription starts at the E6 promoter P97, which is
regulated by one binding site for Sp1 and two for the HPV-
encoded factor E2 (11, 47). The activity of P97 is stimulated by
an enhancer with binding sites for several cellular factors,
including AP1, NF1, and the progesterone receptor (1, 10,
16–18). Two specifically positioned nucleosomes can form over
the enhancer and promoter (42) and repress transcription
when they are modified by histone deacetylases (HDACs).
HDACs are associated with CDP, which binds a silencer
between the enhancer and promoter (27, 30). When HPV
genomes integrate into cellular DNA during progression to
malignancy, a nuclear matrix attachment region located down-
stream of P97 becomes a strong transcriptional stimulator (43).
Here we report that a well-known and potent epigenetic mech-
anism, the repression of transcription by methylation of DNA
at CpG dinucleotides, targets HPV-16 genomes, with likely
consequences for viral oncogene expression, the viral life cycle,
and carcinogenic progression of HPV-16 lesions.
In mammals, DNA methylation mediated by a family of
DNA-[cytosine-5] methyltransferases (DNMT1, DNMT3a,
and DNMT3b) (28, 34) occurs at 2 to 4% of all cytosines
located 5 to guanosine (CpG) (7). CpGs are present in mam-
malian genomes at only 20% of the statistically expected fre-
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quency (39), suggesting adverse functional consequences of
methylation as a cause for their loss during evolution. CpG
methylation leading to gene silencing is involved in X-chromo-
some inactivation and genomic imprinting (31). The rare case
of tissue-specific gene expression mediated by CpG methyl-
ation has recently been confirmed (15). Furthermore, CpG
methylation is required for stabilization of the genome against
recombination, which is implicated by the preferential meth-
ylation of repeated sequences (51). During carcinogenesis,
global hypomethylation and regional (CpG islands) hyper-
methylation (21) are frequently observed. CpG methylation
represses gene expression either by preventing transcription
factors from recognizing their cognate binding sites (36, 48) or
by attracting proteins that bind methylated DNA (MeCPs)
(20), which recruit HDAC1 to condense adjacent chromatin.
Methylation of the genomes of the carcinogenic HPV types
in situ has never been studied, but there is evidence for its
potential involvement in the regulation of HPV transcription.
First, CpGs are underrepresented in HPVs, similar to the
situation in their human host. Second, when in vitro-methyl-
ated HPV-16 DNA was transfected into cells, it failed to ex-
press (37), similar to the EcoRI-resistant HPV-16 DNA stud-
ied in one specific cell line (24). Third, methylation of the
DNAs of HPV-1, which causes flat warts, and of cottontail
rabbit papillomavirus was reported 20 years ago (9, 44, 50), but
this report was never followed up by systematic investigation of
medically more important papillomaviruses. Here, we report
findings from a study of CpG methylation of HPV-16 in cell
lines and in clinical samples. We found that HPV-16 DNA is
an efficient target for DNA methylation, that preferentially
methylated regions are asymmetrically distributed over the
genome, that methylation occurs at CpGs overlapping with the
enhancer and promoter, and that the frequency of CpG meth-
ylation decreases during progressive stages of cancer. These
observations suggest that CpG methylation is involved in the
biology of HPV-16 as well as in the etiology of cervical cancer,
where it may be as a diagnostic marker.
MATERIALS AND METHODS
Analysis of the DNA of cell lines. CaSki and SiHa cells originated from the
laboratory of H. zur Hausen at the German Cancer Research Center, Heidel-
berg, Germany, where they were frozen in 1986 and freshly thawed for this study.
Cellular DNA was purified with genomic tips (Qiagen). Fifteen and 150 ng of
each of these DNAs were digested with HpaII and MspI (New England Biolabs),
respectively, and, after heat inactivation of the enzymes, were amplified by PCR.
For digestions with McrBC (New England Biolabs), 250 ng of SiHa or CaSki
DNA was digested with 3 U of enzyme for 1 h at 37°C in 25 l of NE buffer 2
(50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM dithiothreitol [pH 7.9]).
Clinical specimens. Brazilian samples (obtained by L. L.Villa) originated from
cross-sectional studies in two cities in the northeastern part of the country and
consisted of cervical scrapings and tumor biopsies. Cytological and histopatho-
logical analyses were done according to the Bethesda system. For smears clas-
sified as being “asymptomatic,” ectocervical and endocervical cells were collected
with a cytobrush. Tissue biopsies were classified as cervical intraepithelial lesions
(cervical intraepithelial neoplasia I [CIN I] and CIN III) or invasive carcinoma
and were digested with proteinase K prior to DNA isolation. DNA samples were
purified by spin column chromatography and tested for the presence of HPV
DNA by the MY09/11 PCR protocol for specific HPV types (6). All specimens
were number coded for the privacy of the subjects. Asymptomatic and precursor
samples from New Mexico were obtained and characterized during published
epidemiological research (32). Invasive cervical cancer specimens were obtained
from ongoing case-control studies (conducted by C. M. Wheeler) of the same
population diagnosed between 1980 and 1999. In both countries, the original
collection of clinical samples followed the respective guidelines for the protec-
tion of human subjects.
PCR. Table 1 lists the primers used for dissection of the HPV-16 genome and
mapping of the LCR-E6 segment. PCR was carried out in a 25-l volume
containing 0.2 mM concentrations of each of the four deoxynucleoside triphos-
phates (dNTPs), 10 pmol of the primers, 2.5 l of buffer B (20 mM Tris-HCl [pH
TABLE 1. Oligonucleotides used for amplification of segments of the HPV-16 genome
Amplicona Primer Position Sequence
G1 G1F 515–534 GTCTTGTTGCAGATCATCAAGA
G1R 1528–1509 ATTCTGAAAAACTCACCCCG
G2 G2F 1501–1520 GAGTTATACGGGGTGAGTTT
G2R 2526–2505 CAATGGTCTATGCTTTACATCC
G3 G3F 2501–2522 CTATGGATGTAAAGCATAGACC
G3R 3501–3481 TTTCCGGTGTCTGGCTCTGAT
G4 G4F 3471–3490 AGCGACCAAGATCAGAGCCA
G4R 4472–4453 GGCCTTGTTCCCAATGGAAT
G5 G5F 4402–4421 GGTGGGTTAGGAATTGGAAC
G5R 5402–5383 GATGTAGAGGGTACAGATGG
G6 G6F 5367–5386 TTCTACAACCCCGGTACCAT
G6R 6370–6351 GTCGCCATATGGTTCTGACA
G7 G7F 6348–6367 TGGTGTCAGAACCATATGGC
G7R 7173–7150 CAACATACATACAATACTTACAGC
G8 G8F 7145–7184 CGTAAGCTGTAAGTATTGTATGTATGTTGAATTAGTGTTG
G8R 559–528 TTACAGCTGGGTTTCTCTACGTGTTCTTGATG
P2 P1F 7145–7184 CGTAAGCTGTAAGTATTGTATGTATGTTGAATTAGTGTTG
P2R 122–94 CCTGTGGGTCCTGAAACATTGCAGTTCT
P4 P4F 7851–7886 TGTGTGCAAACCGTTTTGGGTTACACATTTACAAG
P1R 559–528 TTACAGCTGGGTTTCTCTACGTGTTCTTGATG
P5 P5F 99–132 ATGCACCAAAAGAGAACTGCAATGTTTCAGGAC
P5R 559–528 TTACAGCTGGGTTTCTCTACGTGTTCTTGATG
P11 P11F 1–38 ACTACAATAATTCATGTATAAAACTAAGGGCGTAACCG
P2R 122–94 CCTGTGGGTCCTGAAACATTGCAGTTCT
a Amplicons G1 to G8 overlap and cover comprehensively the whole HPV-16 genome. Amplicons P2, P4, P5, and P11 were used to study specifically the
enhancer-promoter-E6 segment.
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8], 100 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 50% glycerol, 1% Triton
X-100) (Promega), 2 mM MgCl2, and 0.75 U of Taq (Promega) with 25 or 0.25
l of SiHa or CaSki DNA, respectively, uncleaved or cleaved by McrBC. The
PCR started at 94°C for 1 min, followed by 35 amplification cycles (denaturation
at 94°C for 10 s, annealing at 58°C for 30 s, and extension at 68°C for 45 s,
increasing by 10 s per cycle), with final extension at 68°C for 7 min. PCR with Taq
Gold was carried out in a 25-l volume containing template DNA, 5 mM
concentrations of dNTPs, 10 pmol of primers, 2.5 l of magnesium ion-free
buffer supplied by the manufacturer (Roche), 2 mM MgCl2, and 1.25 U of
AmpliTaq Gold (Applied Biosystems) under the following conditions: 94°C for
9 min, followed by 40 amplification cycles (denaturation at 94°C for 10 s, an-
nealing at 58°C for 30 s, and extension at 68°C for 45 s, increasing by 10 s per
cycle), with final extension at 68°C for 7 min.
Reverse transcription and PCR. RNA was prepared by using a Qiagen RNA
kit. One microgram of RNA was primed with 5 pmol of oligo(dT) primer, topped
up to 11 l with H2O, heated at 70°C for 10 min, and placed on ice for 5 min. A
master mix containing 2 l of 10 Moloney murine leukemia virus reverse
transcriptase buffer (New England Biolabs), 100 mM dithiothreitol, 0.5 mM
concentrations of each of the four dNTPs, 100 U of reverse transcriptase enzyme
(New England Biolabs), and 20 U of RNase inhibitor (Roche) was added to each
sample, followed by incubation for 50 min at 42°C. The enzyme was heat inac-
tivated at 70°C for 15 min. PCR was carried out in a 25-l volume containing 0.2
mM concentrations of each of the four dNTPs, 10 pmol of primers, 2.5 l of
buffer B (Promega), 2 mM MgCl2, 0.75 U of Taq polymerase (Promega), and 1.5
l of the cDNA preparation. The PCR started at 94°C for 2 min, followed by 25
amplification cycles (denaturation at 94°C for 10 s, annealing at 55°C for 30 s, and
extension at 68°C for 45 s), with final extension at 68°C for 7 min.
Bisulfite sequencing. For mapping of methylated cytosine residues (14), DNAs
were modified by a CpGenomeTm DNA modification kit (Intergen Inc.) and the
reaction products were amplified with primers specific for modified HPV-16
DNA. Msp3F (genomic positions 4322 to 4348; ATTTGATATTATATTTAAG
GTTGAA) and msp3R (4970 to 4946; AATAATTACAAAAACAAAATCT
ACA) spanned part of the L2 gene. Msp4F (7498 to 7522; TAGTTTTATGTT
AGTAATTATGGTT) and msp4R (161 to 140; ACAACTCTATACATAACT
ATAATA) amplified a segment with the enhancer-promoter. The amplification
products were directly sequenced with the same primers.
RESULTS
Most HPV-16 genomes of the cancer cell line CaSki, but not
the single HPV-16 genome of SiHa cells, contain meCpGs.
With genome sizes of 7,900 bp and GC contents close to
40%, HPV genomes may be expected to contain about 400
CpG sites. However, the common papillomavirus types,
HPV-6, -11, -16, -18, -31, and -45 (26), have 160, 155, 112, 172,
122, and 154 CpGs, respectively. This lower-than-expected fre-
quency, similar to what is found in the human host, suggests a
function of CpGs in the biology of genital HPVs. Methylated
CpGs (meCpGs) can be detected with the restriction enzymes
HpaII and MspI. Both enzymes cleave the sequence CCGG,
but CpG methylation inhibits cleavage by HpaII. Figure 1A
shows the positions of two HpaII/MspI sites in the LCR and E6
gene of HPV-16.
The cervical carcinoma cell lines CaSki and SiHa contain
about 500 genomes and a single genome, respectively, of
HPV-16 integrated into the chromosomal DNA. The HPV-16
genome in SiHa cells is integrated by interruption of its E2
gene at positions 3132 and 3384, accompanied by deletion of
251 nucleotides of viral sequence (3) and 7.8 kb of the cellular
DNA flanking the site of recombination (4). The HPV-16
genomes in CaSki cells are inserted in numerous loci. In most
of these, HPV-16 is transcriptionally silent, while E6 and E7
transcripts stem from a single locus (49), possibly due to an
epigenetic repression mechanism. We confirmed that SiHa and
CaSki cells express similar levels of E6 and E7 transcripts, in
spite of the large excess of HPV-16 genomes in CaSki cells (3)
(Fig. 1B and C).
To determine whether CpG methylation may explain this
observation, we analyzed the methylation statuses of the two
HpaII/MspI sites in the LCR and the E6 gene, which are
present in the PCR amplicons P5 (corresponding to the E6
gene), P2 (containing the LCR), and P11 (containing just E6
promoter sequences) in both DNAs. In the case of SiHa DNA,
these amplicons could not be generated after cleavage with
either of the two enzymes, while in the case of CaSki cells, most
of the DNA was resistant to HpaII but was readily cleaved by
MspI (Fig. 1D). These findings indicate that the LCR and the
E6 gene contain CmeCGG in most HPV-16 genomes of CaSki
cells but not in the HPV-16 genome of SiHa cells.
Conservation of preferential CpG methylation throughout
the HPV-16 genomes of SiHa and CaSki cells and a cervical
carcinoma. Screening with the restriction enzyme McrBC is
more powerful than analysis by HpaII/MspI, as McrBC cuts
close to the sequence purine-meC (PumeC) in the context of a
second, arbitrarily spaced PumeC (41, 45). As a consequence,
McrBC recognizes pairs of PumeCpG residues and, on aver-
age, cleaves every other meCpG, while HpaII/MspI analysis
resolves the methylation status of only 1 in 16 CpGs.
The HPV-16 genome contains 112 CpGs, and 81 of these are
part of the sequence purine-CpG and are potential targets of
methylation as well as for cleavage by McrBC. To establish a
crude map of the distribution of methylation throughout the
HPV-16 genomes of SiHa and CaSki cells, we used McrBC to
digest the chromosomal DNA and PCR amplified segments
with sizes of about 1 kb (Fig. 2). As expected from the HpaII/
MspI data, the LCR-E6 segment from positions 7145 to 559
could not be digested in SiHa DNA, indicating a lack of meth-
ylated targets. Most of this amplicon was digested in CaSki
DNA and therefore methylated, while a reproducible weak
undigested band indicated lack of methylation of some copies.
Also, the segments 515-1528 and 1501-2526 were not cleaved
in SiHa cells and were partially cleaved in CaSki cells, suggest-
ing lack of and partial methylation, respectively, of the
genomic region spanning the E7 and E1 genes. The amplicon
between positions 2501 and 3501 could not be amplified with
SiHa DNA, as expected from the recombination of this seg-
ment. Most of this amplicon was digestible with CaSki DNA.
Three of the remaining segments (3471-4472, 5367-6370, and
6348-7143) were almost completely cleaved with both SiHa
and CaSki DNA, while a fourth segment (4402-5402) was par-
tially cleaved. This part of the genome, with the late genes L2
and L1, is apparently well recognized by the cellular methyl-
ation machinery. In SiHa, this segment is—due to the recom-
bination—upstream of viral promoters and may be transcrip-
tionally silent.
To examine whether one would find a similar distribution of
McrBC cleavage in situ, we analyzed the DNA from a cervical
carcinoma (tumor 6), our only DNA preparation among 33
tumor-derived DNAs which contained a strongly methylated
LCR-E6 segment (see below). This tumor DNA was preferen-
tially cleaved in an uneven manner that was similar to what was
done with the HPV-16 genomes in SiHa and CaSki cells, with
strong methylation of all segments between positions 3471 and
7173. The 7145-557 and 2501-3501 segments were moderately
methylated, while there was low methylation in the segment
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from positions 515 to 2526 (Fig. 2). Differential cleavage by
McrBC was not biased by unequal distribution of McrBC sites,
since amplicons G1 to G8 all have numerous potential McrBC
sites (11, 8, 15, 13, 5, 7, 10, and 13 sites, respectively). For
example, G6, with seven sites, is efficiently cleaved in CaSki,
SiHa, and T6 DNA, in contrast to G2, which has eight sites.
We also examined the DNA from a carcinoma, whose
LCR-E6 segment, like those of nearly all of the tumors we
studied, had no detectable DNA methylation (see below). The
DNA of tumor 4 was not cleaved by McrBC throughout the
HPV-16 genome (Fig. 2B). The segment 5367-6370 led only to
a weak amplicon. We also analyzed the complete HPV-16
genome of a precursor lesion (CIN I). None of the amplicons
of this sample, initially found to have a hypomethylated
LCR-E6 region (see below), was cleaved by McrBC.
We conclude that HPV-16 DNA can be extensively modified
by DNA methylation, that methylation varies quantitatively in
different parts of the genome, and that hypermethylation in
three DNA isolates correlates with the positions of the late
genes. Methylation of HPV-16 DNA is not necessary but de-
pends on as-yet-unknown circumstances, as suggested by the
lack of detectable methylation in two lesions, with the tumor
and CIN I likely containing integrated and episomal DNA,
respectively.
HPV-16 methylation is frequent in asymptomatic smears,
uncommon in precursors lesions, and rare in carcinomas.
Since we asked whether CpG methylation occurs only sporad-
ically in cell lines and invasive carcinomas or is frequent in
clinical specimens, we analyzed DNA from cervical smears
classified as being normal (asymptomatic smears), biopsies of
low-grade and high-grade precursor lesions (CIN I and CIN
III), and invasive carcinomas by McrBC digestion and PCR
amplification. The strategy and selected data are shown in Fig.
3.
We examined DNA from 48 clinical specimens from New
Mexico and 33 from Brazil. Among the latter group of speci-
mens, 8 of 14 asymptomatic smears, 0 of 3 CIN I lesions, and
2 of 16 samples from carcinomas contained hypermethylated
viral DNA (Table 2). One of these two carcinoma DNAs was
lightly methylated, while the other, from tumor 6, was strongly
FIG. 1. HpaII/MspI cleavage identifies CpG methylation of SiHa and CaSki DNA as a likely source of transcriptional repression. (A) Distri-
bution of CpGs in the LCR (positions 7154 to 7906 and 1 to 96) and in the E6 gene of HPV-16 (positions 97 to 559) and positions of two
HpaII/MspI sites, one (position 57) overlapping with elements of the E6 promoter P97 and the other located in the 3 part of the E6 gene (position
502). (B) Reverse transcription-PCR confirms that similar amounts of E6 and E7 transcripts are generated by SiHa and CaSki cells. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase, served as the cellular control transcript. (C) Genomic PCR confirms the large excess of HPV-16 DNA
in CaSki cells. (D) Chromosomal DNA of SiHa and CaSki cells was not cut (CT, control) or was cleaved with one of the two enzymes (H, HpaII;
M, MspI) and PCR amplified to generate the amplicons P2, P5, and P11. None of the three amplicons could be generated after cleavage with either
of the two enzymes in the case of SiHa cells, indicating lack of any methylated CCGG sequences. In the case of CaSki cells, most of the DNA was
resistant to HpaII digestion but was readily cleaved by MspI, indicating methylation of these two sites in most of the 500 HPV-16 copies in CaSki
cells.
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methylated and was described in detail above. Among the
samples from New Mexico, DNA of 5 of 11 asymptomatic
smears, 3 of 10 CIN I lesions, 2 of 10 CIN III lesions, and 0 of
17 cancers contained methylated HPV-16 genomes. Taking
both cohorts together, 52% of the HPV-16 genomes from
asymptomatic smears, 21.7% of those from precursor lesions,
and only 6.1% of those from the carcinomas contained meth-
ylated DNA, indicating that, as judged by McrBC cleavage,
methylation of the LCR and the E6 gene decreases with pro-
gression of the infection (Table 2). A scan of the methylation
pattern of the whole HPV-16 genome from cervical smears of
asymptomatic patients could not be attempted because of the
small amounts of DNA available.
Mapping of meCpGs by bisulfite modification. meCpGs can
be mapped precisely by sequencing after bisulfite modification
(14). As it is very laborious to completely analyze 7.9-kb ge-
nomes in numerous samples, we used this technique only for
selected samples and an analysis of the enhancer-promoter
region between genomic positions 7498 and 161. This segment
contains 11 CpGs, at positions 7535, 7554, 7677, 7683, 7695,
7862, 31, 37, 43, 52, and 58 (Fig. 1). The first five of these CpGs
are in close proximity to important AP1 and NFI sites of the
FIG. 2. McrBC cleavage of segments of the HPV-16 genomes in SiHa and CaSki cells and three clinical samples detects patterns of hyper- and
hypomethylation. (A) Genomic map of HPV-16 (7,906 bp), with genes E6, E7, E1, E2, E5, L2, and L1, the LCR, and the relative locations of
amplicons G1 to G8 indicated. (B) Cleavage of amplicons G1 to G8 by McrBC (right lane of each pair of samples) indicates methylation, compared
with uncleaved controls (left lane of each pair). The cleavage pattern indicates hypermethylation throughout most HPV-16 genomes in DNA from
CaSki cells and tumor 6, hypermethylation of the late genes in the single HPV-16 genome of SiHa cells, and hypo- or no methylation in tumor
4 and a CIN I lesion.
FIG. 3. McrBC cleavage identifies hypomethylation of HPV-16 DNA in cervical cancers and hypermethylation in asymptomatic smears.
Amplicon P4 includes the genomic segment from positions 7850 to 559 with the E6 promoter elements, the E6 oncogene, and cis-responsive
elements within E6 (left side of figure). The upper panel at right shows two typical McrBC-resistant, i.e., unmethylated, amplicons detected in DNA
from invasive cancers, and the lower panel shows two typical McrBC-sensitive and methylated amplicons from asymptomatic cervical smears.
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HPV-16 enhancer (1, 5, 18). The last five CpGs overlap with an
Sp1 and two E2 binding sites, which regulate the transcription
start at position 97 (11, 47). In SiHa cells, all 11 of these CpGs
were modified, i.e., unmethylated. In contrast, the same 11
CpGs were methylated in most of the 500 HPV-16 DNA copies
in CaSki cells. An unmodified and transcriptionally active
background of one or a few HPV-16 genomes would not have
been detectable in this experiment. A segment of the L2 gene
(4322-4946) served as a control and did not differ between
SiHa and CaSki cells, as all four CpGs of this amplicon were
methylated.
We also studied 15 patient samples by bisulfite modification
(Table 3). In five asymptomatic smears, all 11 CpGs were
methylated. In two separate CIN I samples, three and four of
the five CpGs at the promoter were not methylated, while all
CpGs of the enhancer were methylated in one sample and two
were methylated in the other. In the five invasive tumors, we
observed heterogeneous methylation patterns, while in a CIN
III sample and two tumor samples, all CpGs of the enhancer
and promoter were methylated. Notably, however, the only
CpG residue between the enhancer and promoter (position
7862) was unmethylated in these three samples and all other
CIN and invasive cancer lesions. This site is the only CpG
dinucleotide between the two specifically positioned nucleo-
somes that overlap the enhancer and promoter elements and is
close to CDP and AP-1 sites that are essential for transcrip-
tional repression and activation during epithelial differentia-
tion (5, 30, 42, 43). We conclude that bisulfite modification
detected the same trend of hypomethylation, when lesions
were compared with asymptomatic smears, as that observed
with McrBC cleavage, although the latter technique is less
sensitive and underreported CpG methylation.
DISCUSSION
Our data provide compelling evidence that the HPV-16 ge-
nome is efficiently modified by cellular DNA methylation and
raise questions about how HPV-16 genomes are recognized,
which role DNA methylation has in the HPV-16 life cycle, and
whether analyzing methylation helps us to understand the eti-
ology of and to diagnose cervical cancer.
Our data suggest that the recognition of HPV-16 DNA is not
based on a single physical property. HPV-16 DNA is efficiently
targeted as an episome, since we observed methylation very
frequently in asymptomatic smears, which generally contain
only episomally replicating HPV-16. However, since we also
detected methylation in a few invasive tumors and in cell lines,
which typically contain HPV-16 genomes integrated into chro-
mosomal DNA (40, 52), one may consider that either arrange-
ment into tandem repeats or chromosomal recombination also
provides a methylation signal. Repeated DNA is known to be
a preferred target for CpG methylation (51), and in the case of
cottontail rabbit papillomavirus, tandem repeats of the viral
DNA that were generated during progression of cutaneous
lesions correlated with increased methylation (44, 50). Even in
the absence of tandem arrangements, nontranscribed parts of
the single intrachromosomal HPV-16 genome are strongly
methylated in the SiHa cell line, suggesting that recombination
per se is a de novo methylation signal, as extensively studied in
the adenovirus system, which has been the paradigm for DNA
methylation studies for more than 20 years (33, 46).
We showed by meCpG mapping that the methylation of the
HPV-16 LCR does not follow a singular and simple pattern but
that groups of CpGs in alternative locations and with alterna-
tive extents can become modified. Methylation of numerous
CpGs of the enhancer may indicate repression of its function.
It is known that CpG methylation does not interfere with
binding of the E6 promoter factor Sp1 (19), while it displaces
E2 protein (48), which, however, is a repressor of the P97
promoter. Therefore, a methylated promoter may be transcrip-
TABLE 2. Methylation of the LCR and E6 gene of HPV-16 in
clinical samples from Brazil and New Mexicoa
Site(s) Sample type(total no.)






Brazil Asymptomatic (14) 8 6 57.1
CIN I (3) 0 3 0
Invasive cancer (16) 2 14 12.5
New Mexico Asymptomatic (11) 5 6 45.4
CIN I (10) 3 7 30
CIN III (10) 2 8 20
Invasive cancer (17) 0 17 0
Bothb Asymptomatic (25) 13 12 52
CIN I and III (23) 5 18 21.7
Invasive cancer (33) 2 31 6.1
a CpG methylation was determined by cleavage of the DNA preparations with
the restriction enzyme McrBC and subsequent PCR amplification of a genomic
segment of HPV-16 corresponding to the promoter and E6 gene as shown in Fig.
3.
b Data from both cohorts were combined, results with CIN I and CIN III were
united into one group of precursor lesions, and DNA preparations that could not
be amplified were omitted.
TABLE 3. Methylation of 11 CpGs in the LCR of HPV-16 in two
cell lines and 15 clinical samples
Cell line or
samplea
Methylation of CpG at positionb:
7535 7554 7677 7683 7695 7862 31 37 43 52 58
SiHa           
CaSki           
As16           
As22           
As23           
As24           
As33           
CIN I A1           
CIN I A6           
CIN III A20           
T6           
T8           
T9 ?          
T10           
T20 ? ?         
T37           
T39           
a The five CpGs between positions 7535 and 7695 are close to cis-responsive
elements of the viral enhancer; the CpGs between positions 31 and 58 overlap
with promoter elements; and the CpG at position 7862 is located between the
borders of two specifically positioned nucleosomes, one of which overlaps the
enhancer while the other overlaps the promoter.
b , methylation; , lack of methylation; , both methylated and unmethyl-
ated residues in the same sample; ?, unknown.
6232 BADAL ET AL. J. VIROL.
tionally active independent of the epithelial specific enhancer,
particularly as it is under the stimulatory influence of the nu-
clear matrix attachment region in the E6 gene (43).
The normal HPV-16 life cycle is restricted to asymptomatic
infections and CIN lesions, while carcinogenic progression is
an accident, as there is no further virus production. Conse-
quently, the high prevalence of methylated HPV-16 genomes
in asymptomatic epithelia may indicate that methylation is part
of normal HPV-16 biology. Two speculative and opposing
views might explain this observation. The cell may have an
antiviral defense that senses viral DNA as foreign and targets
it for transcriptional repression. Alternatively, DNA methyl-
ation may be yet another example of the numerous strategies
developed by HPVs that favor a subclinical, long-term main-
tenance of the viral infection (5). Such a model would be
reminiscent of the life cycle of Epstein-Barr virus, which in-
cludes DNA methylation-dependent silencing of a specific pro-
moter during one form of latency (35, 36). Likewise, the HPV
genome may contain molecular properties that induce methy-
lation-dependent latency under some conditions, while under
different conditions this mechanism may be overruled. This
could be achieved by the conserved nuclear matrix attachment
regions (43) and Sp1 sites at the E6 promoters of all genital
HPVs (47). Both elements have been reported to antagonize
DNA methylation in the context of certain cellular genes (8,
12, 23). Preferential methylation of late genes may suggest an
additional role in the early-late switch, which is a multifaceted
event involving differential promoter usage, splicing, elonga-
tion, and mRNA stability (2, 29). This possibility has been
discussed based on studies of the HPV-1 genome with the
limited HpaII/MspI technology (9).
Our data document the power of molecular diagnoses by
revealing the epigenetic diversity of pathologically similar sam-
ples. The analysis is limited by the problem that one may study
DNA populations that may be heterogeneous due to inclusion
of surgical margins, different progression stages within one
biopsy, and molecularly divergent HPV-16 genomes even in
single cells. McrBC is an excellent tool for a crude scan of
whole viral genomes but may be prone to underreporting of
meCpGs, as suggested by the detection of meCpGs in bisulfite-
modified tumor DNAs, which were not cleaved by McrBC.
HPV DNA methylation may become important for the diag-
nosis of cervical smears if further research confirms that
asymptomatic infections and precursor lesions fall into classes
that either express or repress the viral oncogenes, leading to
different prognoses, as E6/E7 expression is required for con-
tinued transformation and viability of HPV-containing tumors
and tumor cell lines (13).
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Human papillomaviruses (HPVs) infect epithelia, including the simple and the squamous epithelia of the cervix, where they can cause
cancer and precursor lesions. The molecular events leading from asymptomatic HPV infections to neoplasia are poorly understood. There is
evidence that progression is modulated by transcriptional mechanisms that control HPV gene expression. Here, we report the frequent
methylation of HPV-18 genomes in cell culture and in situ. DNA methylation is generally known to lead to transcriptional repression due to
chromatin changes. We investigated two cell lines derived from cervical cancers, namely, C4-1, which contains one HPV-18 genome, and
different clones of HeLa, with 50 HPV-18 genomes. By restriction cleavage, we detected strong methylation of the L1 gene and absence of
methylation of parts of the long control region (LCR). A 3-kb segment of the HPV-18 genomes downstream of the oncogenes was deleted in
both cell lines. Bisulfite sequencing showed that in C4-1 cells and two HeLa clones, 18 of the 19 CpG residues in the 1.2-kb terminal part of
the L1 gene were methylated, whereas a third HeLa clone had only eight methylated CpG groups, indicating changes of the methylation
pattern after the establishment of the HeLa cell line. In the same four clones, none of the 12 CpG residues that overlapped with the enhancer
and promoter was methylated. In six HPV-18 containing cancers and five smears from asymptomatic patients, most of the CpG residues in
the L1 gene were methylated. There was complete or partial methylation, respectively, of the HPV enhancer in three of the cancers, and lack
of methylation in the remaining eight samples. The promoter sequences were methylated in three of the six cancers and four of the six smears,
and unmethylated elsewhere. Our data show that epithelial cells efficiently target HPV-18 genomes for DNA methylation, which may affect
late and early gene transcription.
D 2004 Elsevier Inc. All rights reserved.Keywords: HPV-18; Methylation; Cancer
Introduction differ in their pathogenicity, as HPV-6 and 11 are mostHuman papillomavirus-18 (HPV-18) is one of the most
common HPV types involved in genital neoplasia (Bosch
et al., 1995). Together with HPV-6, 11, 16, and 31, it is
one of the model systems for transcriptional studies of
HPVs. The comparison of these viruses is desirable be-
cause they belong to three remotely related HPV groups
(HPV-6/11, HPV-16/31, and HPV-18) within the super-
group of genital HPVs (Chan et al., 1995). They also0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.002
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Biochemistry, University of California, 114 Sprague Hall, Irvine, CA
92697-3900. Fax: +1-949-824-8551.
E-mail address: hbernard@uci.edu (H.-U. Bernard).often associated with genital and laryngeal warts. HPV-
16/31 and HPV-18 give rise to cervical cancer and its
precursors, but among these lesions, HPV-16 and 31 are
preferentially associated with squamous carcinoma of the
cervix and HPV-18 with adenocarcinoma, respectively
(Andersson et al., 2001).
Only a small fraction of HPV infections progresses to
neoplastic lesions. While immunological phenomena may
determine the clearance of some HPV infections, many
infections may lead to persistence of the viral DNA in
the absence of symptoms. The mechanisms that determine
whether a persistent HPV infection remains free of
symptoms or progresses eventually to clinically detectable
neoplasia remain enigmatic. Modulation of the transcrip-
S. Badal et al. / Virology 324 (2004) 483–492484tion of the HPV oncogenes is likely one of the factors
that determine the clinical outcome of an HPV infection:
There is evidence for the stimulation of HPV oncoprotein
expression by physiological stimuli such as steroid hor-
mones (Chan et al., 1989), for major differences in HPV
transcription depending on the infected cell type (Sailaja
et al., 1999), for the differentiation state of epithelia
(O’Connor et al., 2000; Pattison et al., 1997), and for
transcriptional heterogeneity in situ in different cell pop-
ulations within individual lesions (Stoler et al., 1992).
This paper describes a part of our effort to describe
regulatory phenomena acting through specific transcrip-
tion factors or through epigenetic mechanisms that affect
the biology and pathology of genital HPVs.
The study of the viral gene expression has for many years
concentrated on the identification of cis-responsive elements
and the sequence-specific transcription factors binding these
elements (Bernard, 2002). More recently, it has become
clear that epigenetic mechanisms play a major role in
modulating the viral gene expression (Stu¨nkel and Bernard,
1999). The term ‘‘epigenetics’’ refers to regulation by
higher-order structures of the DNA, such as chromatin
conformations that either favor or repress gene expression.
The methylation of DNA is one of several mechanisms that
influences chromatin conformation (Bird, 1992). Methyla-
tion normally occurs at CpG dinucleotides, and the fact that
CpGs are present only at 20% of the statistically expected
frequency in mammalian genomes (Schorderet and Gartler,
1992) suggests adverse functional consequences of methyl-
ation as a cause for their loss during evolution. The same
applies to HPV genomes (Badal et al., 2003). With a
genome size of 7857 bp and G + C content close to 40%,
one may expect to find in the HPV-18 genome about 400
CpG sites, although it actually contains only 172.
It has been known for 20 years that the genomes of HPV-
1 and the cottontail rabbit PV can become methylated
(Burnett and Sleeman, 1984; Sugawara et al., 1983; Wett-
stein and Stevens, 1983), and that in vitro methylated HPV-
16 genomes are transcriptionally incompetent after trans-
fection into cell culture (Rosl et al., 1993). However, only
recently, we and others observed that HPV-16 DNA meth-
ylation takes regularly place in vivo in cervical samples
from asymptomatic patients, in cervical carcinoma (Badal et
al., 2003), and in cell cultures with episomal HPV-16
genomes (Kim et al., 2003). This shows that de novo
methylation regularly targets papillomavirus genomes in
somatic cells. It raises the questions of where and how
HPV genomes are recognized by the cellular DNA methyl-
ation mechanism, which enzymatic components are in-
volved in the epithelial de novo methylation, and about
the role of this transcription repression mechanism during
the normal HPV-16 life cycle and HPV-16-dependent car-
cinogenesis. The research presented in this paper addresses
the question of whether DNA methylation phenomena are,
among the genital HPVs, restricted to HPV-16, or also occur
in the remotely related type HPV-18. Our data confirm thatHPV-18 is as efficiently recognized as HPV-16. We detected
methylation preferentially in the late gene L1, but also in the
long control region (LCR), which opens the possibility that
methylation modulates HPV-18 oncogene as well as L1
transcription.Results
The restriction enzyme McrBC detects methylated HPV-18
DNA segments in several clones of HeLa and in C4-1 cells
To examine whether methylated CpG dinucleotides
(meCpGs) may occur in HPV-18 genomes, we used a
strategy successfully employed in studying HPV-16 meth-
ylation (Badal et al., 2003), namely, cleavage of the
HPV-18 genomes in certain cervical cancer-derived cell
lines by the restriction enzyme McrBC, followed by
polymerase chain reaction (PCR) amplification of seg-
ments of the viral genome and the analysis of the ampli-
cons in agarose gel electrophoresis. McrBC is an unusual
restriction enzyme, which recognizes two PumeGpGs
closely (50 bp) or even remotely (>1 kb) located relative
to one another and cleaves at unspecific positions close to
one of these meCpGs (Sutherland et al., 1992); in other
words, it recognizes on the average every other meCpG. If,
after McrBC cleavage, a DNA segment can be readily
detected after PCR amplification, one has to conclude that
in the original chromosomal DNA, the sequence was
hypomethylated. However, if the amplicon is weakened
or absent, the original DNA was hypermethylated. The
reaction is powerful in scanning larger genomic segments,
but cannot exactly quantify the amount of methylation in
each of these segments.
HeLa is a widely used cell line with about 50
genomic copies of HPV-18 recombined with cellular
sequences (Ambros and Karlic, 1987; Durst et al.,
1987; Mincheva et al., 1987; Popescu et al., 1987;
Schwarz et al., 1985). HeLa cells were among the first
cell lines ever brought into culture, derived in the middle
of the 1950s from an adenocarcinoma of the cervix of an
African American patient. Since then, HeLa cells have
been cultured separately by countless labs around the
world. During this time, they changed genetically by
chance as well as by selection, and cell lines called
‘‘HeLa’’ today diverge substantially from one another.
Here, we analyzed six different clones of HeLa (see
Materials and methods). We present the data for only
three of them as the outcome of the McrBC digestion
was the same for all six clones. Among these three, we
considered HeLa CCl2, a typical representative of the
widely used ‘‘wildtype’’ HeLa clones, D98 is a well-
known HGPRT negative mutant of HeLa, and 444 is a
clone generated during fusion studies between HeLa cells
and fibroblast. C4-1 is unrelated to HeLa, but is another
widely used cell line derived from a cervical cancer,
Fig. 2. PCR amplification and McrBC cleavage of the HPV-18 genomes in
three different HeLa clones (CCl2, D98, and 444) and the unrelated cell line
C4-1. The figure documents lack of cleavage, that is, lack of methylation of
amplicons G1–G4, deletion of amplicons G5–G7, and partial or complete
cleavage of amplicon G8, overlapping with the L1 gene. Identical data were
obtained with the HeLa clones S3, H21, and HD.
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al., 1994; Kruczek et al., 1981; Schwarz et al., 1985).
The inner circle of Fig. 1 shows a genetic map of the
HPV-18 genome, a double-stranded circular DNA with a
size of 7857 bp. The LCR is a segment of the genome
(position 7134 to 105) with most cis-responsive elements
that govern transcription and replication. Transcription of
the early genes starts counterclockwise at a promoter at
the genomic position 105 (p105) and generates multi-
cistronic transcripts of the early genes E6, E7, E1, E2,
and E5 and the late genes L2 and L1. The outer circle of
the same figure shows the division of the HPV-18
genome into eight segments that we designed as ampli-
cons, G1–G8, each with an approximate size of 1 kb.
The numbers between the amplicons indicate the 5V ends
and the arrows the orientation of the oligonucleotide
primers used for generating these amplicons.
Fig. 2 shows the McrBC digestion and PCR amplifi-
cation analysis of HeLa CCl2, HeLa D98, HeLa444, and
C4-1. We could generate the amplicons G1–G4 and G8
from all four clones but not for G5, G6, and G7. This
result was expected, as a 2- to 3-kb deletion within HPV-
18 of HeLa had been reported (Schwarz et al., 1985).
The deletion is fairly exactly defined by the borders
given in Fig. 1 (i.e. genomic position 2808 to 5918),
as experiments failed to extend the amplicons G4 and G8
even by small increments of 10–50 bp into the direction
of the deletion (data not shown). We also confirmed that
this region is deleted and not just rearranged since we
tried to generate nine different small (200–1000 bp)
amplicons throughout the G5–G7 range, without detect-
ing any HPV-18 sequences (data not shown). Strangely, aFig. 1. HPV-18, genome organization (inner circle), and position of PCR
primers (outer circle) (see also Table 1A).seemingly identical deletion of G5 to G7 occurred in C4-
1 with approximately the same borders and absence of
internal amplicons. We excluded the possibility that C4-1
cells may be a mislabeled HeLa contaminant, as sequenc-
ing of the HPV-18 variants confirmed the presence of
unrelated HPV-18 variants as published (Ong et al.,
1993).
McrBC digestion of the chromosomal DNA of these
four cell types showed no change of G1 in HeLa CCl2,
but a slight reduction in HeLa D98 and 444 and C4-1.
This may indicate, that this region with the enhancer,
promoter and replication origin of HPV-18 (Garcia-Car-
ranca et al., 1988; O’Connor et al., 1995), is not
methylated in HeLa CCl2, but that possibly some of
the 50 genomes in HeLa D98, HeLa444, and C4-1
contain meCpGs. The amplicons G2, G3, and G4, with
the early genes E6, E7, and E1, are unaltered, that is, not
methylated in all four cell lines. The amplicon G8 is
slightly reduced in HeLa CCl2, suggesting that the L1
gene in amplicon G8 is partially methylated in this clone.
The complete digestion of G8 in the other three clones
suggests heavy methylation of L1.
Six tumor samples lack major deletions of the endogenous
HPV-18 genomes
The similarity of the HPV-18 deletions in HeLa and
the unrelated C4-1 cells led to a side line question of our
methylation research, namely, the question whether this
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during carcinogenesis. To address this possibility, we
amplified the HPV-18 DNA from six tumors, two from
German (Ge18-1 and 2) and four from Scottish (Sc18-3,
2, 6, 7) patients (Ong et al., 1993). Fig. 3 shows that
there is no systematic loss of the G5-G7 segment in these
six tumors. All eight amplicons are present in the
samples Ge18-1, Sc18-3, Sc18-2, and Sc18-7, and the
missing amplicons G3 in samples Ge18-2 and G7 and
possibly G5 in sample Sc18-7 may indicate segments of
recombination between the viral and the cellular DNA.
Bisulfite sequencing of a 2022-bp L1-LCR-E6 segment of
the HPV-18 genomes in HeLa clones and C4-1
Our next objective was to establish a precise map of
the meCpGs in HeLa clones and the C4-1 cell line by
using the bisulfite sequencing technique. From this, we
hoped to learn whether there are precise correlations
between methylation patterns, genes, and cis-responsive
elements, and whether methylation may occur sporadical-
ly or continuously throughout many flanking CpG dinu-
cleotides. We decided to limit this laborious approach toFig. 3. PCR amplification of the HPV-18 genomes in six tumors, a control
experiment to confirm that loss of the amplicons G5–G7 is not a systematic
event in HPV-18-dependent carcinogenesis. Lack of other amplicons likely
indicates recombinational interruption of the HPV-18 genome in the
respective tumor.a subsegment of the HPV-18 genome, namely, the ge-
nomic position 5940 to 161, which we considered par-
ticularly informative. This segment, with a total size of
2022 bp, contains 39 CpG dinucleotides, 26 of these
potential McrBC half sites. Nineteen of these CpGs are
located in the L1 gene, which ends at position 7133.
Three are located in the 5V part of the LCR (position
7134 to an E2 binding site extending to position 7469).
Six are located in the central part of the LCR with the
enhancer, which is roughly the region between the two
E2 binding sites remote from the promoter, positions
7470 and 7821. Seven are located in the 3V part of the
LCR with the HPV-18 replication origin and promoter
(position 7822 to 104), and four downstream of p105,
within the transcript encoding the E6 gene (Fig. 4).
Fig. 4 (upper panel) summarizes our findings for three
HeLa clones and C4-1 cells. In HeLa D98, HeLa444, and
C4-1 cells, all CpGs within the L1 gene were methylated
except one at position 6871. In HeLa CCl2, only seven
CpGs were methylated in L1, no methylation being detected
at position 6039, and all methylation was discontinued after
position 6367. This explains the McrBC resistance observed
in Fig. 2. From the difference between HeLa CCl2 and
HeLa D98 and 444, one has to conclude that methylation of
chromosomally integrated HPV-18 copies can change after
integration.
Interestingly, the first CpG residue in the 5V part of
the LCR, that is, upstream of known transcriptional
regulators (position 7318), was also methylated in three
clones, whereas all CpGs downstream of this position
overlapping with the enhancer and promoter and the E6
gene were unmethylated. In the case of C4-1 cells, this
result had to be expected because the oncogenes of the
only HPV-18 genome in this cancer-derived cell line
should be transcriptionally active, that is, unmethylated.
The data suggest that in HeLa cells, all 50 HPV-18
copies are also potentially transcriptionally competent.
This outcome is discrepant from previous observations
with CaSki cells, where most of 500 HPV-16 genomes
are methylated, and only one or few remain unmethylated
and transcriptionally active (Badal et al., 2003; Van Tine
et al., 2001).
We confirmed published data (Schwarz et al., 1985) that
the HeLa clones and C4-1 cells have an active early
promoter by quantifying the E7 mRNA in a reverse tran-
scription experiment (Fig. 5). This was expected due to the
absence of methylation of the enhancer and promoter region
and shows that the methylation of the L1 gene does repress
over a long distance. We also excluded a modulation of the
early promoter by methylation of the L1 gene by treatment
of the cells with 5-azacytidin (5-azaC), a known antagonist
of DNA methylation, since we measured that 5-azaC did not
stimulate early HPV-18 transcription in any of the HeLa
clones or in C4-1 (data not shown). However, transcription
in HeLa cells may be negatively affected by a different
mechanism such as the site of genomic recombination, as
Fig. 4. Methylated CpG residues (black boxes) in a 2022-bp genomic segment of HPV-18, stretching over 1.2 kb of the L1 gene (position 5940 to 7133), the
LCR, and the 5V end of E6 (downstream of position 105). The segment contains 39 CpG dinucleotides. The top of the figure shows the overlap with genetic
elements, the vertically listed numbers the genomic positions of CpGs. White boxes: unmethylated CpGs. Grey boxes: not analyzed due to lack of material.
Fig. 5. Transcription of the HPV-18 E7 gene in four cell lines demonstrates
that methylation of the L1 gene and the 5V part of the long control region
does not repress the early promoter. (A) E7 gene of HPV-18 and the
amplicon assayed by reverse transcription PCR. (B) Reverse transcription
PCR of three HeLa cell clones and the cell line C4-1. The weaker
expression of E7 in C4-1 likely results from a gene dosage effect. No
stimulation of transcription occurred under the influence of 5-aza-C. (C)
Transcription control of a cellular gene, glyceraldehyde-3-P dehydrogenase
(GAP).
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al., 2001), as the amount of E7 mRNA was only slightly
higher in HeLa than in C4-1.
Bisulfite sequencing of a 2022-bp L1 gene-LCR segment of
the HPV-18 genomes from six cervical cancers
The central panel of Fig. 4 shows a methylation
analysis of the tumors discussed above. Some of these
data resembled the observations made with the cell lines,
others diverged. Throughout L1, most CpGs were meth-
ylated just like in the HeLa clones and in C4-1, strange-
ly, the only consistent exception being a lack of
methylation at the CpG at position 6871. Among the
remaining 18 CpGs, G18-1, G18-2, and Sc18-7 had six,
one, and two unmethylated sites. Just as in three of the
four HeLa cells, the first CpG in the 5V-LCR at position
7318 was methylated. We conclude that in cervical
cancers, just like in cancer-derived cell lines, the L1
sequences and the 5V-LCR are preferentially methylated.
The LCR and E6 sequences of these six tumors
showed a less consistent pattern. All CpGs were unme-
thylated in Ge18-1, Sc18-6, and Sc18-7. All enhancer,
promoter, and E6 sequences were methylated in Ge18-2,
Sc18-3, and Sc18-2, except three neighboring CpGs
overlapping with the enhancer of Sc18-2. We conclude
that the LCR can become methylated, although by far not
as consistently as the L1 gene. It has to be stressed that
the detection of methylated transcription units in the LCR
does not necessarily mean that all HPV-18 genomes in
these tumors were transcriptionally repressed, as exem-plified in the previously studied CaSki cell line and one
HPV-16-containing tumor (Badal et al., 2003), where
bisulfite sequencing detected a majority of methylated
and transcriptionally repressed genomes, although some
other HPV genomes remained transcriptionally active and
thereby maintained the tumor phenotype.
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HPV-18 genomes from five smears from asymptomatic
patients
We also addressed the question of whether methylation
could be found in HPV-18 genomes in cervical smears
from asymptomatic patients. Toward this, we studied five
samples from a recently published analysis of HPV-18
genome variants found in a cohort in the city of Monterrey,
Mexico (Calleja-Macias et al., 2004), Mx18-1036, 1200,
1230, 1232, and 1249. Unfortunately, due to the low
amounts of sample, we could not sequence the complete
2022-bp L1-LCR-E6 segment, but only a segment from L1
with eight CpGs and a promoter-E6 segment with 11 CpGs.
The bottom panel of Fig. 5 shows that the L1 sequences of
all four samples were completely methylated. This meth-
ylation might continue through the unsequenced part of the
3V side of the LCR, as the neighboring position 7318 was
methylated, just as in most the previously described sam-
ples. Interestingly, the enhancer of all five samples was
unmethylated, although the promoter and E6 sequences
were methylated.
It should be pointed out that all bisulfite sequencing
data analyzed directly the amplification product rather
than individual clones. As a consequence, we detected
only the predominant methylation pattern, but not micro-
heterogeneities between different HPV genomes in the
same clone or sample as recently observed (Kim et al.,
2003; our unpublished observations).Discussion
The expression ‘‘DNA methylation’’ refers to the fact that
a methyl group can be added to cytosine residues. This can
occur in any sequence constellation, but is maintained typi-
cally at CpG dinucleotides, as the palindromic nature of this
site, with methylation of the C on the upper and the lower
strand, is a prerequisite for maintenance of methylation
following replication. DNA methylation has two consequen-
ces, namely, (i) interference with the binding of some, but not
all, transcription factors (Harrington et al., 1988; Thain et al.,
1996), and (ii) being one step in a complex network of
chromatin modifications, which also includes the activities
of histone methylases and histone deacetylases (Jaenisch and
Bird, 2003). De novo DNA methylation plays a major role in
reprogramming of genetic information in early embryogen-
esis where it has been intensely studied (Jaenisch and Bird,
2003). It is enzymatically under the control of the DNA
methylases DNMT3A and B, which can also target viral
DNA that enters embryonic stem cells (Dodge et al., 2002). It
also occurs during tumorigenesis, as methylation of the
promoters of tumor suppressor genes is found in cancer as
a mechanism with similar consequences as the deletion of
tumor suppressor genes (Paulsen and Ferguson-Smith, 2001).
Very little is known about de novo methylation in somatictissue, which may occur rarely or not at all, although
DNMT3A and B could be detected in several cell types.
Under in situ conditions, the Epstein–Barr Virus (EBV) was
until recently thought to be the only virus targeted by de novo
methylation. Here, methylation may have the function to
repress the EBNA promoters, thereby reducing the availabil-
ity of immune targets during EBV-induced carcinogenesis
(Robertson, 2000).
Against this background it was a surprise when we
recently found that HPV-16 DNA is frequently methylat-
ed in cell lines and in clinical material (Badal et al.,
2003). This observation was complemented by the report
that HPV-16 DNA is frequently methylated in undiffer-
entiated cells in culture, but becomes demethylated in
differentiated cells (Kim et al., 2003). These data revived
historic reports that one can detect DNA methylation in
HPV-1 and the cottontail rabbit papillomavirus (CRPV)
(Burnett and Sleeman, 1984; Sugawara et al., 1983;
Wettstein and Stevens, 1983). From these observations,
it has to be concluded that mucosal and cutaneous
epithelia are competent to perform de novo DNA meth-
ylation, and that HPV genomes can be efficiently
detected as targets of this process. It has to remain the
objective of future research to identify, which of the
many diverse methylation patterns have transcriptional
consequences. But there is no doubt that methylation
will correlate with repression, as suggested by the study
of methylated cellular genes, by the observation that in
vitro methylated HPV DNA is transcriptionally incompe-
tent in vivo (Rosl et al., 1993), and in CaSki cells, most
of the 500 endogenous HPV-16 copies are transcription-
ally repressed correlating with their extensive methylation
(Badal et al., 2003; Van Tine et al., 2001). The phenom-
enon of HPV DNA methylation leads to many obvious
and fascinating research questions regarding the cell
populations and the enzymatic mechanisms that perform
this reaction, the recognition of HPV genomes, and the
role of methylation in the normal HPV life cycle and
during neoplasia. To study these phenomena, we decided
to firstly determine in several different HPV types the
patterns of DNA methylation. Here, we report that we
found methylation in each of 18 samples with HPV-18,
namely, in six cell lines, seven cervical cancers, and five
cervical smears from asymptomatic patients.
As a sideline of our research, we confirmed reports
that HeLa cells have about 3 kb of their genomes
deleted, and these genomic arrangements apparently did
not change over five decades of separate cloning. HeLa
was reported by one group to have HPV-18 genomes
integrated in a single chromosomal site, chromosome 8,
band q24 (Durst et al., 1987; Mincheva et al., 1987;
Schwarz et al., 1985), whereas two other groups (Ambros
and Karlic, 1987; Popescu et al., 1987) reported integra-
tion into four different chromosomal regions, one of
which confirmed as 8q24. These integration events are
apparently even more complex, as amplification of HeLa
S. Badal et al. / Virology 324 (2004) 483–492 489at one locus has been reported to involve the cellular
flanking sequences (Lazo et al., 1989). We did not follow
up on these contradictory findings, but we point out the
puzzling consequence of the latter reports with possibly
identically deleted HPV-18 genomes in four different loci.
We also report that the similar deletion in C4-1 cells was
apparently a fortuitous event, as no such deletion was
observed in six cancers. Contamination of C4-1 cells by
HeLa cells could be excluded due to the different HPV-
18 variants in the two cell lines.
In spite of the limited diagnostic power of the McrBC
analysis of clones of the six HeLa cell lines and C4-1
cells, one can conclude that methylation is absent or rare
throughout the early genes and the LCR (amplicons G1–
G4) and only detectable in the late gene L1 (G8). No
conclusions could be drawn about L2, which would have
been part of the deleted G7 segment. While McrBC is a
useful tool to scan larger genomic segments, we contin-
ued this study by bisulfite sequencing technique of a
partial genomic segment, as only few amplification
experiments were possible due to the small amounts of
DNA from clinical material.
In spite of the small number of samples analyzed by
bisulfite sequencing, our data lead us to the following
conclusions.
1. As HeLa and C4-1 cells express the E6 and E7
oncogenes, no long distance repression results from the
methylated region around L1 to the enhancer and
promoter elements located 250–600 bp 3V from the last
methylated site at position 7318.
2. Changes of the methylation status of the HPV-18 genome
can occur after clonal integration, as seen by the
differences between CCl2 and D98/444.
3. Selected sites can be resistant to methylation as
documented by site 6871, which is not only unmethy-
lated in the cell lines, but also in six tumors.
4. In many samples, methylation ends at position 7318.
This site is nearly 200 bp downstream of the 3V end of
L1, and we conclude that methylation does not strictly
correlate with the L1 gene.
5. Lack of methylation may correlate with transcription
factor binding sites since all CpGs 3V of position 7318
overlap with cis-responsive elements of the enhancer or
promoter.
6. In the cell lines and in most tumors, HPV-18 genomes are
integrated, and sequences upstream of the HPV-18
promoters are only transcribed, if they happened to
come under the control of cellular elements. This lack of
transcription, however, cannot explain the methylated
status of L1, as L1 and site 7318 are also methylated in
five smears of asymptomatic patients, likely to contain
circular HPV-18 genomes and competent to transcribe
L1. This leads to the speculation that methylation of L1
may be involved in the early-late switch of HPV-18
transcription.7. The enhancer and promoter are completely or partially
methylated in three tumors, likely indicating transcrip-
tional repression of these HPV-18 genomes. It is likely,
however, that some of the numerous HPV genomes in
these tumor cells are unmethylated and express the HPV-
18 oncogenes, as observed in CaSki cells for HPV-16.
8. In seven samples, we observed methylation of the
promoter and the E6 gene. These sequences might be
repressed by the chromatin configuration, but methyl-
ation would not affect the transcription factors directly,
as Sp1, which activates the E6 promoter, is not
affected by methylation (Harrington et al., 1988), and
E2, which is affected (Thain et al., 1996), functions in
this position as a repressor of transcription, and its
displacement would activate the promoter (Tan et al.,
1994).
Our study confirms HPV genomes as fascinating models
to study DNA methylation and makes it likely that this
mechanism has profound effects on the HPV life cycle and
carcinogenesis.Materials and methods
Origin of cell lines
Since its original cultivation in the 1950s, different cul-
tures of the HeLa have diverged substantially. We included in
this study six HeLa clones of different origins. HeLa H21
(Defilippi et al., 1987) was obtained from A.G. Porter at the
Institute of Molecular and Cell Biology (IMCB), Singapore,
who originally received it fromWalter Fiers, Rijksunivesiteit
Te Gent University. HeLa D98 was also obtained from A.G.
Porter. It is a hypoxanthine guanine phosphoribosyltransfer-
ase (HGPRT) negative, 8-azaguanin resistant mutant of HeLa
constructed more than 30 years ago (Bengtsson et al., 1975).
HeLa CCl2 (Chou et al., 1978) was received from the
American Type Culture Collection (ATCC). HeLa S3 is an
methylguanine DNA methyltransferase (MGMT)-positive
cell line (Painter and Robertson, 1959), which was obtained
from Peter Karran (Imperial Cancer Research Fund, UK), the
original source cited to be the American Type Culture
Collection. Yet another line with unknown pedigree was
obtained by one of us (H.U.B.) in 1985 at the German Cancer
Research Center in Heidelberg and maintained in our lab
since that time. HeLa444 cells were constructed during a
study of the properties of fusion cells between HeLa D98 and
fibroblasts (Srivatsan et al., 1986), and were made available
to us by Dr. E. Stanbridge (University of California Irvine).
The cell line C4-1, also derived from a cervical carci-
noma (Kruczek et al., 1981), has been reported to contain
one or few HPV-18 genomic copies (Gallego et al., 1994;
Schwarz et al., 1985) and has been made available by E.
Schwarz, Heidelberg, in 1985, and was maintained in our
Singapore laboratory since then.
logy 3Clinical specimens
Samples from cervical cancers were obtained during a
published study of the genomic diversity of HPV-18 genomes
from German and Scottish patients (Ong et al., 1993). HPV-
18 smears were identified during an epidemiological study in
Monterrey, Mexico, part of which has been published (Call-
eja-Macias et al., 2004).
Purification of DNA
DNA derived from cell lines or smears was purified with
Qiagen genomic tips following protocols suggested by the
supplier. The purification of tumor DNA has been described
(Ong et al., 1993).
McrBC cleavage
The restriction enzyme McrBC cuts close to the se-
quence purine-meC (PumeC) in the context of a second,
arbitrarily spaced PumeC (Sutherland et al., 1992). As a
consequence, McrBC recognizes pairs of PumeCpG resi-
dues, and, on the average, cleaves every other meCpG. For
digestions with McrBC (New England Biolabs), 250 ng of
chromosomal DNA was digested with 3 units of enzyme
for 1 h at 37 jC in 25 Al NE buffer 2 [50 mM NaCl, 10
mM Tris–HCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT),
pH 7.9].
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Table 1A summarizes the primers for dissection of the
HPV-18 genome. PCRwas carried out in 25 Al containing 0.2
mM of each of the four dNTPs, 10 pmol primers, 2.5 Al of
buffer B supplied by the producer (Promega), 2 mM MgCl2,
and 0.75 units Taq (Promega) with 25 or 0.25 Al of C4-1 and
HeLa DNA, respectively, uncleaved or cleaved by McrBC.
The PCR started at 94 jC for 1 min followed by 35
amplification cycles (denaturation 94 jC, 10 s, annealing
58 jC, 30 s, extension 68 jC, 45 s increasing by 10 s per
cycle), final extension at 68 jC, 7 min. PCR with TaqGold
was carried out in 25 Al containing template DNA, 5 mM
dNTPs, 10 pmol primers, 2.5 Al of magnesium ion free buffer
supplied by the manufacturer, 2 mM MgCl2, and 1.25 units
AmpliTaqGold (Applied Biosystems) at 94 jC, 9 min fol-
lowed by 40 amplification cycles (denaturation at 94 jC, 10 s,
annealing 55 jC, 30 s, extension 68 jC, 45 s increasing by 10
s per cycle), final extension at 68 jC, 7 min.
Bisulfite modification, PCR, and direct sequencing
For mapping of methylated residues, DNAs were mod-
ified by the CpGenomeTm DNA modification kit of Inter-
gen Inc. or by modifications adjusted in our laboratory as
follows: 50–1000 ng sample DNA supplemented with 1 Ag
of salmon sperm DNA in a total volume of 18 Al in water
were denatured with 2 Al of 3 M NaOH and incubated at
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and 2 Al 100 mM hydroquinone were added and incubated
in a thermal cycler for 20 cycles each at 55 jC for 15 min
and 95 jC for 30 s. The modified DNA was desalted with
the QIAquick PCR purification protocol. The modified
DNA was desulfonated by adding 5.5 Al of 3 M NaOH,
5 Ag glycogen, and incubation at 37 jC for 15 min. The
DNA was precipitated with 5.6 Al of sodium acetate and
150 Al of 100% ethanol. The pellet was washed with 70%
ethanol and dissolved in 30–50 Al TE buffer (10 mM
Tris–HCl, pH 8, 1 mM EDTA). The reaction products
amplified with primers specific for modified HPV-18 DNA
(Table 1B) and sequenced directly. Since bisulfite-treated
DNA is partially degraded, large amplicons, it cannot be
generated, and we divided this segment in four amplicons
(5940–6482, 6847–7186, 7282–7747, 7753–186).
Reverse transcription and PCR
RNA was prepared using the QIAGEN RNA kit. One
microgram of RNA was primed with 5 pmol of oligodT
primer, topped up to 11 Al with H2O, heated at 70 jC for 10
min, and placed on ice for 5 min. A mastermix containing 2
Al of 10 New England Biolab (NEB) M-MuLV reverse
transcriptase buffer, 100mMDTT, 0.5mMof each of the four
dNTPs, 100 units NEB Reverse transcriptase enzyme, and 20
units of RNAse Inhibitor (Roche) was added to each sample
and incubated for 50 min at 42 jC. The enzyme was heat
inactivated at 70 jC for 15 min. PCR was carried out in 25
Al containing 0.2 mM of each of the four dNTPs, 10 pmol
primers, 2.5 Al of buffer B (supplied by the producer,
Promega), 2 mM MgCl2 and 0.75 units Taq polymerase
(Promega) and 1.5 Al of the cDNA preparation. The PCR
started at 94 jC for 2 min followed by 25 amplification cycles
(denaturation 94 jC, 10 s, annealing 55 jC, 30 s, extension 68
jC, 45 s), final extension at 68 jC, 7 min.Acknowledgments
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